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Abstract 
 
Obesity affects about 520 million people world-wide and more recently studies 
have shown that fat cells produce proteins called adipokines which have 
various influences on the human metabolism and has helped to change the 
perspectives of researchers on the concept of the adipose tissue being just a 
store of energy. As a result of this, adipokines have been reported to represent 
a connection between obesity and cardiovascular diseases (CVD) and diabetes 
mellitus. The concentrations and the bases of the effects of the adipokines in 
beta cell failure of diabetes mellitus and endothelial cell dysfunction of 
cardiovascular diseases are still not fully understood. 
 
The effect of leptin and adiponectin, which are two adipokines with opposing 
effects, has been explored in this study. In the present study, therefore, the 
concentrations of leptin and adiponectin with significant effect on beta cell and 
endothelial cell function and the basis of these functions were explored. Also, 
attempts were made in the present study to correlate the concentrations of 
leptin and adiponectin with possible clinical pointers to complications. 
 
In order to achieve this, beta cells (BTC) were grown, made into pseudo-islets 
(which are said to produce more insulin) and treated with various concentrations 
of leptin and adiponectin and cells assayed for insulin and amylin (to investigate 
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the role of amylin in insulin secretion). Also the cells were collected and mRNA 
extracted from these cells, reverse transcription PCR carried out to find out the 
role of protein phosphatase 1 (PP-1) in the effect of leptin on insulin secretion. 
PP-1 is a substrate that increases insulin secretion by allowing calcium influx 
into the cell and is said to be blocked by leptin). Leptin at 500ng/ml was found 
to significantly (p<0.05) inhibit the secretion of insulin and the expression of 
PP1 gene, thus supporting this as a basis for the effect of leptin on insulin 
secretion. Adiponectin however increased insulin secretion significantly but was 
not as consistent in its effect as leptin was in inhibiting insulin secretion. 
 
In order to explore the role of adipokines in cardiovascular diseases, EAHY 
human endothelial cells were cultured and treated with various concentrations 
of adiponectin and leptin both individually and in combinations and cells 
collected and mRNA extracted in order to carry out a reverse transcription PCR 
for the expression of angiogenic (TIMP2, TIMP3 and MMP2) genes and 
atherosclerotic (LPA and LPL) genes. Leptin (1nM) was shown to increase the 
expression of atherosclerotic and angiogenic genes while adiponectin (100nM) 
inhibited the expression of the atherosclerotic and angiogenic genes. A 
combination of leptin and adiponectin caused a reduction in the stimulatory 
effect of leptin on the expression of atherosclerotic and angiogenic genes. This 
shows that leptin may predispose to CVD while adiponectin reduces the risk of 
CVD. 
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The clinical part of this study involved recruiting 150 patients with diabetes after 
the ethical approval for the clinical study was granted. The data collected from 
the patients included their age, sex, race, and physical parameters like the body 
mass index (BMI). Also blood samples were collected to measure the clinical 
indicators for CVD and renal function such as cholesterol, HDL levels, eGFR, 
albumin levels and their retinopathy status checked as these are the common 
complications seen in diabetic patients. The blood samples were also assayed 
in the laboratory for leptin and adiponectin levels and the leptin, adiponectin and 
the leptin/adiponectin ratio (LAR) were then correlated with the laboratory 
determinants of CVD, renal and retinopathy risks. It was found that the LAR and 
the leptin levels correlates significantly with the BMI, while the leptin levels were 
significantly correlated with the risk of nephropathy in diabetic patients while 
adiponectin levels correlated significantly with a reduced risk for developing 
CVD. The role of the enzymes in the leptin and adiponectin signaling pathway 
was also explored and it was discovered that ERK, P38 and AMPK all had roles 
in the effect of leptin and adiponectin on the expression of atherosclerotic and 
angiogenic genes.  
 
These data indicate that leptin and adiponectin play significant roles in the beta 
cell and endothelial cell function and are links between obesity and CVD and 
diabetes mellitus. 
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1.0 Background and link of obesity to diabetes mellitus and 
cardiovascular diseases 
 
Recent statistics show that about 520 million people worldwide are obese 
(WHO 2014 review) and this statistics is significant in relation to recent research 
which demonstrates a link between obesity, cardiovascular diseases and type 2 
diabetes mellitus (Bravo et al., 2006, Barnes 2011). Further research has 
shown the adipose tissue to be an active endocrine organ made up of fat cells 
(adipocytes) which releases proteins called adipokines (Belkina and Denis 2010 
and Strienstra et al., 2007). As a result of the reported high concentrations of 
most circulating adipokines in subjects with large amounts of adipose tissue 
mass (obesity), it has been suggested that the high concentrations of these 
adipokines seen could be linked to beta cell failure (Rabe et al., 2008). Also, 
due the pro-inflammatory effect of some of these adipokines, and because 
adipokines are a product of adipocytes, it has been suggested that they may 
represent a connection between obesity and cardiovascular diseases. Some of 
the first adipokines discovered were leptin and adiponectin (Lange and Rathke 
2009). Other adipokines that have been reported include visfatin, resistin, 
apelin, vaspin, omentin (Lago et al., 2007). 
 
Adiponectin is a 30kDa peptide (Michalakis and Segar 2010) which is anti-
atherogenic as it inhibits inflammatory, angiogenic and artherogenic processes 
(D'iez and Iglesias 2003) by suppressing the multiplication and movement of 
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smooth muscle cells induced by platelet derived growth factor in damaged 
endothelial cells (Lang and Rathke 2009), decreases macrophage conversion 
into foam cells thereby inhibiting the formation of atherosclerotic plaques within 
the blood vessels. It also decreases the uptake of oxidized LDL and inhibits 
foam cell formation (Balistreri et al., 2010). It was suggested that low 
adiponectin concentration as seen in obesity could be linked to type 2 diabetes 
because low levels of adiponectin leads to an increase in blood glucose due to 
the fact that there is not enough adiponectin to reduce gluconeogenesis in the 
liver (Miller et al., 2011). Other mechanisms linking low adiponectin in obesity to 
diabetes was associated with the fact that the low levels of adiponectin leads to 
a decrease in insulin secretion (Okamoto et al., 2008), and this leads to lower 
levels of insulin in the blood. When this was viewed in the light of the fact that 
adiponectin increases insulin sensitivity (Rabe et al., 2008), together with the 
fact that reduced concentrations of adiponectin in obesity will further reduce 
tissue sensitivity to insulin, a reduction in the levels adiponectin in an individual 
can thus lead to a situation where there is not enough insulin to transport 
glucose and also not enough sensitivity to insulin, which is what is seen in Type 
2 Diabetes. Adiponectin is reported to inhibit insulin secretion at low glucose 
concentrations and increase insulin secretion in high glucose (Winzella et al., 
2004)  
 
Leptin is one of the first adipokines to be discovered. It is 16kDa in size and its 
pro-inflammatory features results in vascular smooth muscle cell movement, 
increased inflammatory cytokine production, increased platelet collection and 
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attachment and atheromatous plaque formation (Beltowski 2006, Stapleton et 
al., 2008). In relation to type 2 diabetes, leptin inhibits insulin secretion thereby 
leading to an increase in the blood glucose (Zhao et al., 1998, Ahrens and 
Havel 1999). It is also reported to protect beta cell in-vivo in high glucose 
concentrations and reduces cell death in beta cells at physiological 
concentrations (Balistreri et al., 2010). 
 
Most of the previous studies have looked at the effect of either leptin or 
adiponectin individually (and not in combinations) (Brown et al., 2002, Brown 
and Dunmore 2007, Madani et al., 2006) on endothelial cells and beta cells and 
also their effect on monolayer cells and not pseudo islets (for beta cells) and the 
concentrations at which these adipokines had their effects vary considerably 
between reports.  
 
Also in the present study, the effect of various concentrations of adipokines 
alone and in combination on pseudo-islets (pseudo-islets have been suggested 
by Persaud et al. in 2010 to have a better dose-related insulin secretion to 
glucose in comparison to mono layer beta cells) was studied in order to 
elucidate the effect the adipokines have individually and in combination at a 
range of adipokine concentrations which are related to those found in 
physiological (lean) and pathological (obese) conditions. Also, the study looks 
at the role of adipokines on amylin in insulin secretion and the insulin: amylin 
ratio calculated in order to have an idea of how much the adipokine treatment 
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affects amylin secretion and if there is any impact of adipokines on the insulin: 
amylin balance as suggested by Ionescu-Tirgoviste et al. (2010). Attempts will 
also be made to correlate the levels of leptin-to-adiponectin ratio (LAR) to 
complications in diabetic patients clinically. 
 
1.1 Obesity 
 
Obesity is defined as a body mass index (BMI) greater than 30 kg/m2. The BMI 
is calculated as weight in Kg divided by height in meter squared [(Wt (Kg)/ (Ht in 
meters)2]. BMI correlates strongly with adiposity. The BMI classification by the 
National Heart, Lung, and Blood Institute for adults (age 18-85) defines an 
individual as being overweight for BMI between 25 and 29.9, and obese for BMI 
greater than 30 (Karam and McFarlene 2010). Obesity is defined a condition in 
which the body mass index (BMI) is equal to or greater than 30 or an 
individual’s  waist circumference is greater than 94 cm for men and 80 cm for 
women (Wang and Nakayama 2010). 
 
1.1.1 Epidemiology of obesity  
 
In 2005, data from the World Health Organization estimated that over 400 
million adults all over the world are obese. It was also suggested that the 
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incidence continues to increase at an alarming rate (Vachharajani and Granger 
2009). In the report by the World Health Organization (WHO) in 2008, it was 
estimated that more than 1 billion adults worldwide were overweight, over 300 
million of whom are clinically obese (1.4 billion overweight and over 500 million 
obese in the 2008 statistics by WHO).  
 
Data from many of the previous studies suggest that there has been a 
progressive rise in the prevalence of obesity worldwide over the last few 
decades. In the United States of America in 2000, there was an estimated rise 
of 61% in obesity (assessed by BMI) in 10 years, while it has been estimated 
that more than half of the American adults in data collected in the year 2000 
were overweight. In 2013, data collected shows that the prevalence amongst 
adults 20-74 years had tripled since 1962 in the men while it had doubled in the 
female population (10% -34.4% in men and 15.7%- 36.7 in women) (AHA 
2013). This data also showed about 154 million overweight with 78 million of 
these being obese. The phenomenon was also disturbingly recorded to be on 
the increase in the younger age group leading to childhood obesity with a 5 fold 
increase in boys and 3 fold increase in girls since 1971 (4%- 18% in boys and 
6.1.-18.2% in girls) (AHA 2013).  
 
Data has shown that obesity is commonest in the western population. It has 
been shown, however, that the populations with the highest numbers are seen 
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in United States of America, the Middle East,  Europe and the lowest in sub-
saharan Africa and East Asia (Roth et al., 2004).  
 
In the United Kingdom however, data from the Poverty Site (2009), a site 
dedicated to gathering statistics on social welfare all over the UK, show that  the 
increase in prevalence has not been quite as dramatic and an increase from 
14%- 25% in men and 17-26% in women in the period between 1993 to 2012 
(in individuals over 16 years) was recorded by public health England in 2013 
with Scotland having the highest percentages followed by England, Northern 
Ireland, Wales and the Republic of Ireland. It is also interesting to note that 
about 7 million working age individuals (compared to 4 million in 2004) were 
found to be obese in 2009 (Poverty site 2009). This data show that about 20% 
of the population in the United Kingdom (UK) is obese with over 25% of the 
population in Birmingham city being obese. The report further states that the 
average percentage of the male population in the 15-75 year age range that 
was overweight is 40% with over 20% being obese with women having a lower 
statistic for overweight and higher numbers of obese individuals (University of 
Birmingham 2014). In children in Birmingham and West Midlands, in 2006, 
there was an average of 12% of the children of primary school entry age (5 
years) who were overweight with 10% of these obese, and by the time they left 
primary school at about 11 years, 40% of these children were either overweight 
or obese. This is suggested to be a disturbing pattern as childhood obesity 
tends to last into adulthood, thus leading to an increase in the population of 
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obese adults and a rise in the number of diabetics and people ending up CVD 
in the United Kingdom (University of Birmingham 2014). 
 
1.1.2 Structure and function of Adipose Tissue 
 
The adipose tissue is a tissue made up of adipocytes and is a vital source of 
energy in the postprandial fasting state of mammals. Originally, researchers 
viewed adipose tissue as a passive storage tissue, but more recently, it has 
become more apparent that adipose tissue acts like an endocrine gland as it 
secretes hormones, peptides and cytokines which influences many processes 
in the human body (Cushman and Rizack 1970 and Yu and Ginsberg 2005) 
 
The two types of adipose tissues are White Adipose tissue (WAT), and Brown 
Adipose Tissue (BAT). The WAT makes up most of the components of the 
adipose tissues in the body and is the main source of Free Fatty Acids (FFA) 
which is used in times of starvation to generate adenosine triphosphate (ATP) 
via oxidative phosphorylation (Striensa 2007).  
 
The WAT is found in various parts of the body and the largest collection is 
within the abdomen around the intestines, omentum and around the kidneys, 
and in the subcutaneous tissue in areas such as the buttocks, thighs and 
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abdominal wall in the body. Therefore researchers have grouped WAT into the 
areas where they are found and as such, we have the visceral, muscle, 
epicardial, perivascular and kidney which are all distinct depots of adipose 
tissues which have different physiological properties and functions (Balistreri et 
al., 2010). 
 
Recent studies have shown that the main functions of WAT are the control of 
metabolism by regulating the balance in energy generation and use, the growth 
and regulation of adipocyte division and function and sensitivity of tissues to 
insulin. WAT has also been shown to regulate inflammation because they 
secrete factors that may predispose to or reduce the risk for inflammation 
(Balistreri et al., 2010). The amount of WAT present can therefore affect the 
level of inflammation as there may be pathologies associated with the excessive 
accumulation of WAT in any part of the body (Trayhurn and Wood 2004). When 
there is excess WAT in the upper body (central and visceral) as seen in men, 
there is an increase in inflammatory related cardiovascular conditions, while 
excess accumulation of WAT in the lower part of the body (peripheral or 
subcutaneous) as seen in women may result in a rise in metabolic disorders 
(Trayhurn and Wood 2004).  
 
It has been reported by studies that there is a link between central obesity and 
inflammation. One of the reasons why central obesity is associated with 
inflammation has been hypothesized to be as a result of the location of the 
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adipocytes which is said to be close to the portal circulation which can easily 
take the FFA mediators of inflammation into the liver, thus affecting metabolism 
(Balistreri et al., 2010). It was also suggested that the inflammatory markers 
may not be directly from the adipose tissues, but from the liver. It was also 
suggested that the adipocytes may produce factors that stimulate the 
production of inflammatory markers from other organs such as the liver 
(especially C-reactive protein) (Trayhurn and Wood 2004). Balistreri et al., 
(2010) however also suggested a more localized cause by suggesting that it is 
due to the differences in the cell biology and properties of the adipocyte cells in 
the central region, evidenced by different mediator profiles and expression of 
several genes observed between the visceral and peripheral WAT and also the 
difference in various body depots of WAT, hence there is a tendency for the 
WAT in central obesity to be associated with major risk for pathologies.  
 
Previous studies have shown that brown adipose tissue (BAT) is made up of 
fewer quantities of fat cells but these have more blood vessels supplying them 
with more mitochondrial chromagens which is why the colour is brown (Balistreri 
et al., 2010). It has been suggested that BAT is responsible for non-shivering 
thermogenesis and this is as a result of a more rapid response to the nervous 
system (sympathetic) which rather than producing ATP, produces heat. The 
heat production is from an oxidative phosphorylation which is uncoupled carried 
out by an uncoupling protein-1 (UCP-1) which is found on the internal 
mitochondrial membrane and causes a proton leak which leads to an 
exhaustion of the electrochemical gradient needed for oxidative 
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phosphorylation.  BAT is difficult to find postnatally but it has been located by 
Positron Emission Tomography (PET) scan to be located in the cervical, supra-
clavicular, axillary and para-ventral regions of the body (Virtanen et al., 2009). 
 
1.1.3 Adipose tissue and energy homeostasis 
 
Studies have shown that the adipose tissue is involved in the maintenance of 
energy levels in such a way that the amount of adipose tissues remains the 
same without excessive weight loss or gain (Galic et al., 2010). This process is 
achieved by the regulation of appetite and intake of and weight gain, the use of 
energy and weight loss. This process is regulated by the hypothalamus via 
neuropeptide (Klaus 2001). 
 
The process of homeostasis is controlled by the nervous system which consists 
of contributions from central and autonomic nervous systems. When there is 
urgent need for energy in states where there are low levels of glucose 
(starvation), the sympathetic nervous system (SNS) stimulates WAT lipolysis 
leading to a release of FFA which are metabolized to produce ATP while on the 
other hand when there is less need for energy, the parasympathetic nervous 
system (PNS) stimulates the storage of fat as energy (Romijin and Fliers 2005). 
Balistreri et al., (2010) suggested that the evidence of the effect of the SNS and 
PNS was seen in the fact that both WAT and BAT have SNS innervations and 
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β3 adrenergic receptors. The BAT is responsible for cold-induced shivering 
thermogenesis and this process involves SNS activity which generates heat 
from uncoupled oxidative phosphorylation. WAT stimulated by upregulated SNS 
activity in response to cold is commonly seen in obesity and increases 
thermogenesis from oxidative phosphorylation of FFA seen in the liver, muscle 
and fat cells (Balistreri et al., 2010) 
 
Summarizing, research has shown that obesity occurs as a result of conditions 
in which there is an increase in caloric intake and reduction in calorie use and 
BAT mass and function are decreased in obese individuals 
 
1.1.4 Pathophysiology of obesity 
 
Obesity is associated with over-nutrition and lack of physical activity. Research 
has shown, however that there are other issues that are important contributory 
factors to the pathogenesis of obesity which are linked to diabetes and 
cardiovascular diseases (Balisteri et al., 2010) 
 
Stress, as one of the factors predisposing to visceral obesity is also said to be 
caused by obesity (therefore forming a vicious cycle) due to the impairment of 
metabolic homeostasis of the human body. When there is an increase in White 
32 
 
Adipose Tissue (WAT) in sites which are metabolically active such as the liver 
and immune cells, there is a release of pro-inflammatory cytokines which 
influences inflammation. The cytokines released in situations like this are called 
adipokines (Rabe et al., 2008). 
 
Obesity and stress have been described as relating in a vicious cycle because 
when obesity induces stress for a prolonged time, the hypothalamic-pituitary-
adrenal axis and the central and peripheral components of the autonomic 
nervous system are stimulated to counter the stress by releasing 
glucocorticoids (Balisteri et al., 2010). Glucocorticoids are steroid hormones that 
induce the differentiation of pre-adipocytes into adipoctyes that further 
encourages the growth of mass of WAT which further leads to an increase in 
the stress stimulus and a further increase in the WAT mass in addition to a 
chronic state in which there is a high level of inflammatory adipokines release, 
this being responsible for the link between obesity and cardiovascular disease 
and diabetes (Balisteri et al., 2010). 
 
Recent studies have shown that in normal circumstances in the WAT tissue, 
inflammation is mediated as a result of the infiltration by the M1 and the M2 
macrophages. The M1 macrophages are suggested to encourage inflammation 
due to the presence of a surface marker (CD11c+) which causes the release of 
iNOS and other pro-inflammatory cytokines while the M2 macrophages have 
been shown to reduce inflammation by inhibiting cytokines that encourage 
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inflammation such as interleukins by the release of arginase (Striensa 2006). In 
the normal state, WAT is in an environment that is anti-inflammatory as a result 
of the actions of the M2 macrophages and also due to the activities of the 
peroxisome proliferator-activated receptor (PPAR-α and -γ) and liver X receptor 
(LXR) which are all involved In the transport of transport and metabolism and 
able to antagonize inflammatory activity (Balistreri et al., 2010).  
 
It is therefore important to consider why there is a link between WAT and 
inflammatory conditions if the WAT environment is designed to be anti-
inflammatory. It has therefore been suggested that it is as a result of the WAT 
cellular composition restructuring which involves an increase in the number of 
cells (hyperplasia) and size (hypertrophy) of adipocytes and macrophage 
infiltration and the resulting fibrosis within the WAT tissue in inflammatory states 
related to obesity (Treyhurn and Wood 2004). 
 
Adipocyte hypertrophy is one of the important factors that tilt the WAT 
environment into a pro-inflammatory one. The hypertrophy occurs when there is 
an increase in deposition of fat in adipocytes that are fully differentiated, and 
when there is a rise in the expression of inflammatory mediators. Hypertrophy in 
adipocytes tends to influence the immune system to produce more pro-
inflammatory cytokines (Balistreri et al., 2010) and the change in the cytokine 
profile leads to the modification of the M2 macrophages around the WAT to M1 
macrophages which are more pro-inflammatory. Also because of the 
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differentiation of the monocyte recruited by the WAT, there is an increase in the 
number of M1 macrophages (Striensa et al., 2006). In a condition where there is 
high adiposity, studies have shown that there is an increase in the infiltration of 
the inflamed visceral WAT by macrophages which leads to production of 
cytokines which bind to receptors and aid the production of adhesion molecules 
that affect endothelial cells by attracting more macrophages and monocytes to 
the endothelial cells as a result of the inflammatory WAT cytokine profile (M1 to 
M2). This also forms the basis for the relationship between angiogenesis and 
adipogenesis (Sell and Eckel 2010). 
 
1.1.5 Adipokines and role of adipokines in type 2 diabetes and 
cardiovascular diseases 
 
Adipokines are protein molecules released by the adipocytes and are molecules 
that are biologically active and that have been shown to mediate various stages 
of metabolism. Adipokines help to mediate the regulation of food consumption, 
the metabolism of glucose, protein and lipids, blood pressure regulation, 
modulation of inflammation and immunity, and they work together to regulate 
inflammation, insulin action, and glucose metabolism locally and systemically 
(Striensa 2006). In an obese person, the adipokine/cytokine network is altered 
leading to a state that encourages inflammation and the impairment of 
adipocyte metabolism (Treyhurn and Wood 2010). 
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Adipokines that stimulate inflammation such as pro-inflammatory cytokines, 
chemokines, molecules associated with thrombosis, and hypertension are 
produced in several pathways and these are initiated by stressors from both 
within and outside the cells. The leading stressor from within the cell are the 
free fatty acids (FFA) which are chronically increased in obesity as a result of 
insulin becoming limited in its ability to inhibit lipolysis and consumption of 
dietary lipids in excess (Trayhurn and Wood 2004). It has been suggested by 
previous studies that there are receptors in WAT called toll like receptors (TLR-
4) and their expression is increased in obese individuals and these receptors 
mediate inflammatory processes (Balistreri et al., 2010). Factors that activate 
TLR-4 include FFA, hypoxic conditions in obesity, and lipopolysaccharides 
(LPS). LPS is found in high levels in subjects consuming a high-fat diet, and is 
continually being produced when the gut gram-negative bacteria die from where 
it is taken up into the intestinal capillaries and they move within lipoproteins in 
the blood around the body. Thus gut bacteria have been linked to chronic 
obesity-related inflammatory conditions (Waki and Tontonoz 2007). 
 
The activities of FFA in mediating inflammatory conditions via TLR-4 are 
thought to involve the activation of macrophages (especially the CD11c+ 
subset) via the TLR-4 pathway. The inflammatory state in WAT also involves a 
paracrine loop between adipocytes that are hypertrophied and macrophages 
(Balistreri et al., 2010). This loop makes macrophages secrete pro-inflammatory 
TNF-α and this acts via the TNF-α receptor 1 subtype. This mediates a process 
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of inflammation in adipocytes that are hypertrophied and increase the release of 
FFA.  
 
 The FFA generated is metabolically active and may feedback to influence the 
adipocytes leading to an inflammatory response and adipokine overproduction 
via the TLR pathway (Vacharajani and Granger 2009). Within the adipocytes, 
the mitochondria and the endoplasmic reticulum appear to be sensitive to 
metabolic stressors (Rockl et al., 2008). Furthermore, hypoxia has been 
reported to be a strong inflammatory factor in WAT in obese states. This is as a 
result of an increase in reactive oxygen species which cause oxidative stress as 
mentioned earlier in the present study. All the factors related to inflammation 
culminate predominantly in the activation, principally via TLR4 receptor, of NF-
κB (nuclear Factor kappa-light-chain-enhancer of activated B cells) 
transcriptional factor, responsible for the production of inflammatory mediators 
(Sell and Eckel 2010).  
 
With regards to the process involved in the development of obesity, it has been 
reported by previous studies that there is an interaction between genes and the 
environment (diet and physical activity). Genetically there has been a 
description of a rare, monogenic disorder associated with obesity with a 
suggestion that the inheritance is polygenic. Due to the fact that more recently, 
food has become more affordable and is now more available, and also the fact 
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that more people are becoming sedentary, the incidence of obesity is on the 
increase (Draznin and Marakhovski 1973) 
 
Some environmental factors may have genetic components such as the 
variations in individual metabolic rate which has been explored emphasizing the 
thermic effect of food, and non-exercise activity thermogenesis as being 
important in the caloric expenditure (Rockl et al., 2008). Previous studies have 
not been able to come to an agreement as to whether the increase in obesity 
seen is mainly due to an increase in food intake or a decline in physical 
activities or an equal contribution from the 2 factors. Early childhood nutrition, 
sleep deprivation, infection and stress are all addition environmental factors that 
may contribute to obesity (Roth et al., 2004). 
 
The theory behind many of the studies suggest that evolution is in favour of 
storage of energy and therefore in an environment where there is plentiful, there 
is likely going to be an increase in energy storage in the form of obesity 
(Schwatz and Porte 2005). Previous studies have suggested that in the brain, 
mechanisms include changes in behavior (in appetite, food intake, and physical 
activity), changes in autonomic function, leading to effects on thermogenesis 
and on metabolism. Also it has been suggested that some of the other factors 
that have impact on development of obesity are seen in changes in the thyroid 
and neuroendocrine functions (Schwartz and Porte 2005, Draznin and 
Marakhovski 1973). 
38 
 
Centres in the brain such as the hypothalamic satiety centre and the feeding 
centers get feedback from the periphery in conditions such as starvation 
(feedback is via signals like, glucose, and  fatty and amino acids) satiety signals 
(the satiety signals are cholecystokinin, peptide-YY, ghrelin, leptin, glucagon-
like peptide-1, and amylin, as well as vagally mediated neural signals). Also 
there is another pathway called the hedonic pathway with signals originating 
from the olfactory, taste, visual, and tactile senses (Lutter and Nestler 2009). 
Lutter and Nestler (2009) also noted the differences between circuits involved in 
homeostatic (appetite) and hedonic pathways involved in addiction, with 
neurons involved in metabolic pathways as well as those related to hedonic 
centers expressing leptin receptors, suggesting that both are important in 
understanding obesity. 
 
Leptin is a fat derived adipokine and it was thought to originally function as an 
endogenous anti-obesity factor as it is one of the response stimulus sent to the 
brain in times of abundance to suppress food intake and stimulate metabolic 
processes to use up the excessive energy stores (Lutter and Nestler 2009). It 
has been reported by more studies that there can be resistance to the actions 
of leptin seen in obesity. The consequence of this is that the inhibitory effect of 
leptin in food intake is reduced and the body develops a state of “insatiety” 
(Gertler 2009).  
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The concept of leptin resistance in obese individuals has been shown to be due 
probably to the circulating factors that antagonize its actions, or a reduction in 
the blood-brain barrier transport of leptin (Flier et al., 1987). 
 
1.1.5.1 Leptin and its role in cardiovascular diseases and beta 
cell failure 
1.1.5.1.1 Structure and function of Leptin  
 
Leptin is one of the protein molecules released by the adipocytes specifically 
from the white adipose tissue (WAT) which are biologically active and have 
been shown by previous studies to mediate metabolism in the body (Dardeno et 
al., 2010). Structurally, Leptin is made up of 167 amino-acids and has a four 
bundle motif (4 alpha helices) and 2 short beta strands, which is similar to the 
structure of cytokines and has a molecular weight of about 16-kDa and is 
encoded by the OB (lep) gene (Dubey and Hesong 2006). 
 
In the human body, leptin secretion has a circadian rhythm which is pulsatile 
with a pattern of producing the highest leptin levels in the period between 
midnight and early part of the morning and lowest levels are seen in the early 
mornings to the middle of the afternoon. Also studies have shown that leptin 
levels may be as high as 75.6% higher than levels seen in the afternoon during 
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the night. The rhythms of leptin secretion in obese and lean individuals are 
similar except in some obese individuals that have been shown to have higher 
pulse amplitudes (Dardeno et al., 2010). 
 
The in-vivo function of leptin includes the regulation of food taken in and the 
body weight, the reduction of appetite, and the regulation of energy use by 
increasing the sympathetic activation leading to an increase in the use up of 
energy and a subsequent reduction in body weight and the size of adipose 
tissues (Bravo et al., 2006).  Due to the fact that leptin is increased after long 
periods of overfeeding, the homeostatic control mechanism of leptin suggest 
that leptin in in-vivo, is an anti-obesity hormone but research has shown that 
this effect of leptin doesn’t exist in most obese individuals due to a state of 
leptin resistance that leads to high levels of leptin in obese individuals (Yu et al., 
2004). 
 
The role of leptin in the development of CVD involves the activation of the 
sympathetic nerve system activation, the regulation of renal blood vessel 
control, the general blood vessel tone, and the control of blood pressure (Bravo 
et al., 2006). Leptin has been shown to promote the oxidation of fatty acid in the 
liver, pancreas and skeletal muscle and also modulates hepatic 
gluconeogenesis and pancreatic beta cell function (Rabe et al., 2008) 
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1.1.5.1.2 Leptin Signalling Pathway 
Leptin has its effects by binding to a receptor called the leptin receptor (ObR) 
which is encoded by the db gene and has been shown by studies to be a 
member of the cytokine receptor superfamily called the class I (Dubey and 
Hesong 2006). The ObR gene is expressed as short (a,c,d,f with 30-40 
cytoplasmic residues) and long isoform (ObRb with 300 cytoplasmic residues) 
(Fruhbeck 2006). The ObRB is the functional form of ObR (ObRb) and is 
expressed mosty in the hypothalamus, and in endothelial and the immune 
system cells (Dubey and Hesong 2006). ObRb is considered to be of major 
importance for leptin signalling, with full signalling capacity being achieved 
when leptin activates the mitogen-activated protein (MAP) kinase and Janus 
kinase/signal transducer and activator of transcription signalling pathways 
(JAK/STAT pathway) (Dubey and Hesong 2006). ObR a and c are expressed in 
the vessels surrounding the brain and are said to be responsible for the uptake 
of leptin into the brain during signalling from the body. ObRe encodes a soluble 
receptor and has been reported to act as a buffering system for free circulating 
leptin (Fruhbeck 2006). 
 
After leptin binds to ObRb, there is activation of JAK2 (Janus kinase 2) by 
autophosphorylation and this leads to activation of Ob-Rb by phosphorylation at 
Tyr 985 and Tyr 1138 . Phosphorylation at Tyr 1138 further leads to the binding to 
STAT3 (Signal Transducer and Activator of Transcription 3) which is further 
phosphorylated and activated by JAK2 to form activated STAT3. Activated 
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STAT3 then forms homodimers which is able to move into the nucleus to 
influence gene transcription of the target angiogenic genes such as TIMPs and 
MMPs (especially TIMP1) (Handy et al., 2011). As seen in figure 1.1 leptin 
influences the regulation of NF-кB induced genes and with high leptin levels as 
seen in obesity this may lead to incorrect regulation and a state of inflammation. 
Figure 1.1 also shows that leptin increases gene expression for VEGF and 
influences the IRS pathway thereby leading to cell migration and invasion which 
is one of the components of the process of atheromatous plaque development 
in the endothelium. A combination of all these effects of leptin described above 
provides evidence for the role of leptin in the predisposition to cardiovascular 
diseases. Figure 1.1 also shows that leptin reduces Ppp1ca gene expression 
which codes for the PP1 thereby reducing calcium influx into beta cells and the 
release of insulin. Also leptin, via the IRS pathway influences GLUT 4 
translocation and the uptake of glucose in target tissues. These effects of leptin 
suggest a link between adipokines (in obesity) and type 2 diabetes mellitus. 
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Figure 1.1 Leptin Signalling Pathway. Leptin Influences insulin secretion via 
IRS and endothelial cells via its influence on ERK and STAT. It also influences 
gene expression in CVD via the JAK-STAT pathways. Modified from Kanehisa 
Laboratories 2013) 
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 1.1.5.1.3 Role of leptin in CVD 
 
Studies have suggested that most of the pathogenic role of leptin in CVD 
involves the formation of atheromatous plaque and thrombus in the 
cardiovascular system (Dubey and Hesong 2006). Leptin has been linked to the 
development of CVD via a process that involves a trigger factor (trauma to 
endothelium or myocardium by friction, elevation of blood pressure, high levels 
of cytokines) which leads to compensatory mechanisms such as inflammation 
(which can be exaggerated), angiogenesis in an attempt to repair the damage, 
the deposition of smooth muscle cells and fat cells (in dyslipidemia) which forms 
the basis of atherosclerosis (Wang and Nakayama 2010, Dubey and Hesong 
2006). 
 
In terms of inflammation, it is suggested that leptin plays a controversial role in 
endothelial cell function as studies demonstrate that leptin at high 
concentrations elicits endothelium-dependent NO-mediated vasorelaxation in 
non-obese rats (Sweeney 2010). However, it has been suggested that leptin 
may increase NO synthase which increases the amounts of NO production, 
thereby leading to the impairment of endothelial function and the promotion of 
atherogenesis by inducing oxidative stress (Koh et al., 2008). When it is 
exposed to free radicals generated from oxidative stress, NO may undergo 
conversion to toxic molecules such as peroxynitrite that impair endothelial 
function. Furthermore, research has also shown that leptin at concentrations 
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found in obese people (“obese-range” concentrations), (but not at low 
physiological concentrations) impairs NO-dependent vasorelaxation induced by 
acetylcholine both in vitro and in vivo, an effect that has not been demonstrable 
in non obese individuals (Koh et al., 2008). In order to understand this better, 
further research has been done and this suggests that leptin promotes the 
secretion of tumour necrosis factor and interleukin 2 and 6 and also facilitates 
the accumulation and production of reactive oxygen species (ROS), and the 
enhancement of the production of monocyte chemo-attractant protein-1 which 
further stimulates production of pro-inflammatory cytokines (Dubey and Hesong 
2006). 
 
In the process of the repair of an injury to the endothelium, leptin stimulates 
migration and multiplication of vascular smooth muscle cells and the expression 
of matrix metalloproteinase-2 (Park et al., 2001). In addition to this, leptin has 
been shown to enhance the secretion of endothelin-1 and increase sympathetic 
nervous activities in the kidneys and adrenals of rats that cause high blood 
pressure as a result of hyperleptinemia in obese rats (Dubey and Hesong 
2006). In addition to calcification of blood vessels, in conditions such as 
diabetes where there is beta cell dysfunction and hyperglycemia, leptin 
stimulates lipoprotein lipase (LPL) secretion in macrophages and in high 
glucose conditions, increases the collection of cholesterol esters in foam cells in 
the body (Koh et al., 2008). However, other studies have suggested that at 
normal glucose levels, leptin may prevent the accumulation of cholesterol within 
macrophages. Leptin has also been shown to promote the clearance of hepatic 
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HDL by increasing the scavenger receptor type B1, thereby decreasing plasma 
HDL level. This suggests that when there is high levels of glucose, leptin may 
inhibit cholesterol removal from peripheral tissues by reducing the concentration 
of HDL thus affecting the local cholesterol balance in diabetic patients (Koh et 
al., 2008) 
 
With regards to the heart, when there is damage to the endocardium, there may 
be formation of a thrombus which when infected can form a vegetation in the 
heart and embolism of this can lead to stroke, pulmonary hypertension and 
other complications such as ischaemic heart disease from embolism. Leptin is 
suggested to contribute to a reduction in oxidation rates of fatty acid (the first 
observable abnormalities in failing hearts) in the hearts of obese individuals 
who tend to have high levels of leptin (Sweeney 2010). Leptin stimulates 
oxidation of fatty acids via a pathway that involves STAT3, NO and MAPK 
(Sweeney 2010). High levels of Leptin may play a part in platelet hyperactivity, 
hypercoagulability and a shift in the coagulation-fibrinolysis balance to a 
pathologic pattern, thus predisposing to thrombosis (Koh et al., 2008). Leptin is 
also suggested to be negatively inotropic and also to stimulate hypertrophy of 
cardiomyocytes associated with MAPK activation which is p38 dependent 
(Karmazyn et al., 2009). 
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1.1.5.1.4 Role of Leptin in beta cell Failure 
 
Studies to explore the role of leptin in the process of developing diabetes 
reveals that this involves a decrease in insulin secretion from beta cells and 
also the development of insulin resistance (Seufert 2004).  
 
As seen in figure 1.1, Akt is the kinase that phosphorylates GLUT-4 (Glucose 
transport protein-4) and helps its translocation to the cell membrane where it 
binds to the cell membrane and allows the diffusion of glucose from the blood 
into the cell via tubules on the GLUT-4(Wilcox 2005). Therefore when leptin 
binds to its receptor, it dysregulates IRS proteins by the inhibition of the 
phosphorylation of IRS-1, thus leading to a chain reaction that leads to a 
decrease in the phosphorylation of Akt and subsequently a decrease in the 
phosphorylation of GLUT-4 which helps to transport glucose into target cells, 
thus leading to insulin resistance (Laakso 2010). 
 
With regards to insulin secretion, numerous studies suggest that leptin inhibits 
insulin secretion by a direct action on the beta cells mediated by activation of 
PI3-kinase, and opening of ATP-regulated K + -channels, by impairment of the 
cyclic AMP-PKA-pathway and perhaps in the longer term, by reduction of beta 
cell lipid content. Studies have also suggested that leptin suppresses prepro-
insulin mRNA in the pancreas thus leading to less insulin secretion (Seufert 
2004). 
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1.1.5.2 Adiponectin and its role in beta cell failure and 
cardiovascular diseases  
 
1.5.5.2.1Structure and function of adiponectin 
 
Adiponectin (also called GBP-28, apM1, AdipoQ and Acrp30) is an 
adipocytokines or adipokines which are produced by adipoctyes and help to 
modulate metabolism (Goldstein and Scalia 2004). Adiponectin is a large 
protein with a molecular weight of about 30 kDa (Acrp30). Adiponectin is a 244-
amino acid protein and its origin is exclusively from adipocytes in white adipose 
tissue and is shown to be a product of the APM1 (which is the adipose tissues 
most abundant gene transcript 1), located on the chromosome 3q27, close to 
the site of the genes responsible for type II diabetes and adiposity (Barseghian 
et al., 2011). In the human body, adiponectin has been shown to be one of the 
most abundantly secreted adipokines and corresponds to 0.05% of the proteins 
in the serum in the human body. Researchers have found serum levels of 
between 3-30 µg/mL in humans and 3-6 µg/mL in rodents (Michalakis and 
Segars 2010). In the plasma, adiponectin circulates mainly as a full length 
adiponectin (fAd) and a smaller globular fragment (gAd) (Adya et al., 2012). 
Adiponectin is secreted by adipose tissue in here forms; in the form of one 
trimer which is a low-molecular-weight (LMW) form, a combination of two 
trimers as a middle-molecular-weight (MMW) type, or as six trimers in a high-
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molecular-weight (HMW) form and circulates either as a trimer or an oligomer 
(Michalakis and Segars 2010).  
 
The formation of high molecular weight (HMW) multimers depends on the 
disulfide bond between Cys residues at the amino terminus. Studies have also 
suggested that a truncated globular domain form of adiponectin is generated by 
proteolytic cleavage. The globular domain of adiponectin (gAd) appears more 
potent than the full-length protein in at least some actions (Waki and Tontonoz 
2007). 
 
As seen for leptin, men have lower adiponectin levels than women. It is also 
lower in obesity, diabetes and coronary artery disease. The effect of 
adiponectin are mediated via receptors AdipoR1, AdipoR2 and t-cadherin. 
AdipoR1 has been shown to be expressed in many tissues unlike the AdipoR2 
which is expressed most abundantly in the liver. Studies have shown that 
AdipoR2 stimulates the release of energy by increasing the oxidation of fatty 
acid and inhibits oxidative stress and inflammation (Rabe et al., 2008).  
 
AdipoR1 has been shown to have a high affinity for the gAd receptor and very 
low affinity for fAd, and AdipoR2 has intermediate affinity for both types of 
adiponectin form.  While AdipoR1 is expressed in large amounts in skeletal 
muscle and at moderate levels in other tissues, AdipoR2 is predominantly 
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expressed in the liver (Goldstein and Scalia 2004). These findings are 
consistent with the observation that fAd has a greater effect on hepatic 
metabolic signaling, whereas both gAd and fAd elicit metabolic effects in 
skeletal muscle. Aortic endothelial cells express both adiponectin isoforms, but 
appear to preferentially express mRNA for AdipoR1, suggesting a signalling role 
for gAd in this cell type (Goldstein and Scalia 2004). 
 
Adiponectin has been shown to inhibit the gluconeogenesis and oxidation of 
fatty acid in the liver.  Studies have also shown that adiponectin stimulates 
insulin secretion and increase the uptake of glucose by skeletal muscle and to 
mediate food intake and energy use (Galic et al., 2009). 
 
1.1.5.2.2 Role of adiponectin in cardiovascular diseases and 
beta cell failure 
 
Adiponectin influences the Pathogenesis of CVD via the following pathways; 
Activation of  AMP Kinase (AMPK) 
Inhibition of oxLDL-Induced Superoxide Production 
Endothelial Apoptosis  
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1.1.5.2.3 Anti-inflammatory effects of adiponectin  
 
It has been suggested by previous studies that when adiponectin binds to 
adiponectin receptors on the endothelial cells, it stimulates phosphatidyl 
inositol-3 (PI-3) kinase which stimulates PDK-1 (Phosphoinositide dependent 
kinase 1) activation. PDK-1 is required to activate Akt. Akt is responsible for 
phosphorylation of eNOS leading to increased production of NO (Nitric Oxide) 
which is responsible for its anti-inflammatory effect on the endothelial cells 
(Goldstein and Scalia 2004). Nitric oxide inhibits the increase of endothelial cell 
adhesion molecules induces by cytokines (E-selectin, VCAM-1) thus reducing 
the risk of CVD. NO also reduces the risk of CVD by relaxing the blood vessel 
and thus reducing the chance of an injury from high blood pressure 
(Vachharajani and Granger 2010). Previous studies have also shown that 
adiponectin reduces lipid accumulation, the reduction of the expression of 
scavenger receptors in macrophages, and encourages macrophage 
polarization, which all results in its anti-inflammatory activities and helps to 
reduce the risk of CVD (Laakso 2010).  
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Figure 1.2 Effect of adiponectin on endothelial cells. Adiponectin stimulates 
NO synthesis and angiogenesis. Adiponectin also encourages cell proliferation 
via the MAPK pathway. (Modified from Goldstein and Scalia 2004) 
 
1.1.5.2.4 Adiponectin and its effects on Vascular smooth 
muscle proliferation/angiogenesis 
 
It has been suggested in previous studies that adiponectin may modulate 
inflammatory signalling in endothelial cells via the influence of interaction 
between the cAMP-protein kinase A and nuclear factor-B pathways (figure 1.2). 
As oxLDL-induced super-oxide generation in endothelial cells is linked to an 
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NADPH (nicotinamide adenine dinucleotide phosphate) oxidase pathway, the 
suppression of this process by gAd may involve regulation of the activity of 
certain isoforms of NADPH oxidase or its protein subunits in the vascular cells 
(Golstein and Scalia 2004). This pathogenesis involves adiponectin binding to 
the AdipoR receptor leading to the inhibition of the NADPH oxidase and a 
decrease in the ROS (reactive oxygen species) activity due to a decrease in the 
production of ROS. A decrease in ROS activity leads to a removal of the 
inhibitory effect ROS has on NO production from eNOS and also the inhibitory 
effect on angiogenesis, thus leading to vascular relaxation and angiogenesis. 
The effect of ROS inhibition leads also to a reduction of MAPK production which 
leads to a decrease the cellular proliferatory effect of MAPK. All these activities 
result in angiogenesis and vascular dilation and a reduction in risk of CVD 
(Goldstein and Scalia 2004). 
 
1.1.5.2.5 Adiponectin and atherosclerosis  
 
Adiponectin has been shown in previous studies to have direct anti-
inflammatory and anti-atherosclerotic effects. Adiponectin inhibits TNF-α-
induced inhibition of nuclear factor-kappa B (NF-κB)-alpha (IκB-α) 
phosphorylation and sub-sequent NF-κB activation, as well as the expression of 
monocyte adhesion molecules in human aortic endothelial cells (Galic et al., 
2009). It has also been shown that this effect inhibits the ability of monocytes to 
adhere to endothelial cells, a key step in the formation of the atherosclerotic 
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lesion thus leading to a reduction in the risk of CVD. Adiponectin also inhibits 
the expression of the class A macrophage scavenger receptor and lipid 
accumulation in human macrophages derived from monocytes, and inhibits 
smooth muscle cell proliferation (Zhu et al., 2008). 
 
Furthermore, adiponectin is suggested to favour plaque ‘stabilization’ by 
increasing IL-10 (interleukin-10) secretion and subsequent production of TIMP-1 
(tissue inhibitor of metalloproteinases-1). Also the proliferation of VSMC 
(vascular smooth muscle cell) induced by growth factors can also contribute to 
atherogenesis. In cultured VSMCs, adiponectin has been shown to suppress 
VSMC proliferation and migration via direct binding to PDGF-BB (platelet-
derived growth factor-BB) and generally inhibits growth-factor-stimulated ERK 
(extra-cellular-signal-regulated kinase) signalling in VSMCs (Okamoto et al., 
2008). 
 
1.1.5.2.6 Adiponectin and reduction in apoptosis of endothelial 
cells 
 
It has been suggested from previous studies, that HMW multimers of 
adiponectin suppresses apoptosis of endothelial cells and this is shown in its 
effect on caspase-3 activity in human umbilical vein endothelial cells through 
the AMPK pathway (Waki and Tontonoz 2007) 
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1.1.5.2.7 Role of adiponectin in Type 2 Diabetes 
 
The role of adiponectin in the development of diabetes has been studied. It has 
been shown that the structure of adiponectin which is made up of a globular 
adiponectin which is in the form of a trimer, and the full-length adiponectin 
which is produced as 3 species of multimers: an LMW trimer, an MMW 
hexamer, and an HMW multimer. Studies have also shown that of the roles of 
adiponectin in diabetes is carried out by binding the receptors. The inhibition of 
AdipoR1 by RNA interference leads to an inhibition of the binding of globular 
adiponectin while the inhibition of AdipoR2 by RNA interference inhibits full-
length adiponectin-specific binding (Adya and Randeva 2012). 
  
The role of adiponectin in diabetes is said to be mediated by AMPK or PPAR 
and in previous studies where these have been inhibited, it has been shown 
that there was partial reduction in adiponectin-stimulated glucose uptake. It has 
also been shown that the overexpression of AdipoR1/R2 in liver cells have led 
to PPAR or AMPK activation and fatty-acid oxidation. It has also been shown 
that adiponectin reduces the levels of glucose in the plasma. These studies 
support the conclusion that AdipoR1 and AdipoR2 serve as receptors for 
globular and full-length adiponectin and mediate increased AMPK, PPAR ligand 
activities, p38 MAPK, and biological functions of adiponectin (Kadowaki et al., 
2006). 
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It has been shown that adiponectin levels are decreased in obese humans 
despite increased fat mass and hypoadiponectinemia has been seen to 
correlate with insulin resistance in most circumstances (Wilcox 2005) 
 
The role of adiponectin in glucose metabolism is said to be seen mostly seen in 
the liver and skeletal muscles and adiponectin has been shown to increase 
AMPK phosphorylation and via this pathway it stimulates glucose uptake and 
the oxidation of fatty acid in the muscle, and reduces the expression of 
enzymes involved in gluconeogenesis such as phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase in the liver (Waki and 
Tontonoz 2007). 
 
In other studies into humans, plasma adiponectin levels were correlated 
negatively with adiposity, insulin resistance (type 2 diabetes), and metabolic 
syndrome and positively correlated with markers of insulin sensitivity in 
frequently sampled intravenous glucose tolerance tests. It was also suggested 
that in addition to its insulin-sensitizing effects, adiponectin may alter glucose 
metabolism through stimulation of pancreatic insulin secretion in vivo (Rabe et 
al., 2008). 
 
The role of lowered adiponectin in the pathogenesis of diabetes involves its 
glucose-lowering effect due partly to its activation of the AMP-activated protein 
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kinase (AMPK) cascade and also  AMPK mediated the catabolism of existing 
intracellular stored energy reserves, such as triglycerides and glycogen and an 
insulin-independent influx of energy sources outside the cells as seen in the 
influx of glucose.  Adiponectin has also been shown by research to sensitize 
tissues to insulin and reduce inflammation. Because of the link between 
inflammation and obesity and the development of diabetes, adiponectin may 
reduce the risk of development of both diabetes and atherothrombotic diseases 
(CVD). Another potential mechanism for adiponectin’s protective effect is 
improved insulin secretion, in that it has been recently shown to counteract 
cytokine and fatty acid induced cell dysfunction (Duncan et al., 2004).      
 
1.1.5.3 Effects of leptin and adiponectin in combination 
 
Leptin and adiponectin are both important for the maintenance of appropriate 
insulin sensitivity and overall energy balance. The effect of both leptin and 
adiponectin has been studied individually but little is known about the potential 
interactions when they are combined. Research reveals that elevated leptin 
concentrations reduced adiponectin signalling and metabolic effects in skeletal 
muscle cells, while hyperleptinaemia may be an important contributory factor 
leading to adiponectin resistance in skeletal muscle, thus exacerbating the 
disturbed metabolic milieu. Handy et al. (2011) suggested that adiponectin 
inhibits the function of leptin by inhibiting leptin-stimulated activation of Jak2, 
and as Jak2 activation represents the most upstream event in leptin signal 
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transduction, this inhibition was suggested to be the basis for the interaction of 
leptin and adiponectin in beta cell function. Research has also shown that 
protein tyrosine phosphatase 1B (PTP1B) dephosphorylates and thus 
deactivates Jak2, acting upstream of Ob-Rb and Stat3 to negatively regulate 
leptin signal transduction. PTP1B is an important inhibitor of leptin signalling in 
the hypothalamus, where PTP1B participates in the control of glucose and fat 
metabolism (Zhu et al., 2008). 
  
Leptin induces expression of Supressors of Cytokine Signaling 3 (SOCS-3), 
which in turn negatively regulates leptin signalling. SOCS-3 inhibits leptin 
signalling by binding Ob-Rb and preventing Jak2 phosphorylation of Stat3, and 
targeting the activated receptor complex for degradation. Adiponectin inhibits 
leptin-stimulated formation of TIMP-1/MMP-1 complexes which stimulate 
fibrinogenesis (Handy et al., 2011). 
 
1.2 Diabetes: Epidemiologic impact of Diabetes 
 
Diabetes affects about 3-5% of the western population, and has been described 
as one of the major health issues of this century (Laakso 2010). In 2001, the 
global estimate of prevalence of people with diabetes was 151 million and this 
number is estimated to have increased to 221 million by 2010 (representing a 
46% increase) (Laakso 2010). More recent statistics put the number of affected 
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individuals with type 2 diabetes worldwide at an estimated 347 million (WHO 
2014 review) almost exceeding the predicted increase to 380 million by 2025 by 
Sicree et al. (2003). Zimmet et al. (2001) further stated that the prevalence of 
type 2 diabetes and obesity continues to increase in both developed and 
developing countries, thus presenting a major public health issue with various 
impacts on varying socio-economic issues. 
 
Reports from the USA estimates that type 2 diabetes affects about 18.2 million 
people with data from studies done showing an increase in the prevalence 
amongst young people (Lin et al., 2004). Also in aboriginal Canadians, type 2 
diabetes mellitus has become an epidemic as the estimated prevalence in this 
population is 3-5 times higher than non-aboriginal Canadians (Ley et al., 2009). 
In the study by Dyck et al. (2010), it was stated also that out of the 1500 first-
nation people that were used for an experiment In Saskatchewan in 1937,  
diabetes was not detected among any of them. This statistic had changed by 
1990, when research showed that almost 10% of the province’s first-nation 
adults had diabetes, and this had increased in 2006, to over 20%, while it 
remained at about 6% in the general population in Canada (Dyke et al 2010). 
 
These statistics beg the question of why the prevalence of diabetes appears to 
be on the increase world-wide. This therefore has led to studies into the 
possible risk factors of diabetes in order to prevent or delay the onset or 
properly manage the increase in the prevalence of diabetes. Traditionally some 
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of the risk factors that have been identified with diabetes are obesity, 
dyslipidemia, hyperglycemia and hypertension (Laakso 2010). 
 
Overall, studies have shown that there is a link between obesity, cardiovascular 
diseases and diabetes (Barnes 2011). Obesity and diabetes mellitus are also 
suggested to be important independent conditions that may increase the risk of 
developing cardiovascular disease while obesity is the leading risk factor for 
Type 2 diabetes (Wang and Nakayama 2010). The Centers for Disease Control 
(CDC) in the United States of America further reported that the risk of 
developing diabetes in obese individuals is 93 times more than individuals with 
normal BMI, if the body mass index (BMI) is 35 kg/m. Data collected in the USA 
in 2007 showed that the national prevalence rates of diabetes had increased in 
parallel with the rates of obesity (Barnes 2011) 
 
Previous studies also show that diabetes prevalence is on the increase in 
Africa, contrary to the belief in the last century that diabetes mellitus is rarely 
found in individuals in Africa. Studies carried out in Europe and America on 
African American, Afro-Caribbean subjects and African migrants in Europe 
showed that these populations had a high prevalence. African immigrants were 
reported to have higher prevalence and complications than the Caucasians 
living within the countries studied (Evaristo-neto et al., 2010). In a study carried 
out in Angola, it was stated that the origin of this increase in prevalence may be 
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due to population growth, aging, urbanization, and increasing prevalence of 
obesity and physical inactivity (Evaristo-neto et al., 2010).  
 
Also, in the USA (Framingham in Massachusetts), a study by Hubert et al. in 
1983 called The Framingham Heart Study (FHS), which was a longitudinal, 
multigenerational cohort study of obesity as the main predicting factor for the 
development of CVD. This study provided evidence which supports the fact that 
changes in the environment, behavior, and life-style of individuals has lead to a 
dramatic change in the incidence and prevalence of obesity in the volunteers 
and the corresponding increase in CVD. The Framingham study showed a 
similarity to statistics that came from the USA (Barnes et al., 2011) and other 
developed countries (Shaw et al., 2006) as it was noted that the prevalence of 
obesity (BMI 30 kg/(m)2) had risen (or is predicted to rise) and is associated not 
only with CVD, but also with diabetes.. 
 
The term diabetes mellitus is described by the WHO report of 1999 as a 
metabolic disorder characterized by chronic hyperglycemia (high blood sugar) 
which results from a deficiency in insulin production alone (type 1 DM)  or in 
combination With a reduction in the sensitivity of target tissues to insulin. This 
report states further that the effects of this reduced availability of insulin results 
in disturbances in the metabolism of carbohydrate, fat and protein (WHO 1999). 
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1.2.1 Classification of diabetes mellitus 
 
The fitting of an individual’s diabetes mellitus into a particular classification is 
difficult as this depends on the circumstances of the individual which can make 
the person fall into more than one class at a time (for example a pregnant 
woman classified as having gestational diabetes can end up having type 2 
diabetes after delivery)(American diabetes association (ADA 2008). Therefore, 
even though it’s important to discuss the classification, it is also important to 
think of the classes in terms of their causes. 
 
The earliest classifications of diabetes mellitus were described in the 1980 and 
1985 classifications by the WHO expert committees. The 1980 classification 
included the classes IDDM (insulin dependent diabetes mellitus) or Type 1, and 
NIDDM (Non-insulin Dependent Diabetes Mellitus) or Type 2 (WHO 1999). 
However in the 1985 classification there was no mention of the Type1 or Type2 
classifications but the classes IDDM and NIDDM were retained. The 1985 
classification also included a class called the Malnutrition-related Diabetes 
Mellitus (MRDM) (WHO 1999) 
 
In addition to these classifications both the 1980 and 1985 reports also included 
other types such as the Impaired Glucose Tolerance (IGT) as well as 
Gestational Diabetes Mellitus (GDM).The 1985 classification was widely 
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accepted and was used internationally because it allowed individual subjects 
and patients to be grouped in a more clinically useful manner even when the 
specific cause was unknown (WHO 1999). 
 
It is however recommended that the ideal classification would encompass the 
clinical and etiological classifications (WHO 1999). The most recent 
classification by the American Diabetes Association recognizes the Type1, 
Type2, Gestational and the "other specific types" of diabetes (Genetic defects, 
Disease of exocrine pancreas, endocrinopathies, drug and chemical related  
gestational DM and infections related) (ADA 2008) 
 
1.2.1.1 The clinical classification of diabetes mellitus 
 
According to WHO (1999), diabetes mellitus can be clinically classified as 
diabetes requiring insulin for survival (equivalent to IDDM), those requiring 
insulin for control (equivalent to the NIDDM), and those that do not require 
insulin for blood glucose control as their blood glucose can be controlled with 
oral hypoglycaemic agents. It is further stated that clinically, the Impaired 
Glucose Tolerance (IGT) or the Impaired Fasting Glucose (IFG) are stages in 
the natural progression of the disorder in carbohydrate metabolism. However 
IGT have been used interchangeably with IGF but were shown not to be the 
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same conditions as IFG is a stage of derangement during fasting, while IGT is a 
stage after eating.  
 
With regards to this, blood glucose was chosen as an objective measure to 
assess diabetes and the parameters used for IFG are; a fasting glucose 
concentration of 6.1 mmol/L (110 mg/dl) or greater (whole blood 5.6 mmol/L; 
100 mg/dl), but less than 7.0 mmol/L (126 mg/dl) (whole blood 6.1 mmol/L ; 110 
mg/dl)  (WHO 1999).  
 
When an Oral Glucose Tolerance Test (OGTT) (75mg of Glucose dissolved in 
300mls of water is taken and blood glucose measured over 2 hours) is 
administered, some individuals with IFG can have results that suggest they 
have IGT or diabetes. Therefore whenever possible it is recommended that 
individuals with IFG have an OGTT to rule out Diabetes (Mayfield 1998). 
 
Reference has also been made to  a transit state of normoglycemia which is a 
clinical state where a patient has a "normal" glucose level with a fasting venous 
plasma glucose concentration of less than 6.1 mmol/l (110 mg/dl) (Mayfield 
1998). This value is seen in individuals who have normal glucose tolerance but 
may have IGT on OGTT (WHO 1999). In this case it was suggested that the 
process that triggers diabetes starts when the individual has normal blood 
glucose. 
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1.2.1.2 The aetiological classification of diabetes mellitus 
 
The aetiological classification is based on processes that may have led to the 
decline in the function of the insulin producing cells or the resistance of insulin 
target tissues to insulin (insulin resistance) (WHO 1999). 
 
Seino et al. (2010) explains that aetiologically, type 1 DM is a type of diabetes 
that is due to the destruction of beta cells which reduces insulin in the blood due 
to inadequate amount of beta cells, thus making the individual dependent on 
insulin for survival. Without supplementing the insulin in these individuals, they 
become prone to comas, ketoacidosis or even death (ADA 2008). The presence 
of anti-GAD (antibodies to Glutamic Acid Decarboxylase), insulin and other islet 
cell antibodies suggest an auto-immune basis to Type 1 diabetes mellitus. In 
the paper produced by the WHO (1999), it was suggested that this auto-
immune process may be slow in some and fast in others, thereby leading to an 
early and late onset in different individuals. When this occurs later than the 
usual onset, it is called the Latent Auto-immune Diabetes in Adults (LADA).  
 
Type 1 diabetes is therefore highest in childhood or in adolescence but can 
occur at any age up to the 9th decade (WHO 1999) and the chances of the 
auto-immune destruction of the Beta cells are genetically pre-determined. 
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The WHO (1999) classification also includes the type 2 (T2DM) aetiological 
classifications which is the commonest and is characterized by poor insulin 
action and secretion. The etiology for the T2DM is unknown but is reported to 
be neither auto-immune nor caused by some specific causes of diabetes such 
as endocrinopathies, drug, infection and diseases of the exocrine pancreas. 
However many studies including that by Karam and McFarlene (2010) have 
shown that people with the type 2 diabetes are usually obese (BMI> 30). The 
risk of developing type 2 diabetes is also said to increase with age, obesity and 
lack of physical activity and said to be strongly associated with genetic links 
(WHO 1999). 
 
Type 2 DM is different from Type 1 as it tends not to present with ketoacidosis 
except in severe infections and insulin levels may be found to be normal or high 
and may remain undiagnosed for many years as the high blood sugar is usually 
not high enough to provoke symptoms of diabetes (Mayfield 1998). 
 
The reference in the present study to diabetes will be mainly to the type 2 
diabetes as this is the most common (90%) (Stumvoll et al., 2005) and reported 
to be most linked to obesity and cardiovascular diseases (Laarkso 2010) which 
are the areas this research is focused on. 
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Studies have shown that the early pathophysiology of type 2 diabetes is 
controversial and uncertain (ADA 2008) and the following sections explore 
further what previous researchers have proposed.  
 
1.2.2 Structure and Chemical Properties of Insulin  
 
Insulin is a polypeptide discovered in 1928 but it was not until 1952 that the 
amino acid sequence was discovered. It was reported that the amino acid 
sequence is arranged into two chains of different amino acid lengths which 
were called the A and B chains (Wilcox 2005). These chains together have 51 
amino acids connected by disulphide bridges, with a molecular weight of 5802 
and an iso-electric point of pH 5.5 (Please refer to figure 1.3). 
 
 Looking more closely at the structure of insulin, figure 1.3.shows that the  A 
chain is made up of 21 amino acids with an N-terminal helix which is connected 
to an anti-parallel C-terminal helix  on the B chain which has 30 amino acids. 
The two chains are connected by 2 disulphide bonds which connect the N and 
C terminal helices of the A chain to the central helix of the B chain. In pro-
insulin, a connecting peptide links the N-terminus of the A chain to the C-
terminus of the B chain (Wilcox 2005). 
 
68 
 
 
Figure 1.3 Figure showing the structure of the insulin. Chain A has 21 
amino acids while chain B has 30.They both have a C and an N terminal that is 
linked by a disulphide bond (Modified from Ball et al., 2011). 
 
1.2.3 How insulin is synthesized and released 
 
The gene that codes for insulin is found on the chromosome 11 (short arm) 
(Owerbach et al., 1981). The process of synthesis of insulin begins by the 
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synthesis of its precursor (pro-insulin) in the β cells which are found in the 
pancreatic islets of Langerhans. Pro-insulin is first formed as pre-proinsulin in 
the ribosome of the rough endoplasmic reticulum (RER). Pre-proinsulin 
however, is synthesized by the formation of a protein which carries out 
signalling and which is linked to the B, C peptide and an A peptide chain. Pro-
insulin is formed from pre-proinsulin by the removal of the protein which carries 
out the signalling from the pre-proinsulin (Wilcox 2005). 
 
The pro-insulin that has been synthesized is then moved within a secretory 
vesicle from the rough endoplasmic reticulum to the Golgi apparatus. Due to the 
high concentration of zinc and calcium in the Golgi apparatus, there is the 
formation of pro-insulin molecules (hexamers) which contain zinc. The immature 
vesicles that are formed are acted on by the enzymes which act outside the 
Golgi therefore releasing insulin and C-peptide from proinsulin. Insulin therefore 
forms insoluble zinc containing hexamers which precipitate as crystals which 
are stable at a pH of 5.5 (Wilcox et al., 2005).  
 
Through exocytosis, equal amounts of insulin and C peptide and secreted 
within the mature granules into the portal vein in a pulsatile pattern (Wilcox et 
al., 2005). Studies have also shown that the secretion of insulin in response to 
glucose stimulus occurs in 2 phases; the first being rapid and the second less 
rapid but more prolonged (Miele 2007). 
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1.2.3.1 Kinetics of Insulin Secretion 
 
This can be described in stages and the first stage is triggered by a rise in blood 
sugar resulting in the secretion of insulin and C peptide from mature granules in 
the β cell. This process is usually mediated by a rise in the blood glucose but 
can be stimulated by other triggers (Rockl et al., 2008). When the circulating 
blood glucose increases, the increase makes it possible for glucose to enter the 
beta cells where glucokinase phosphorylates glucose to glucose-6-phosphate 
using a molecule of adenosine triphosphate (ATP). Glucose-6-phosphate is 
then metabolized further by the TCA and glycolytic pathways leading to ATP 
production. As can be seen in figure 1.2, the production of ATP leads to an 
increase in the ATP/ADP ratio and the closure of KATP thereby leading to the 
depolarization and the activation of the voltage dependent calcium channels 
with an influx of calcium into the cells which triggers insulin secretion in a 
pulsatile manner (Miele 2007). 
 
The second stage begins after the secretory granules have been refilled with 
insulin from the reserve pools. Acetylcholine (Ach) is then seen to stimulate 
phospholipase and protein C activation. Also this stage can be mediated with 
the activation of adenylyl cyclase activity, β cell protein kinase A, which 
encourages insulin secretion. The hormones that mediate the second phase are 
hormones such as vasoactive intestinal peptide (VIP), PACAP (Pituitary 
adenylate cyclase activating polypeptide), GLP-1 (Glucagon-like peptide-1) and 
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GIP (Gastric inhibitory peptide) (these are referred to as “other signals” in figure 
1.2) (Wilcox 2005). 
 
 
Figure 1.4 Figure showing the mechanism of insulin secretion from beta 
cells. The influx of glucose into the cells generate ATP which triggers a 
pathway that closes the potassium (K) channels on the cell membrane and 
therefore causes a depolarization which leads to the calcium channel (Ca) to 
open and an influx of calcium into the cells and a corresponding increase insulin 
secretion. (Modified from Henquin 2000) 
 
1.2.4 Insulin signalling Pathway 
 
After a meal, the carbohydrate component of food is broken down to glucose 
and this is used mainly in the muscles, adipose tissues and the liver. The 
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pathway that controls the movement of glucose between the blood and these 
tissues is called the insulin signalling pathway (Rockl et al., 2008).  
 
As seen in figure 1.5, the pathway begins when there is an increase in the 
blood glucose that supplies the pancreas which results in the beta cells of the 
pancreas releasing insulin into the blood stream and the insulin is carried to the 
tissues where they will be used after binding to the insulin receptors in these 
tissues. The insulin receptor consists of two α subunits and two β subunits that 
are disulfides linked into a α2β2 heterotetrameric complex. The α subunit are 
extracellular and insulin binds to these first. The binding of insulin sends a 
signal that activates the tyrosine kinase unit of the β unit which causes 
intramolecular transphosphorylation in which the β subunit causes 
phosphorylation of adjacent subunits in their tyrosine residues (Saltiel and Kahn 
2001). 
 
The binding of insulin to the receptor increases the affinity of the receptor for a 
protein called insulin receptor substrate 1(IRS-1). The receptor is also 
responsible for the phosphorylation of IRS-1. The phosphorylated IRS-1 then 
phosphorylates phosphatidyl inositol-3 (PI-3) kinase which therefore 
phosphorylates phosphatidyl inositol diphosphate (PIP2) by adding a phosphate 
group to it to form phosphatidyl inositol triphosphate (PIP3). This extra 
phosphate group added creates a binding site for PDK1 which when 
phosphorylated helps to phosphorylate AKT (Stumvoll et al., 2005). 
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AKT (also called protein kinase B-PKB) is the kinase that phosphorylates 
GLUT-4 (Glucose transport protein-4) and helps its translocation to the 
membrane of the cells where it is anchored to the cell membrane and allows the 
diffusion of glucose from the blood into the cell via tubules on the GLUT-
4(Wilcox 2005) 
Insulin
Ins Receptor 
PI3K 
PIP3 
Akt
IRS 
GLUT 4
Glucose 
Uptake
GYS
GSK-3β
Glycogen 
Synthesis
PP1
PDK 1/2 
Insulin Secretion
PKC
SREBP-1C
A
M
P
K
ACC
Lipogenesis
MEKRas/Raf ERK
Proliferation
Glycolysis and Lipolysis
MTOR
Protein 
Synthesis
S6
 
Figure 1.5 Figure showing the insulin signalling pathway. Insulin goes 
through IRS, PI3K, Akt to influence GLUT4 which translocates to the cell 
membrane and allows glucose to go into cells. (Modified from Kanehisa 
laboratories 2013). 
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1.2.4.1 Insulin Receptors and Insulin Binding  
 
In order to carry out its effects, insulin binds to a receptor which consist of 2 α 
and 2 β glycoprotein subunits which are found on the cell membrane and are 
connected by disulphide bonds (Saltiel and Kahn 2001). 
 
The gene that codes for the insulin receptor is found on the short arm of 
chromosome 19 (Wilcox 2005) and once insulin binds to the α subunit, the 
effect inhibits the kinase activity in the β subunit leading to a conformational 
change which makes it possible for ATP to bind the intracellular β subunit part 
of the receptor and carry out phosphorylation (Wilcox 2005). The binding of ATP 
stimulates the phosphorylation of the β subunit which gives it tyrosine kinase 
activity. This is followed by tyrosine kinase phosphorylation of intracellular cell 
proteins called Insulin Responsive Substrates (IRS). The IRS then binds other 
molecules that mediate various signal pathways which mediate the function of 
insulin (Hotamismigil et al., 1996). 
 
The insulin receptor substrate (IRS) has been classified into 4 types; IRS 
1,2,3,4 (Saltiel and Khan 2001). IRS 1 is the substrate responsible for the 
mitogenic effects of insulin in skeletal muscles and acts as a link between the 
sensing of glucose and insulin secretion. In order to function, IRS 1 needs to be 
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phosphorylated by the insulin receptor and insulin-like growth factor 1 receptor 
(IGF-1) (Wilcox 2005). 
 
The IRS 2 helps to mediate the actions of insulin at target sites and also 
mediates the growth of pancreatic β cells. The IRS 2 is mainly found in the liver 
(Wilcox 2009). IRS 3 is found mainly in the adipose tissue, pancreatic β cells 
and liver while the IRS 4 is majorly found in the thymus, brain and kidney 
(Saltiel and Kahn 2001). The function of IRS 3 and 4 are not well defined 
(Wilcox 2005). 
 
The pathway by which insulin influences metabolism in the human body 
involves the use of IRS. Insulin stimulates the receptors which use IRS as 
substates within the cell and the binding of the phosphorylated IRS to 
phosphatidylinositol-3 kinase (PI-3K) (which acts on Akt and protein kinase B 
(PKB) leading to the translocation of the glucose transporter proteins (GLUT4) 
to the cell wall) allows the uptake of glucose into the cells. Also phosphorylated 
IRS bound to PI-3 kinase acts on protein kinase C (PKC) and PI dependent 
protein kinases1 and 2 (PIPK 1 and 2) leading to  the conversion of glucose to  
glycogen and also prevents the breakdown of lipid and helps to synthesize  
protein and the regulation of hepatic gluconeogenesis (Wilcox 2005).  
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Insulin functions mainly in the mediation of the uptake of glucose by various 
tissues but it also encourages the uptake of other food nutrients such as protein 
and fat. After a meal, the glucose level in the vein that leaves the intestine is 
elevated as there is absorption of glucose. A third of this glucose is absorbed 
into the liver and the rest is used for the metabolic function of the body. The rise 
in blood sugar leads to a corresponding increase in insulin synthesis by the 
pancreas. The presence of insulin therefore makes it possible for skeletal 
muscles to make use of glucose. Insulin influences the metabolism of 
carbohydrate, lipid, and protein and is seen to influence the transcription and 
translation process of the messenger ribonucleic acid (mRNA) (Wilcox 2005). 
 
1.2.4.2 Insulin Receptor substrate-1 (IRS)-1 and 2  
 
The first major receptor substrate for insulin receptors and the IGF-1(Insulin-like 
growth factor 1) receptor tyrosine kinases to be identified is the Insulin Receptor 
Substrate (IRS)-1. In the earlier report by Sun et al. in 1991, it was reported that 
insulin carries out its function by binding to the alpha subunit of the insulin 
receptor, resulting to the stimulation of the beta subunit of the receptor to cause 
a tyrosine phosphorylation of the proteins within the cells. The first protein that 
was discovered was called the Insulin Receptor Substrate 1(IRS-1). 
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Other studies carried out on cells have shown that many of the responses to the 
effect of insulin are mediated by counter-regulatory hormones and pro-
inflammatory cytokines via the effect of Tyrosine and Serine which 
phosphorylates insulin receptor substrate 1 and 2. (IRS-1,2) (Lin et al., 2004) 
 
Glucose tolerance was also noted to have been impaired by the dysregulation 
of these IRS proteins by pro-inflammatory cytokines or genetic deletion which 
leads to insulin resistance (Lin et al., 2004). Furthermore, the deficiency of IRS-
2 was found to lead to life threatening type-2 diabetes due to its role in cell 
growth, function and survival. This is further evidenced by the fact that the 
progression to a state of type-2 diabetes was found to be prevented by 
modifying elements of the insulin/IGF-signaling cascade that promote 
compensatory cell function (Lin et al., 2004). 
 
Kubota et al. (2000) investigated the role of the IRS in the execution of insulin’s 
function and it was discovered that homozygous IRS-1 deficient mice were 
deficient in embryonic and post natal growth, therefore suggesting that the IRS-
1 is critical in the growth promoting function seen in insulin and IGF. Also in this 
study, resistance to the effect of insulin and IGF in lowering blood glucose was 
suggested as a basis for insulin resistance in diabetes. In spite of all these, it 
was realised that the mice maintained a normal fasting glucose which is 
ascribed to compensatory beta cell hyperplasia. It was therefore suggested that 
the signal transduction in insulin and IGF can be IRS-1 dependent and also be 
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IRS-1 independent. This IRS-1 independent transduction pathway was later 
identified to be mediated by an alternative substrate in the liver which was 
named IRS-2 by Kahn’s group (Kubota et al., 2000).  
 
Another line of research uncovered a protein called pp-190 which is a protein 
with molecular weight of 190kDa protein first discovered in a study on rats 
which were IRS deficient. It was reported to be located in the liver of the rats 
and has now been identified as IRS-2 (Lin et al 2004). It was suggested that 
this protein is responsible for the tyrosine phosphorylation by insulin and that 
this molecule has the capacity to bind both 85-kDa subunit of 
phosphatidylinositol (PI) 3-kinase (Kubota et al., 2000). In the study by Kubota 
et al. (2000) it was also noted that there was a corresponding amount of 
tyrosine phosphorylation of IRS-2 in the liver of IRS-1 deficient mice when 
compared to tyrosine phosphorylation of IRS-1 seen in wild-type mice thereby 
compensating fully for the effect of IRS-1 deficiency in the normal actions of 
insulin. Furthermore, the activation of PI 3-kinase stimulated by insulin was 
noted to be normal in the liver of IRS-1 deficient mice which had a defective PI-
3 activation in the skeletal muscle. This was attributed to a reduction in the 
tyrosine phosphorylation of IRS-2 compared with IRS-1 in wild type mice further 
suggesting the possible importance of IRS-2 in the functions of insulin 
especially in the liver (Lin et al., 2004). 
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1.2.4.3 Protein phosphatase (PP-1) expression in beta cells 
 
Figure 1.1 shows that leptin binds to its receptor and activates the ObR-
associated JAK2 tyrosine kinase via transphosphorylation. This process 
phosphorylates tyrosine residues of ObR and the phosphorylated STATs 
dimerize and translocate to the nucleus to regulate gene transcription (Marroqui 
et al., 2012). STAT is said to affect the expression of the catalytic subunit 
Ppp1ca of PP-1 due to the influence of leptin signalling resulting in a decrease 
in the expression of PP-1 gene which leads to reduced PP-1 enzyme activity 
and a subsequent reduction of intracellular calcium concentrations (Seufert 
2004). Previous research has shown that insulin secretion is inhibited by 
reduced intracellular calcium in pancreatic cells (Saltiel and Kahn 2001). 
Therefore the suggestion in the report by Kuehnen et al. (2011) that leptin 
reduces the generation of the mRNA for the Protein phosphatase (PP-1) gene 
and the protein that it codes for can be explained by the fact that the insulin 
secretion stimulated by glucose is inhibited by nuclear inhibitor of PP-1, which 
subsequently leads to reduced PP1 in the cytosol and then a reduction of 
calcium influx which is normally stimulated by the presence of PP-1. Therefore 
in the present study, beta cells will be treated with a range of concentrations of 
leptin at various glucose levels. The cells will be collected, mRNA extracted 
from them and reverse transcription PCR done to assess the effect of leptin on 
the expression of PP1A gene.  
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1.2.5 Insulin and the uptake and use of nutrients 
1.2.5.1 Insulin and the uptake and use of carbohydrate 
 
The process of carbohydrate metabolism is highly influenced by the effect of 
insulin. Insulin helps to move glucose into fat and muscle cells as a result of its 
effect on GLUT 4 translocation (Saltiel and Kahn2001).  
 
As can be seen in figure 1.5, insulin facilitates the synthesis and storage of 
glycogen by increasing the uptake of glucose into the liver and the mediation of 
glycogen synthesis in the body. The accumulation of glycogen starts when 
insulin stimulates the dephosphorylation of the glycogen synthetase by 
inhibiting kinases such as protein kinase A (PKA) and the stimulation of protein 
phosphatase 1 (leptin inhibits this and therefore leads to the inhibition of 
glycogen synthesis) (Saltiel and Kahn 2001). This further leads to activation of 
Akt and a reduction of the phosphorylation of glycogen synthetase and an 
increase in its activity. 
  
In the liver, however, insulin blocks gluconeogenesis and glycogenolysis 
thereby causing an inhibition of glucose synthesis in the liver. Insulin is said to 
have its influence in the body by either phosphorylation or dephosphorylation or 
the regulation of genes that code for some of the substrates and enzymes 
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which are responsible for glycolysis and gluconeogenesis. Insulin is able to 
inhibit gluconeogenesis by inhibiting the gene that codes for 
phosphoenolpyruvate carboxylase which is the enzyme responsible for carrying 
out the most critical step in gluconeogenesis. (Saltiel and Kahn 2001) 
 
When there is need for energy, however, insulin causes pyruvate kinase 
dephosphorylation leading to the stimulation of glycolysis and the inhibition of 
gluconeogenesis by the dephosphorylation of 2,6 biphosphate kinase, thus 
making more glucose available for use to generate energy. Also, intracellular 
energy abundance results in the activation by insulin, of intra-mitochondrial 
pyruvate dehydrogenase. This however leads to an irreversible conversion of 
pyruvate to acetyl co-A, which is oxidised by the Krebs cycle in the synthesis of 
fatty acid (Wilcox 2005). 
 
1.2.5.2 Insulin and the use and uptake of lipids and fat 
 
Insulin helps to mediate the uptake and utilization of lipid and fat in various 
target tissues. Some of these tissues are the adipose tissue, the liver and 
lactating mammary glands. Insulin also helps in the formation and storage of 
triglycerides in adipose tissue (Wilcox 2005). Just like its effect on carbohydrate, 
it encourages the production of lipids and reduces their breakdown. 
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Insulin mediates the synthesis of triglycerides via a process which involves the 
esterification of glycerol phosphate, but the suppression of the breakdown of fat 
by oxidation occurs when insulin inhibits carnitine acyl transferase and also via 
the dephosphorylation of the hormone sensitive lipase which helps to break 
down triglycerides (Wilcox 2005). Insulin inhibits the activity of the lipase 
primarily through reductions in cAMP levels, owing to the activation of a cAMP-
specific phosphodiesterase in fat cells (Saltiel and Kahn 2001).  
 
An alternative method for the control of metabolism of lipids by insulin is seen 
when we consider the effect of insulin on carbohydrate metabolism. Therefore 
in the fat cells, when there is an excess of glucose, insulin mediates the 
conversion to lipids via the activation of lipid synthetic enzymes, including 
pyruvate dehydrogenase, fatty acid synthase and acetyl-CoA carboxylase (ACC 
as seen in figure 1.5) (Saltiel and Kahn 2001).  
 
Insulin also regulates the uptake and metabolism of cholesterol by activating 
and dephosphorylation and activation of HMG Co-A reductase. The breakdown 
of cholesterol ester is however inhibited by the inhibition of cholesterol esterase 
by insulin (Wilcox 2005). 
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1.2.5.3 Insulin and the uptake and use of protein 
 
Insulin functions as a mediator in the synthesis of protein. The protein synthesis 
action of insulin is seen in many target tissues and is intracellular in nature. 
Furthermore, insulin helps in the protein synthesis process by transcription of 
specific mRNA and the translation of these mRNA into protein intracellularly, a 
process which is carried out in the ribosomes. Examples include mRNA 
transcription for fatty acid synthetase protein kinases and glucokinase (Wilcox 
2005). 
 
Protein is made up of amino acids and the amount of protein in the body is a 
reflection of the amount of amino acids present. The total amount of amino 
acids left in the body is a balance between the amount taken in and the amount 
removed and these processes are influenced by the use in protein synthesis, 
amino acids that come out of tissues after tissue breakdown and oxidation in 
the body. The effect of insulin on protein metabolism involves a reduction in 
plasma amino acids, an effect which is most marked for the branched-chain 
amino acids (BCAA)' and minimal for alanine (Fukagawa et al., 1985). 
 
 The effect of insulin on transcription is also seen in albumin synthesis which 
occurs in the liver, the pyruvate carboxylase process in the adipose tissues, 
casein synthesis in the mammary glands and amylase in the pancreas. 
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However, insulin action may reduce mRNA synthesis for enzymes in the liver 
such as carbomyl phosphate synthetase which is one of the enzymes that 
influences the urea cycle (Wilcox 2005). It was also stated by Wilcox (2005) that 
insulins’ effects on translation are seen in many tissues and insulin works by 
itself and in partnership with growth factors such as Insulin Growth Factor 1.  
 
1.2.6 Role of insulin in energy homeostasis. 
 
Most cells in the body utilize glucose for metabolism. This therefore suggests 
how useful insulin is as a result of the fact that insulin is very important in 
mediating the regulation of cellular energy and macronutrient balance. With 
regards to metabolism, insulin helps to maintain homeostasis of energy by 
suppressing the breakdown of adipose tissue when there is abundance of 
energy and allowing glucose to enter cells and in the muscles, the entry of 
glucose into the cells enables the synthesis and storage of glycogen. Glycogen 
forms a reserve of energy for the body when it is in a condition where the 
immediate energy supply is inadequate (fasting or exercise). If in this case the 
glycogen store is used up and there is still no supply of energy, then the body 
uses amino acids or fatty acids (Stumvoll et al., 2005).  
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1.2.7 Pathophysiology of diabetes mellitus 
1.2.7.1 Genetic basis of diabetes mellitus 
 
The process of developing type 2 diabetes is typified by 2 main factors; 
resistance to insulin in tissues like muscle and liver and also a dysfunction of 
insulin secretion. Previous researchers have however not been able to find out 
if only one genetic defect causes the dysfunction in insulin function and 
secretion at the same time, in the common forms of human diabetes. Studies 
have reported that type 2 DM is polygenic (Sacks and McDonald 1996). This 
has led to further work being done on the genetic and molecular basis of 
diabetes (Vigliotta et al., 2004). 
 
Data gathered over the years have suggested that type2 DM has a genetic link. 
Studies have shown that the presence of a family history gives a 2-4 fold 
increase in the chances of developing type 2 DM. Also it has been reported that 
15-25% of the individuals who are first-degree relatives of patients with type 2 
DM may develop impaired glucose tolerance or diabetes. Also, it was 
suggested that the lifetime chance of developing T2DM at the age of 80 years is 
about 38% if there is a history of one parent having T2DM. Also it has been 
shown that there is a 60% chance of developing T2DM at age 60yrs, in 
offsprings of patients with T2DM, if  both  parents  are  affected (Stumvoll et al., 
2005). 
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Stumvoll et al. (2005)  also suggested that the result of research on twins 
showed that concordance rates for type 2 DM were 35-58% in  monozygotic 
compared to 17-20% in dizygotic individuals older than 60 years, and that when 
impaired  glucose tolerance  was considered, concordance  in monozygotic  
twins was markedly increased to 88%. 
 
Recent research has suggested the involvement of PED/PEA-15 which is a 
mitogen signaling protein and found to be increased in diabetic patients. It was 
suggested that PED/PEA-15 expression leads to the inhibition of the transport 
of GLUT 4 to the membrane for glucose transport thereby leading to insulin 
resistance. Also, insulin receptor substrate 1 (IRS-1) and protein phosphate 
1(PP-1) gene expression have been suggested to be involved as stated in the 
appropriate sections above (Vigliotta et al 2004). 
 
1.2.7.2 Insulin derangements as a basis of diabetes mellitus 
 
Insulin is described by Wilcox (2005) to be a protein hormone which maintains 
normal blood glucose levels by mediating cellular glucose uptake, the 
metabolism of carbohydrate, lipid and protein metabolism, and promoting cell 
division and growth through its mitogenic effects. Insulin is secreted by the β 
cells of the islets of Langerhans in the pancreas.  
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1.2.7.3 Insulin Resistance 
                     
Insulin resistance is a condition in which the insulin mediated glucose uptake 
effect seen is less than that expected for glucose uptake in skeletal muscles 
and also for the suppression of glucose production within the liver (Strumvoll et 
al., 2004). Insulin is responsible for the uptake of glucose in the skeletal 
muscles and the suppression of glucose synthesis by the liver and fatty acids by 
adipose tissue. In type 2 diabetes, endogenous glucose production and fatty 
acid production are increased, while there is a reduction of glucose uptake by 
the skeletal muscle. Due to an increase in blood glucose despite 
hyperinsulinemia, especially in the early stages of T2DM and in impaired fasting 
glucose, the resistance to insulin in the liver is reported to be responsible for 
hyperglycemia in T2DM (Strumvoll et al., 2004). The greatest effect of insulin 
resistance is seen in the skeletal muscle and most tissues in the periphery. 
Insulin resistance typifies the type 2 diabetes mellitus (Wilcox 2005). 
 
Insulin is the main hormone which affects many anabolic processes in the body 
and together with other hormones such as growth hormone and Insulin-like 
Growth Factor (IGF-1), insulin is able to effectively regulate the metabolic 
processes in the human body. Growth hormone which is responsible for growth 
is secreted as a result of the stimulus by insulin when there is a high level of 
insulin to stop insulin from reducing glucose below the normal level, thereby 
ensuring a steady level of blood sugar (Wilcox 2005).  
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There are other hormones that oppose the effect of insulin some of which are 
glucagon, glucocorticoids and catecholamines. These counter-regulatory 
hormones support metabolism in the body in the fasting condition as seen in the 
action of glucagon in glycogenolysis, gluconeogenesis and ketogenesis in 
fasting states. Catecholamines may also encourage lipolysis while 
glucocorticoids encourage glycogenolysis, lipolysis and catabolism. When these 
counter-regulatory hormones are secreted in excess they may lead to insulin 
resistance, but this process is not thought to be responsible for most of the 
insulin resistance states (Wilcox 2005). Further studies have shown that the 
resistance to insulin occurs at the level of the cells and that the mechanism 
responsible for insulin resistance at the cellular level is one of post-receptor 
defects in insulin signalling. Some of the mechanisms include the down-
regulation of receptors, lipotoxicity, gene deficiencies or genetic polymorphisms 
affecting tyrosine phosphorylation of the receptors for insulin sensitivity, IRS 
proteins or kinases of PIP-3 (Phosphatidylinositol (3,4,5)-trisphosphate) and 
derangements of GLUT 4 function (Abdul-Ghani et al., 2007, Abdul-Ghani and 
Defronzo 2009, Wilcox 2005). 
 
Insulin influences the metabolism of various tissues and as the effect of insulin 
varies with the different tissue function. Furthermore, the mechanisms 
responsible for insulin resistance in target tissues also vary. In order to shed 
more light on this, the mechanism and effect of insulin resistance has been 
investigated and will be discussed in the following sections. 
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1.3 Cardiovascular diseases 
 
Cardiovascular disease is defined by Fuster and Kelly (2010) as a condition that 
is made up of cardiac disease, vascular diseases of the brain and kidney, and 
peripheral vascular disease. 
 
1.3.1 Epidemiology of cardiovascular Diseases 
 
Cardiovascular disease has been suggested to be a problem of the very 
developed nations but recent data from the  WHO in 2008 (WHO 2008) shows 
that nearly 30 percent of all deaths in low and middle income countries are 
attributable to CVD, and more than 80 percent of CVD-related deaths worldwide 
now occur in low and middle income countries. 
 
Studies have shown that by 2005, the total number of cardiovascular disease 
(CVD) deaths (mainly coronary heart disease, stroke, and rheumatic heart 
disease) had increased globally to 17.5 million from 14.4 million in 1990 (Fuster 
and Kelly 2010). When considered closely, coronary artery disease was found 
to be responsible for, 7.6 million while stroke accounted for 5.7 million. Further 
studies have shown that of these deaths, more than 80 percent of the deaths 
occurred in low and middle income countries. Considering  these statistics, the 
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World Health Organization (WHO 2008) estimates there will be about 20 million 
CVD deaths in 2015, accounting for about 30 percent of all deaths worldwide 
(WHO, 2005). Projections made, based on the trends, suggest that CVD 
mortality, will over the next few decades be responsible for more deaths than 
infectious and other chronic diseases, and that by 2030,  diseases that are 
communicable will account for less than one-quarter of the mortalities  
worldwide (Fuster and Kelly 2010). Thus, CVD is expected to be the highest 
contributor to global mortality (WHO, 2009b). 
 
Turning to Europe it is estimated that cardiovascular diseases contribute to 
about 40% of the mortality rate for the population across all causes. When the 
various causes of CVD are considered, coronary heart disease and stroke were 
suggested to be the most important (Khromhout 2001). Data collected from 
previous studies shows that coronary heart disease contributes about 50% to 
total cardiovascular diseases and stroke about 25% in Europe (Khromhout 
2001). Data from the USA suggest that CVD was responsible for a mortality of 
36% of all deaths in 2004. 
 
 
 
 
91 
 
1.3.2 Pathophysiology of cardiovascular diseases in the blood 
Vessels 
 
 Data from previous studies have shown that about 45% of the cases of CVD 
were due to coronary heart disease while about 30% were due to Stroke (Fuster 
and Kelly 2010). This suggest that majority of the pathology in CVD is in the 
arteries. The arteries are lined by endothelial cells and one of the pathogenic 
factors in CVD is endothelial cell dysfunction which has various pathways (Libby 
and Theroux 2005). 
 
Previous studies have looked into and have described the normal function of 
the endothelial cells. It was suggested that the endothelium maintains the 
normal homeostasis of the vessel by producing extracellular matrix components 
like collagen, mediators of regulatory processes such as nitric oxide (NO), , 
endothelin-1 (ET-1), ) Von Willebrand factor (VWF) angiotensin II (ANG-II), 
tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-
1), prostanoids (prostacycline, adhesion molecules and cytokines, the most 
important of which is Tumor Necrosis Factor (TNF)(Ambrose and Barua 2004 , 
Barrett et al 2010).  
 
In its role in sustaining the integrity of the vascular wall, fibrinolysis is controlled 
by the endothelium when it produces tissue plasminogen activator (t-PA) and 
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Plasminogen activator inhibitor 1 (PAI-1) which inhibits it. The endothelium also 
influences the function of heparin sulphate/antithrombin, 
thrombomodulin/protein C and tissue factor/tissue factor inhibitor interactions, 
which limit the coagulation cascade (Barrett et al., 2010). In addition to this the 
endothelium influences vascular remodelling by a process that involves the 
release of factors that promote or inhibit the growth and differentiation of the 
blood vessels such as TIMPs and MMPs, platelet-derived growth factor (PDGF) 
and angiotensin II (ANG II). The repair and maintenance of the extracellular 
matrix in the blood vessels is dependent on a balance between MMPs which 
break down the ECM and the TIMP that inhibits MMPs (Libby and Theroux 
2005). 
   
Any deviations in the normal functions of the endothelial cells, therefore leads to 
cardiovascular diseases. In normal physiological situations the production of 
factors that relaxes the endothelium such as nitric oxide (NO) and prostacyclin 
(PGI2), and factors that mediate contraction such as endothelin-1 (ET-1), 
prostaglandins, and angiotensin II (ANG-II) are held at a balance which may be 
affected by risk factors for CVD, thus initiating the process that may result in 
atherosclerosis (Feldman et al., 2000). 
 
There are factors that prevent inflammation in the blood vessels.  NO (Nitric 
Oxide) inhibits the adhesion of leucocytes as well as VCAM expression that is 
cytokine-induced. NO carries out the anti-inflammatory function by the inhibition 
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of transcription factor nuclear factor κB (NF-κB). NO production is diminished in 
cells which are subject to oxidative stress. When there is an increase in oxidant 
generation, a failure to repair oxidative damage or a decrease in antioxidant 
production, there is oxidative stress. The cause of the cells death is said to be a 
reactive oxygen species (ROS). When there is oxidative stress, cells that 
scavenge for damaged cells and mediate inflammation are not able to function 
due to the amount of ROS. Some of the risk factors that have been linked with 
oxidative stress are insulin resistance, dyslipidemia, inflammation, and also 
cigarette smoking (Stapleton et al., 2008). 
 
When insulin binds to the insulin receptor, it stimulates the phosphatidyl-inositol 
pathway (PI-3) which results in the activation of Akt which stimulates both the 
GLUT-4 activation and uptake of glucose in skeletal muscles and the eNOS 
endothelial pathway which stimulates the production of Nitrogen Oxide (NO) 
that is responsible for mediating the relaxation of blood vessels. The other half 
of the insulin signalling pathway also influences endothelial cells via the 
Shc/Ras/ mitogen-activated protein (MAP) kinase pathway which leads to the 
synthesis of endothelin-1 (causes vasoconstriction) and VCAM which 
encourages smooth muscle migration and mitogenesis in endothelium leading 
to angiogenesis (Laakso 2010). 
 
When there is a pathway-specific impairment in the PI 3-kinase dependent 
pathway, insults such as proinflammatory cytokines (tumor necrosis Factor 
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TNF, interleukin (IL)-1, IL-6, and other proteins such as C-reactive protein 
(CRP)), which may cause an imbalance between production of NO and glucose 
uptake in the endothelium and, this may result in insulin resistance and 
endothelial dysfunction. The resulting hyperglycemia further leads to an 
inhibition of NO production. The reduction in NO production together with an 
elevation of FFA levels due to impairment in insulin’s antilipolytic effect causes 
an increase in the reactive specie production which further contributes to the 
decrease in the synthesis of NOs (Laarkso 2010). Hyperglycemia has also been 
linked to an increase in the production of endothelin -1 which leads to 
vasoconstriction. As a result of all these processes mentioned, it has been 
suggested that abnormal smooth muscle cell function may be caused by 
diabetes as a result of an impairment of  NO mediated vasodilation, increased 
levels of endothelin-1, angiotensin II, and plasminogen activator inhibitor 1 (PAI-
1). This suggests that hyperglycemia causes a further down-regulation of the PI 
3-kinase pathway and that there is further up-regulation of the Shc/Ras/MAP-
kinase in the pre-diabetic state, thus demonstrating diabetes as a pathway for 
the development of CVD (Strienstra et al., 2007). 
 
1.3.3 Specific genes of interest in atherosclerosis and 
angiogenesis 
 
Angiogenesis and atherosclerosis account for most of the pathogenesis of CVD 
(Lip 2004). Angiogenesis which is the formation of new blood vessels is linked 
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to atherosclerosis (formation of an atheromatous plaque in the blood vessels or 
heart) and both form most of the basis for CVD (Nagase et al., 2006). Previous 
studies suggest that CVD occurs when there is a derangement in the balance in 
the remodelling process carried out by matrix metalloproteinases (MMP) which 
break down excess tissues formed when blood vessels are repaired and the 
tissue inhibitor of metalloproteinases (TIMPs) which inhibit MMPS, thereby 
ensuring just enough tissue formation in injuries and inflammatory processes 
within the blood vessels (can also lead to excess accumulation of collagen or 
extracellular matrix if there is an expression in higher than normal amounts 
(Hemmann et al., 2007). It is important to note that TIMP in practical terms act 
as a balance to MMPs and TIMP can predispose to CVD (atherosclerosis) if 
there is over-expression without a corresponding amount of MMPs to inhibit, 
while the MMPs can result in angiogenesis and excess expression can lead to 
weakening of blood vessels, and over stimulation of the migration of smooth 
muscle cells and macrophage activation leading to an atheromatous plaque 
(Dollery et al., 1995). 
 
There are 3 angiogenic genes of interest which are MMP2, TIMP2, and TIMP3. 
MMP2 is a metalloproteinases that is found on the endothelial cell surface and 
carries out the function of extracellular matrix turnover by regulating the cell-
ECM interactions (Park et al., 2001). TIMP2 binds to it to form a ternary 
complex thereby inhibiting its function in the body (Stetler-Stevenson et al., 
1989). Metabolic syndrome has been associated with increased levels of 
expression of MMP2 genes (Hopps and Caimi, 2012). Studies have shown 
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raised levels of MMP2 in obese rats in contrast to some studies that have 
shown lower levels of MMP2 in obese individuals than lean (human). Diabetics 
are reported to express MMP2 more in the endothelial cells and monocytes in 
high glucose situations. Also, a higher MMP2 activity has been found in 
hypertensive patients and in dyslipidemic patients (Hopps and Caimi, 2012). 
MMP2 is reported to be linked with cardiac rupture and aortic aneurysms as it is 
said to break down elastin, type IV collagen and other ECM molecules (digests 
collagen I, II, III and intracellularly digest troponin, myosin light chain and poly 
(ADP-ribose) polymerase in cardiac cells (Nagase et al., 2006).  MMP2 gene 
expression is said to be inhibited by adiponectin and expression increased by 
leptin (Madani et al., 2006). 
 
TIMP2 inhibits the actions of MMP2 and leptin increases the expression of 
TIMP2 in endothelial cells (Park et al., 2001). TIMP2 is suggested to be linked 
to human obesity and diabetes complications. It is said to suppress the 
multiplication of endothelial cells by inducing gene expression which promotes 
the G (1) arrest in the cell cycle and inhibits cell migration (Minchenko et al 
2013). Leptin has been found to increase the expression of TIMP2 (Park et al., 
2004) while Chen et al. (2012) and Kim et al. (2009) suggests that adiponectin 
increases TIMP2 gene expression. 
 
TIMP3 is thought to be the only metalloproteinase inhibitor that targets the 
effect of MMPs in the extracellular matrix (ECM) and it was suggested that a 
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polymorphism of TIMP3 is associated with hypertension and a lack of TIMP3 
leads to suppressed hypertensive response to angiotensin II (Basu et al., 2013). 
 
Furthermore, it is important to look at the other basis of the pathogenesis of 
CVD which is atherosclerosis. Atherosclerosis is a process that involves 
formation of an atheromatous plaque which results from injuries to the 
vasculature lining. This injury causes the release of cytokines that attract 
platelets, monocytes (which LPA converts to foam cells), smooth muscle cells 
and endothelial cells (influenced by TIMP) and fats cells (influenced by LPL). 
Therefore angiogenesis also contributes to atherosclerosis. 
 
Lipoprotein lipase (LPL) can be produced from the vessel wall (macrophages 
within plaques) or from the plasma (from adipose cells and muscles cells). The 
vessel wall LPL is reported to cause an increase in the risk of atherosclerosis 
while the plasma LPL decreases the risk of atherosclerosis (Mead and Ramji., 
2002). Also, LPL is reported to promote the retention of lipoproteins in the sub-
endothelial space thereby favouring the adhesion of monocytes to the 
endothelium and it is also reported to mediate the conversion of macrophages 
into foam cells and to stimulate the process that leads to production of 
proinflammatory cytokines, and the proliferation of smooth muscle cells which 
all predispose to atherosclerosis (Maingrette and Renier 2003). Leptin is 
thought to encourage atherosclerosis by increasing the effect of the vessel wall 
LPL from macrophages. Most of the previous studies were unable to show the 
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expression of the LPL gene in endothelial cells and have suggested that the 
tissues that are responsible for the synthesis of LPL are the adipocytes, 
muscles cells, liver cells or macrophages (Hirata et al., 1999). 
 
Lipoprotein-a (LPA) is a protein molecule made up of LDA (an LDL like protein) 
and apolipoprotein. LPA is said to be pro-atherosclerotic because it causes 
accumulation of fibrin as a result of the inhibition of the activation of 
plasminogen to plasmin (which breaks down fibrin in blood clots), thus leading 
to the accumulation of blood clots (Buechler et al., 2001).  
 
1.3.4 Pathophysiology of CVD in the heart 
 
The tumour necrosis factor (TNF) is an important cytokine in the process of 
developing CVD in the heart. In its normal function, some researchers have 
shown that TNF-alpha can have a paradoxical effect as it can stimulate tissue 
building by increasing fibroblast and mesenchymal cell proliferation and the 
stimulation of growth factors such as vascular endothelial growth factor (VEGF) 
(Trayhurn and Wood 2004). On the other hand TNF-alpha can also cause the 
destruction of tissues of the heart by the release of collagenases such as MMPs 
and can cause the inhibition of the synthesis of their inhibitors (TIMPs). TNF 
alpha when expressed in large amounts greater than the TNF receptors 
available, as seen in inflammatory conditions, can result in the destruction of 
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heart tissues and hypertension which may eventually lead to damage to the 
heart by increasing the adhesion molecule expression and increasing 
scavenger receptor class A and the uptake of oxidized LDL by macrophages 
thereby stimulating their infiltration of the cardiac vessel walls (Balistreri et al., 
2010). Nagase et al. (2006) also suggest that an imbalance in the levels of 
TIMP and MMPs can lead to excessive damage to the collagen tissues and 
therefore ballooning of the heart which may lead to a rupture of the heart. 
 
The inflammation mediated by TNF alpha has been shown by previous studies 
to be due to the stimulation of chemotaxis of macrophages and neutrophils and 
the promotion of their phagocytic and cytotoxic influence. Also it is said to 
promote the collection of white blood cells by inducing increased expression of 
intracellular adhesion molecules (ICAMS) and endothelial leukocyte adhesion 
molecules (ELAMS) at sites of inflammation. The inflammatory condition is said 
to encourage the development of atheromatous plaques which may obstruct the 
coronary vessels and damage the heart (as a result of angina or myocardial 
infarction) (Libby and Theroux 2005).  
 
TNF alpha also causes cell death and this is said to be due to various 
mechanisms some of which are the release of oxygen free radicals, nitric oxide, 
protein kinases, transcription of a variety of cytotoxic genes, regulation of 
nuclear regulatory factors and DNA fragmentation (Feldman et al. 2000). 
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1.4 Recent controversies  
 
A lot of studies have been done on the effect of leptin and adiponectin in the 
development of diabetes and CVD. Adiponectin has been widely reported to 
reduce the risk of developing CVD and T2DM (Kim et al., 2009, Nakasone et 
al., 2013, Chen et al., 2012 and Zhu et al., 2008)  but some of the studies done 
recently do not completely agree and this also forms a basis for carrying out the 
present study. It has been suggested in an in-vivo study that high levels of 
adiponectin correlated well and was very predictive of CVD. Also it has been 
shown that Simvastatin which is a medication that lowers plasma lipid levels, 
improved endothelium dependent vasodilatation and reduces levels of 
adiponectin and these differences have been explained by the variations in the 
characteristics of the populations which have been targeted (Koh et al 2010). 
Also some of the studies have shown that adiponectin levels are elevated in 
correspondence to the increase in inflammatory factors observed in chronic 
inflammatory states and states linked to auto-immunity such as type 1 diabetes, 
systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel 
disease, this suggesting that adiponectin may be involved in the increases in 
chronic inflammation or at least does not influence or reduce it in any way in 
obesity. It has been suggested that adiponectin may confer protection in 
inflammation when adipose tissue is lost in starvation and fasting, but not in 
inflammation unassociated with obesity (Aprahamian and Sam 2011). 
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1.5 Research gap, questions, aims and objectives 
 
1.5.1 Aims of the study 
 
The study aimed to establish more precisely what effect various concentrations 
of adipokines (such as leptin and adiponectin) individually and in combination 
have on beta cell function and cardiovascular function  whilst comparing these 
concentrations to concentrations found in lean and obese patients (individuals 
such as obese non diabetic, obese diabetic, non obese diabetic, non obese non 
diabetic (control)). This effect could be assessed by correlating the level of 
concentration of adipokines that have effect with markers of beta cell function 
such as HOMA-B and markers of CVD such as VEGF and VCAM and role of 
inflammatory factors. The effect of adipokines on gene expression for 
angiogenesis and atherosclerosis was also explored in the laboratory. 
 
1. To investigate the effects of leptin and adiponectin individually and in 
combination in beta cell failure and cardiovascular diseases.   
One of the goals of the present study was to find what the effect of leptin and 
adiponectin is on insulin secretion and gene expression in beta cells (to explore 
the basis of effect on insulin secretion) and in endothelial cells for genes for 
angiogenesis and atherosclerosis. 
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2. To examine the concentrations of leptin and adiponectin that has significant 
effects individually and in combination in beta cell failure and cardiovascular 
diseases. 
3. Determining the concentrations of adiponectin and leptin in lean and obese 
patients. 
4. To investigate the basis for the effect of the adipokines on insulin secretion 
and beta cell gene expression and on the expression of genes linked to 
atherosclerosis and angiogenesis. 
 
1.5.2 Objectives of the study 
 
In order to achieve the above aims the following were the objectives of this 
study. 
 
Beta cells were grown and cultured into pseudo-islets which were then treated 
with various adipokines and insulin secretion assessed by ELISA. 
 
Endothelial cells would be grown and RNA collected from them after treatment 
with adipokines. The RNA was to be purified with DNA-ses and reverse 
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transcribed and then PCR was carried out using the appropriate primers 
followed by gel electrophoresis to visualize gene expression. 
 
Patients who met the obese and lean criteria for this study were to be recruited 
and blood samples taken to assess adipokine concentrations, beta cell failure 
markers and endothelial cell dysfunction markers. 
 
The effects of the adipokines were to be explored further in the lab by exploring 
pathways that may be involved in these effects. 
 
1.5.3 Research Gap 
 
Most of the previous studies have looked into the effect of either leptin or 
adiponectin alone on endothelial cells and Beta cells (and not pseudo islets) 
(Balistreri et al., 2010, Belkina and Denis 2010), and the concentrations at 
which these adipokines had their effects vary considerably between reports. In 
this study, we decided to investigate the effect of various concentrations of 
leptin and adiponectin alone and in combination (in pseudo islets  which have 
been shown to have a better dose-related insulin secretion to glucose in 
comparison to mono layer beta cells) to elucidate the counter-regulatory effects 
they have on each other and also to study the effect they have on insulin 
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secretion from pseudoislets (which are clonal beta-cells grown in a configuration 
which mimics the islets of Langerhans) at a range of adipokine concentrations 
which are related to those found in physiological (lean) and pathological (obese) 
conditions in comparison to real values in a range of lean and obese patients. 
 
1.5.4 Research Questions 
 
The following are the research questions that arise from the gap in the previous 
studies; 
 
1) What are the specific concentrations of adipokines (including leptin and 
adiponectin, individually and in combination) that significantly influence insulin 
secretion in beta cells? 
2) What are the specific concentrations of adipokines (including leptin and 
adiponectin, individually and in combination) that significantly influence gene 
expression for genes that control angiogenesis and atheroslerosis in Eahy 
endothelial cells? 
3) What is the basis of the effect of adipokines seen in insulin secretion in beta 
cells and gene expression for atheroclerosis and angiogenesis in Eahy 
endothelial cells? 
105 
 
4) Is there any correlation between the level of adipokines and the risk of 
developing diabetes and cardiovascular disease in patients? 
 
1.5.5 Research Hypothesis 
 
In order to carry out this research the following are the hypothesis that was 
developed from the research questions; 
1) Leptin inhibits insulin secretion and causes upregulation of genes that cause 
angiogenesis and atherosclerosis. 
2) Adiponectin causes an increase in insulin secretion and causes down-
regulation of genes that regulate angiogenesis and atherosclerosis. 
3) Adiponectin reduces the risk of CVD caused by leptin. 
4) There is a high amylin secretion and a high insulin: amylin ratio in diabetics 
(or diabetic model) 
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Chapter 2 
 
Materials and methods 
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2.1 Beta cell Preparation, treatment and result analysis 
 
2.1.1-Materials 
Materials such as equipments, reagents and kits used for the beta cells 
experiments can be found in Appendix 1. 
 
2.1.1.1 Beta cell lines 
 
The clonal mouse pancreatic βTC-6 cells were purchased from the American 
Type Culture Collection (ATCC) from LGC Promochem, UK. The MIN-6 cells 
were received as a gift from Dr Catherine Arden of the University of Newcastle, 
England, United Kingdom. 
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2.1.1.2 Buffer for beta cell treatment 
The buffer used for the experiments on insulin secretion was the Krebes-Hepes 
buffer (KHB) which was made up of sodium chloride (NaCl- 119mM per 100ml), 
potassium chloride (KCl- 4.74mM, 237µl of a 2M solution per 100ml), calcium 
chloride (CaCl2- 2.54mM 254µl 0f 1M solution per 100ml), magnesium chloride 
(MgCl2 1.19mM- 60μl of a 2M solution per 100ml), monobasic potassium 
phosphate (KH2PO4 -1.19mM - 120 μl of 1M solution per 100ml), sodium 
hydrogen carbonate (NaHCO3  25mM- 2.5ml of a 1M solution per 100ml), 
Hepes (10mM- 1ml of a 1M solution per 100ml) bovine serum albumin (BSA- 
0.5% - 1ml 0f 1M solution per 100ml). The salts were dissolved in distilled water 
and BSA added last in order to prevent it from binding to any undisolved salt, 
thereby reducing its concentration. This mixture was then filtered and PH 
corrected to 7.4. 
 
2.1.2 Cell culture/ Pseudo-islet Preparation 
 
The cell culture process involved the following processes; recovery of cells from 
liquid nitrogen, maintaining the cells (change of media, sub-culturing cells and 
freezing cells back into liquid nitrogen for use in experiments at a later date) 
and preparation of pseudo-islets. 
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2.1.2.1 Beta cell recovery from liquid nitrogen. 
 
The Beta cells (MIN6 cells passages 23 and 24) were gifts from Dr. Catherine 
Arden of the Newcastle University. The cells frozen in vials were thawed out 
quickly and resuspended with 5-10ml of cell culture medium (see components 
in section 2.1.2.2) in a universal tube and this was centrifuged at 500g for 5 
minutes to make the cells into a pellet and seperate them from the freezing 
solution. The supernatant which contains the media and the freezing solution 
was then removed and the pellet resuspended in 5ml of media and this was 
mixed thoroughly in the universal tube to ensure an even distribution of cells 
and then placed in a 25cm2 flask. The cells were then checked under the 
microscope and place in the incubator with 5% CO2 and 95% air at 37°C. 
 
2.1.2.2 Maintenance of the Beta Cells 
 
The MIN6 cells were cultured in DMEM (supplemented with 5ml L-glutamine 
and Penicillin/Streptomycin, 75ml of fetal bovine serum and 2μL of 
dimercaptoethanol). The βTC cells used were however cultured in RPMI 1640 
medium supplemented with 10% foetal bovine serum, 100μg/ml Penicillin with 
100μg/ml streptomycin, 11mM glucose, 2mM L-glutamine. 
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Media was changed when necessary by removing the media with a sterile 
pipette and replacing with fresh media (5ml for 25cm2 flask or 10ml for 75cm2 
flask). 
 
When the cells had become 80% confluent in the 25cm2 flask they were 
subcultured into three 75cm2  flasks. This involved removing the media from the 
25cm2 flasks and then washing the excess protein from the cells 3 times with 
2.5ml of Hanks Buffered Salt Solution (HBSS) and this was followed by the 
addition of 0.4ml of 2.5g/L trypsin to the cells and the cells were then placed in 
the incubator for about 3-5 minutes checking regularly to make sure the cells 
had detached. 
 
Once detached, about 5ml of media was added to dilute the trypsin and this 
mixture transferred into a universal tube and spun in a centrifuge for 5minutes 
at 500g to seperate the pellet from the media/trypsin mixture. The pellet was 
then re-suspended in 10ml of media and thoroughly mixed and 3.33ml of cell-
media in each 75cm2 flask. This was then topped up with 6.67mls of media to 
make it 10mls in each 75cm2  flask. The flasks were then placed back in the 
incubator and 10mls of media changed whenever necessary until the cells in 
the 75cm2 flasks were at least 80% confluent and ready to be used for 
experiments or to be frozen down if they were not be used for experiments. 
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The process of freezing cells down involved removing the medium from the  
75cm2 flasks and then washing the excess protein from the cells 3 times with 
5ml of Hanks buffered salt solution (HBSS). This was followed by the addition of 
0.8ml of 2.5g/L trypsin solution to the cells and the cells were then placed in the 
incubator for about 3-5 minutes checking regularly to make sure the cells had 
detached. Once detached, about 5ml of complete medium was added to dilute 
the trypsin and this mixture transferred into a universal tube and spun in a 
centrifuge for 5minutes at 500g to seperate the pellet from the media/trypsin 
mixture. 
 
The  freezing-down involved resuspending the cells in the pellet in 1ml of 100% 
Fetal Bovine Serum (FBS) and adding 1ml of 20% Dimethyl 
Sulphuroxide(DMSO). This mixture was then split into two cryogenic vials (1ml 
each) and the vials placed in the -20°C freezer overnight and transferred into 
the -80°C freezer and then into the Liquid nitrogen tank(-180°C) on the 3rd day. 
 
For the experiment  about 3 x106 cells were seeded per 75 cm2 vented flask 
and grown in a humidified incubator at 37° centrigrade in 5% CO2 and 95% 
atmospheric air and were routinely passaged when they attained approximately 
70-80% confluence when viewed under the microscope. 
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2.1.2.3 Pseudo-islet preparation 
 
This involved preparing 2% bovine gelatin and autoclaving overnight. The 
pseudo-islets were prepared by coating 24 well plates with 500uL of 2% gelatin 
and incubated overnight. BTC Cells were then seeded in culture medium into 
the wells after the excess gelatin was removed. The 24 well plates were then 
returned to the incubators and allowed to grow into Pseudo-islets. Medium was 
changed on the 3rd and 5th days and after 5-9 days pseudo-uislets were fully 
formed. 
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Figure2.1. Stages of formation of pseudo-islets. The figure shows day 1(Fig 
A), Day 2 (Fig B), Day 5 (Fig C), Day 7(Fig D), Day 9(Fig E). 
 
B 
 C 
 
A 
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2.1.3 Treatment of cells with adipokines 
 
The Pseudo-islets were incubated initially with low glucose (2.2mM) in KHB 
(Krebs Hepes Buffer) for a minimum of 2 hours to synchronize the insulin 
secretion to basal levels and then incubated with 5 different concentrations of 
Adiponectin (0.1, 0.2, 0.5, 1 and 5μg/ml) leptin (10, 50, 100, 200, 500ng/ml) in 
triplicates in low (2.2mM) or high glucose (22mM) all in KHB for 1 hour (see 
Figure 2.2). 250µL of KHB containing secreted insulin was then collected and 
centrifuged at 500g for 5 min to remove any loose cells left and then 200uL of 
the supernatant was removed and stored frozen at -20° C until the samples 
were assayed for insulin by immunoassay (mouse insulin ELISA, Mercodia, 
Uppsala, Sweden). 
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LG LG LG HG HG HG  
0 0 0 0 0 0 CONTROL 
10 10 10 10 10 10 LEPTIN 
50 50 50 50 50 50 L 
100 100 100 100 100 100 L 
200 200 200 200 200 200 L 
500 500 500 500 500 500 L 
0.1 0.1 0.1 0.1 0.1 0.1 ADIPONECTIN 
0.2 0.2 0.2 0.2 0. 0.2 A 
0.5 0.5 0.5 0.5 0.5 0.5 A 
1.0 1.0 1.0 1.0 1.0 1.0 A 
5.0 5.0 5.0 5.0 5.0 5.0 A 
 
 
Figure 2.2 Scheme for treating beta cells. Figure shows the treatment with 
adipokines leptin and adiponectin. The treatment was done in triplicate for 5 
different concentrations of each adipokine. Leptin (10, 50, 100, 200, 500 ng/ml), 
Adiponectin (0.1, 0.2, 0.5, 1.0, 5.0 µg/ml). 
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2.1.4 Insulin assay 
 
The assay was performed with Mercodia mouse insulin ELISA kit (From 
Upsalla, Sweden). The assay was carried out according to the 
recommendations of the manufacturer as stated in the protocol contained in the 
kit.  
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2.1.5 Amylin assay 
 
The amylin assay was performed using the amylin enzyme immunoassay kit 
(Phoenix Pharmaceuticals USA). The assay was carried out according to the 
recommendations of the manufacturer as stated in the protocol contained in the 
kit.  
 
2.1.6 Result analysis 
 
This was done using the Mercodia Excel calculator (for insulin assay) and the 
Phoenix Pharmaceuticals’ Excel calculator (for amylin assay), which involved 
imputing the calibrators and using this to plot the mean absorbance values 
against the insulin concentration of the calibrators by drawing an inverted curve 
automatically on a log-log sheet. This calibrator curve converts the 
spectrophotometer reading for all the samples to insulin values automatically 
when inputted. These values were now multiplied by 10 and expressed in µg/L 
and further analyzed by finding the average of the triplicates and drawing a 
graph to represent the various levels on insulin secretion by each sample. The 
minitab 16 software (ANOVA) and the Student’s t-test were then used to find 
the statistical significance (p <0.05) and correlations between the effect of 
glucose and adipokine treatments (The methods used were specified 
individually in the legends of the graphs for various experiments). 
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2.2 Endothelial cell preparation, treatment and result analysis 
2.2.1-Materials   
Materials such as equipments, reagents and kits used for the beta cells 
experiments can be found in Appendix 1. 
 
2.2.1.1 EAHY cell lines 
 
EAHY cells (endothelial cells) were a gift from Dr. James Brown from Aston 
University. 
 
2.2.1.2 Antibodies 
 
The AMPK inhibitor used was 10µg/ml Dorsomorphine Dihydrochloride from 
Tocris Bioscience Bristol, UK. The ERK inhibitor was ERK Inhibitor II, 
FR180204 and the p38 MAPK inhibitor was TAK 715 both from Santacruz 
Biomedicals, USA. 
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2.2.2 EAHY Cell Culture 
 
The cell culture process involved the following processes; recovery of cells from 
liquid nitrogen, maintaining the cells (change of media, sub-culturing cells and 
freezing cells back into liquid nitrogen for use in experiments at a later date). 
 
2.2.2.1 EAHY Cell recovery from liquid nitrogen. 
 
EAHY endothelial cells were frozen in vials and were thawed out quickly and 
resuspended with 5-10ml of culture medium (see contents in 2.2.2.2) in a 
universal tube and this was centrifuged at 500g for 5 minutes to make the cells 
into a pellet and seperate them from the freezing solution. The supernatant 
which is made up of a mixture of the media and the freezing solution was then 
removed and the pellet resuspended in 5ml of media and this was mixed 
thoroughly in the universal tube to ensure an even distribution of cells and then 
placed in a 25cm2 flask. The cells were then checked under the microscope and 
place in the incubator with 5% CO2 and 95% air at 37°C. 
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2.2.2.2 Maintaining the EAHY Cells 
 
The endothelial cells (EAHY) used were cultured in RPMI 1640 medium 
supplemented with 10% foetal bovine serum, 100U/ml penicillin with 100µg/ml 
streptomycin, 2mM L-glutamine. 
 
Complete culture medium was changed when necessary by removing the 
media with sterile pipette and replacing with fresh culture medium (10ml for 
25cm2 flask or 20ml for 75cm2 flasks). When the cells became about 80-100% 
confluent in the 25cm2 flask they were subcultured into three 75cm2 flasks. This 
involved removing the media from the 25cm2 flasks and then washing the 
excess protein from the cells 3 times with 2.5ml of Hanks Buffered Salt Solution 
(HBSS) and this was followed by the addition of 0.5ml of 2.5g/L trypsin solution 
to the cells and the cells were then placed in the incubator for about 3-5 
minutes checking regularly to make sure the cells had detached. 
 
Once detached, about 5mls of media was added to dilute the trypsin and this 
mixture transferred into a universal tube and spun in a centrifuge for 5 minutes 
at 500g to seperate the pellet from the culture medium/trypsin mixture. The 
pellet was then re-suspended in 10ml of culture medium and thoroughly mixed 
and 3.33ml of cell/culture media in each 75cm2 flask. This was then topped up 
with 16.67ml of the culture medium to make it 20ml in each 75cm2 flask. The 
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flasks were then placed back in the incubator and 20ml of culture medium 
changed whenever necessary until the 75cm2 flasks were at least 80-100% 
confluent and ready to be used for experiments or to be frozen down if they 
were not going be used for experiments. 
 
The process of freezing the EAHY cells down involved removing the culture 
medium from the 75cm2 flasks. The excess protein was then washed from the 
cells 3 times with 5ml of Hanks Buffered Salt Solution (HBSS). This was 
followed by the addition of 2.5ml of 2.5g/L of trypsin solution to the cells and the 
cells were then placed in the incubator for about 3-5 minutes checking regularly 
to make sure the cells had detached. Once detached, about 5mls of culture 
medium was added to dilute the trypsin and this mixture transferred into a 
universal tube and spun in a centrifuge for 5minutes at 500g to seperate the 
pellet from the culture medium/trypsin mixture. 
 
The freezing down involves resuspending the cells in the pellet in 1ml of 100% 
Fetal Bovine Serum(FBS) and adding 1ml of 20% Dimethyl Sulphuroxide 
(DMSO). This mixture was then split into two cryogenic vials (1ml each) and the 
vials placed in the -20°C freezer overnight and transferred into the -80°C  and 
then into the liquid nitrogen tank (-180° C) on the 3rd day. 
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For the experiment, about 3 x106 cells were seeded per 75cm2 vented flask and 
grown in RPMI culture medium (supplemented with 5ml L-glutamine and 
Penicillin/Streptomycin, 50ml of Fetal bovine serum) in a 75cm2 flask, and were 
seeded into 6 well plates  when they were 80-100% confluent. 
 
2.2.3 Treatment of endothelial cells with adipokines 
 
The EAHY cells were cultured in RPMI culture medium (supplemented with 5ml 
L-glutamine and Penicillin/Streptomycin, 50ml of foetall bovine serum) in a 
75cm2 flask, and about 3 x106 cells were seeded from each 75cm2 into 6 well 
plates (when they were 80-100% confluent). When the cells had grown for 
about 3 days in the 6 well plates, they were then incubated in low serum (2%) 
RPMI culture medium for about 6 hours to starve the cells of protein and bring 
all the cells to the G0 phase of the cell division process before the experiment 
was started. The EAHY cells were then treated with low and high 
concentrations of leptin (0.5nM and 1nM) and/or low and high concentrations of 
adiponectin (1 and 100nM) (see figure 2.3) with wells having treatments with 
individual adipokines and also adipokines in combination for 24 hours and the 
media collected and frozen down for analysis and the cells collected and 
centrifuged into pellets at 500g for 5 minutes. The cell pellets were then re-
suspended and washed in sterile phosphate-buffered saline and centrifuged at 
500g for 5 minutes. 
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EXPERIMENT SCHEME1 
EXPERIMENT SCHEME2 
LA HL LA+HL 
CLA CHL CLA+HL 
EXPERIMENT SCHEME 3 
HA LL HA+LL 
CHA CLL CHA+LL 
EXPERIMENT SCHEME 4 
LA HL LA+HL 
LA + INHIBITOR HL+ INHIBITOR LA+HL+ INHIBITOR 
Figure 2.3 Scheme for the treatment of EAHY with Adipokines. Figure 
shows treatment with various concentrations of leptin and adiponectin (LL- low 
leptin (0.5nM), HL- high leptin (1nM), LA-low adiponectin (1nM), HA- high 
adiponectin (100nM), combinations-LA+HL, HA+LL. 
LL 
 
HL LA HA LL+LA LL+HA HL+LA HL+HA 
 
C 
 
C 
 
C 
 
C 
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C 
 
C 
 
C 
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2.2.4 Gene Expression Quantification 
 
 There were 6 phases; mRNA extraction, removal of DNA present in the RNA 
sample (RNA purification), reverse transcription, PCR, gel electrophoresis and 
Band analysis. 
 
2.2.4.1 Total RNA extraction and purification and quantification 
 
Total RNA was extracted from the pellet of treated cells using the Norgen Kit 
(Norgen UK, Fradley, Staffordshire) and quantified. The pellet of cells were 
counted with a Coulter counter to make sure  that the cells used were not more 
than the 3 million stipulated to be used with the Norgen kit and then washed 
with PBS and  centrifuged at 500g for 5 minutes. The PBS was then removed 
completely. 350µl of lysis solution was then added to the pellet and left to stand 
for 5 minutes at room temperature to lyse the cells. 200 µl of 95% ethanol was 
then added to the lysine and this mixed thoroughly with a vortex for about 10 
seconds. This mixture was then transferred into an assembly of column and 
collection tubes and this assembly spun at 14000g for 1 minute. The column 
was then washed with 400 µl of wash buffer at 14000g for 1minute 3 times and 
spun an additional 2 minutes to dry. The collection tube was then replaced with 
a 1.7ml elusion tube and 50ul of elusion solution added to the column-elusion 
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tube assembly and spun at 200g for 2minutes and 14000g for 1 minute and hen 
14000g for another 1 minute. 
 
The RNA was quantified using a Thermoscientific 2000c/2000 nanodrop 
spectrophotometer. This involved cleaning the spectrophotometer with distilled 
water on a tissue, and then blanking the spectrophotometer by placing 1.5 µl of 
elution fluid on the nanodrop window and placing 1.5 µl of samples to be 
measured on the nanodrop window and measurements were made with the 
nanodrop.  
 
The RNA extracted was placed in a -80° C freezer until purification 
 
2.2.4.2 RNA Purification 
 
The purification of the mRNA was done with an RNAse- free DNAse. An RQ 
RNAse-Free DNAse (Promega Southampton, UK) was used to remove any 
DNA from the RNA sample.  
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The process involves placing all the enzymes (RQ1 RNase-free DNase 10x 
reaction buffer and RQ1 RNase-free DNase). Heating blocks were preset at 37 
and 65 degrees. 
 
The enzymes were used at 1ul each per 1-8ul of RNA samples (5 µl was used 
to minimize the effect of magnesium on the effect of the DNAse. Samples were 
placed on ice and 5ul of DNAse was added to each sample and then 5ul of 
DNAse buffer added to each sample and placed immediately back into the ice 
to prevent any premature reaction. The samples were then placed in the 37 
degrees block to incubate for 30 minutes and then 5ul of the stop solution 
added to the samples to inactivate the DNAse and samples placed in the 65 
degrees for 10 minutes. 
 
2.2.4.3 RNA Reverse Transcription 
 
This process was done in 2 phases; the annealing and the extension phases. 
 
The annealing phase is the phase that involves heating up RNA and then 
cooling suddenly to allow the primers of the DNA of interest to attach to the 
ends of the RNA sequence and to allow the DNA sequence of interest to be 
formed in the extension phase. The process involves first calculating how much 
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of the RNA solution will contain 1000ng (1µg)/ µl of RNA and this was done by 
dividing 1000 by the concentration of the RNA in the sample (for example if 1µl 
of the sample contains 200ng of RNA, therefore 1ng will be in 1/200ul and 
1000ng will be in 1/200x1000=5ul of the RNA sample). Once the volume of the 
RNA sample that contained 1000ng of RNA was determined, 1µl was added to 
this number and this total was taken away from 10µl (total for annealing phase) 
to find out how much of RNA-se/DNA-se free water was needed to be added to 
the mixture to make a total of 10µl (Annealing phase requires the addition of 1µl 
of primer + Volume of RNA that contains 100ng + RNAse/DNAse free water. 
=10µl). 
COMPONENT  1 REACTION 
RNA template (3pg -2ng)  X μl (Volume of RNA sample that 
contains 1000ng) 
RT primer  1 μl 
RNAse/DNAse free water  Y μl (10-(RNA+ 1) 
Final volume  10 μl 
 
Table2.1 Table showing the components of the mixture for the annealing 
phase of the reverse transcription.  
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The annealing mixture is placed in a block of 65°C for 5 minutes and transferred 
straight into Ice to ensure the primers bind properly to the RNA. 
The extension phase involves preparing a master mix of the following; 
 
COMPONENT 1 REACTION 
NanoScript 10X Buffer  2.0 μl 
dNTP mix 10mM of each 1.0 μl 
DTT 100mM 2.0 μl 
RNAse/DNAse-free water 4.0 μl 
NanoScript enzyme 1.0 μl 
Final volume 10.0 μl 
 
Table2.2 Table showing the contents of the master mix for the extension 
phase of the reverse transcription. The number of reactions (plus an 
additional reaction for pippetting error) was multiplied by each content and total 
added to make the master mix. From the mastermix 10.0 μl was taken and 
added to the 10.0 μl for each sample from the annealing phase to make 20.0 μl 
for the extension phase cycling. 
This mixture is made up to 10 μl for each sample and each component is 
multiplied by the total number of samples we have and from this master mix, 10 
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μl is added to each 10 μl sample on ice from the annealing phase of the reverse 
transcription and this mixture vortexed and placed in a thermocycler. The 
thermocycler is programmed to run at 55 degrees for 20 minutes and then 75 
degrees for 15 minutes to extend and grow the DNA. 
 
The DNA generated was then quantified using the Nanodrop 
spectrophotometer and stored in the -20°C freezer for PCR. 
 
2.2.4.4 Polymerase Chain Reaction (PCR) 
 
The PCR process is a process of amplifying a gene of interest. The experiment 
aims to treat the cells with adipokines in order to see what influence the 
adipokines will have on the expression of angiogenic and atherosclerotic genes 
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Gene Forward Primer Reverse Primer 
Angiogenic Genes   
HIF-1 GGCGCGAACGACAAGAAA
AAG 
CCTTATCAAGAT
GCGAACTCACA 
MMP2 * CCGTCGCCCATCATCAAGT
T 
CTGTCTGGGGCA
GTCCAAAG 
MMP9 TGGCAGAGATGCGTGGAG
A 
GGCAAGTCTTCC
GAGTAGTTTT 
TIMP1 CTTCTGCAATTCCGACCTC
GT 
CCCTAAGGCTTG
GAACCCTTT 
TIMP2* AAGCGGTCAGTGAGAAGG
AAG 
GGGGCCGTGTA
GATAAACTCTAT 
TIMP3* TGCAACTTCGTGGAGAGG
TG 
CACAAAGCAAGG
CAGGTAGTA 
TNFa ATGAGCACTGAAAGCATGA
TCC 
GAGGGCTGATTA
GAGAGAGGTC 
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VEGF-A CAACATCACCATGCAGATT
ATGC 
GCTTTCGTTTTTG
CCCCTTTC 
VEGF-C AGGCTGGCAACATAACAG
AGA 
TCCCCACATCTA
TACACACCTC 
Atheroslerotic  Genes   
ICAM-1 TTGAACCCCACAGTCACCT
AT 
CCTCTGGCTTCG
TCAGAATCA 
VCAM-1 GCTGCTCAGATTGGAGACT
CA 
CGCTCAGAGGGC
TGTCTATC 
E-Selectin ACCTCCACGGAAGCTATGA
CT 
CAGACCCACACA
TTGTTGACTT 
LPL* ACAAGAGAGAACCAGACT
CCAA 
AGGGTAGTTAAA
CTCCTCCTCC 
LPA* ATGGAATCAACTCTCCTCA
CAAC 
ATCACCTCGGTA
GCAGTCCT 
Cadherin  5 GACCGGGAGAATATCTCA
GAGT 
CATTGAACAACC
GATGCGTGA 
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GAPDH GAGTCAACGGATTTGGTC
G 
GGAAGATGGTGA
TGGGATTT 
BACTIN AATCTGGCACCACACCTTC
TCC 
CTCCTTAATGTCA
CGCACGAT 
   
 
Table 2.3 Table showing the various genes of interest that influence 
atherosclerosis and angiogenesis. The genes marked (*) are the genes that 
were well expressed. GAPDH and β-ACTIN were used as house-keeping 
genes.  
 
These were the genes of interest. The PCR involved exploring the expression of 
each of these genes initially in each of the 16 samples (see experiment scheme 
1) and later reduced to 5 genes (2 atherosclerotic and 3 angiogenic genes) and 
6 samples (As seen in experiment scheme 2) as a there were only 5 of these 
genes that were properly expressed. As a form of control for the PCR, PCR was 
done for all the samples to measure the expression of house-keeping genes, 
GAPDH and β-Actin. 
 
The PCR involves preparing a master mix which is added to the sample and 
mixture placed in a thermocycler. The master mix was made up of the following; 
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Component Volume(µl)/Sample 
Taq Polymerase 25ul 
Magnesium Chloride 0.5 
Forward Primer 1 
Reverse Primer 1 
dNTP 1 
RNAse-DNAse Free water 19.5 
Final Volume/ 48µl 
 
Table 2.4 Tables showing the mastermix for the reverse transcription PCR. 
The number of samples (with one added for pippetting error) was multiplied by 
each component to make a master mix. Out of the mastermix, 48µl was added 
to a tube and 2µl of each cDNA was added to each tube and this mixed 
thoroughly and then placed in the thermocycler. 
 
These were all placed in ice initially and after the total master mix was 
prepared, 48ul was added to each tube and 2ul (50ng) of DNA from each 
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sample was added and placed in ice to prevent premature reaction and the 
mixture was then vortexed and placed in a thermocycler wich was set to the  
Following parameters; 
Table 2.5 Table showing the settings for the thermocycler for PCR 
The PCR product which was generated was then  placed in the -20 degrees 
freezer ready for gel electrophoresis. 
Setting Status Duration Temperature 
Lid:  
(Time depends on the size of 
the gene) 
 
  105.0 degrees 
Heated lid before program:  On   
Pause before program Off   
Initial denaturation  5minutes 95 degrees 
Hot start Disable   
Number of cycle  32  
Denaturation  30seconds 95 degrees 
Annealing:  30 seconds 55 degrees 
Extension  (extension  
1min/kb) 
1minute 72 degrees 
Final extension  5minutes 72 degrees. 
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2.2.4.5 Gel electrophoresis 
 
Gel electrophoresis was performed to visualize the amplified products of PCR 
and to quantify them. This involves preparing an agarose gel and placing the 
PCR product in the wells and then running the electrophoresis in TAE (Tris-
Acetate EDTA) buffer. 
 
The gel preparation involved preparing a 1% agarose with TAE buffer. The TAE 
buffer was used as the DNA molecules bind to the salt in the mixture in the TAE 
buffer and moves with the electric charge from the negative pole to the positive 
through the gel. The 1% gel was prepared with 7µl of Ethidium Bromide in order 
to reveal the bands under the UV light. The gel was allowed to cool just enough 
not to solidify and then poured into a mould with a comb in it to form the wells 
where the samples was placed in a Life Technologies electrophoretic tank. The 
gel was allowed to cool and solidify for about 30 minutes. The mould with the 
gel was then placed in the electrophoresis tank and TAE buffer added to just 
below the maximum mark and the comb removed to expose the wells. The 
electrophoresis tank was then covered and the leads connected accordingly 
from the tank to the Voltameter (black to black and red to red). The Voltameter 
was set at 100V and run for 1hour. The gel was taken on a tray to the UV 
illuminator after electrophoresis for 1hour. Pictures of gel were taken and saved 
for the analysis of the bands. 
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2.2.4.6 DNA band analysis 
  
The band (representing the relative expression of genes of interest) on the 
images taken with the UV camera was analyzed with the Image J software 
which measures and records the pixel density of each band. 
 
The Relative expression of gene of interest was also compared to the 
housekeeping gene GAPDH or β-actin, thus calculating the ratio number (= 
pixel density for Sample/Pixel density for GAPDH or β-actin).The average of 
three different experiments was recorded as the ratio number. The ratio number 
was then plotted on a graph in order to compare the gene expression in 
controls to the various treatments made. 
 
2.2.4.7 Real-time PCR 
2.2.4.7.1 Primers 
 
All primers were designed with the help of the reference sequence from the 
NCBI nucleotide sequence base. Taqman primers with high specificity were 
used in these experiments. 
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Primer Strand Primer Sequence 
Mouse 
Actin 
Sense AATCTGGCACCACACCTTCTCC 
 Anti-sense CTCCTTAATGTCACGCACGAT 
MMP2 Sense CCGTCGCCCATCATCAAGTT 
 Anti-sense CTGTCTGGGGCAGTCCAAAG 
TIMP2 Sense AAGCGGTCAGTGAGAAGGAAG 
 Anti-sense GGGGCCGTGTAGATAAACTCTAT 
TIMP3 Sense TGCAACTTCGTGGAGAGGTG 
 Anti-sense CACAAAGCAAGGCAGGTAGTA 
LPA Sense AGGGTAGTTAAACTCCTCCTCC 
 Anti-sense ATCACCTCGGTAGCAGTCCT 
LPL Sense ACAAGAGAGAACCAGACTCCAA 
 Anti-sense ATGGAATCAACTCTCCTCACAAC 
 
Table 2.6 Primers used for the real time PCR. Primers were purchased from 
Qiagen life technologies UK. 
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2.2.4.7.2 mRNA extraction, reverse transcription 
 
The mRNA from the endothelial cells EAHY, purification and reverse 
transcription to cDNA was done in the same way as was described for the 
reverse transcription PCR above. 
 
2.2.4.7.3 Real time PCR studies for gene expression analysis 
for angiogenic and atherosclerotic genes 
 
The real-time RT-PCR reactions were performed using the iCycler Real-Time 
PCR Detection System. Reaction volumes used were 25μl containing 2μl of 
cDNA 1.25μl of each pair of primers, 9.5μl nuclease free water and 12.5μl of 
Mastermix. Two housekeeping genes (β-actin and GAPDH) were amplified in 
separate reaction to normalize results.  
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Thermal cycling conditions were as follows; 
95o C for 1 minute (initial denaturing) 
95oC for 30 seconds 
58oC for 30 seconds 
95oC for 30 seconds 
72oC for 10 minutes (final extension) 
 
Each sample reaction was run in triplicate and expression quantified as the 
number of cycles (CT) after which fluorescence exceeds the background 
threshold minus the CT for the housekeeping control (ΔCT). The RT-PCR 
statistical analysis was performed using student T test for two group 
comparisons and analysis of variance (ANOVA) for multiple comparisons. The 
relative expression levels were calculated by the formula 2-ΔΔCT, comparing 
treatment samples and untreated control samples. 
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2.3 Clinical blood sampling for adipokine assay 
2.3.1 Materials 
Materials such as equipments, reagents and kits used for the beta cells 
experiments can be found in Appendix 1. 
 
2.3.2 Study design and result analysis 
 
This aspect of the study was done in collaboration with Drs Ananth Nayak and 
Baldev Singh (Diabetes Centre, New Cross Hospital, Wolverhampton) in a 
study in 2013 on glycation gap and mortality in diabetes. This therefore 
influenced many of the decisions and planning for the methods and result 
analysis in this section of the study. 
 
2.3.2.1 Ethical committee approval 
The use of the clinical database for this study was approved by the relevant 
local U.K. National Health Service Research Ethical Committee. 
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2.3.2.2 Selection of patients and data collection 
Following ethical approval, it was important to select appropriate patients for the 
study. HbA1c and fructosamine estimations had been undertaken at New Cross 
Hospital Wolverhampton by Nayak et al. over 4 years (2006–2009). In this 
period, adults with diabetes (≥18 years of age) who had paired estimations of 
HbA1c and fructosamine performed on the same day from the same sample set 
were recruited for the study (Nayak et al., 2013). Of these patients, 150 were 
recruited for this present study. 
 
Information about the clinical condition of the patients was obtained from the 
diabetes registry and linked to the information derived from the analysis the 
patients’ blood samples. The diabetes register is validated to be >99% accurate 
for the identification of known diabetes and for mortality status in linkage with 
the National Health Service Strategic Tracing Service (Nayak et al., 2013).  
Exclusion criteria for this study, as in the study by Nayak et al. (2013) were: 
pregnant women, those with creatinine>200 μmol/L, those with known 
hemoglobinopathy, or those with an abnormal electrophoretic pattern on HbA1c 
testing.  
 
The 150 patients that were selected were patients who had 2 pairs of 
simultaneous estimations of HbA1c and 2 calculated G-gaps that were 
consistent in direction (positive or negative direction). The 150 patients selected 
were made of the first 75 had 2 pairs of simultaneous estimations of HbA1c and 
142 
 
2 calculated G-gaps that were consistently positive and the first 75 patients that 
had 2 pairs of simultaneous estimations of HbA1c and 2 calculated G-gaps that 
were consistently negative and not from random selections.  
 
2.3.2.3 Ranking of patients’ risk of developing complications 
such as retinopathy, renal complications and vascular 
complications  
 
Concerning retinal complications, the English National Screening Program for 
Diabetic Retinopathy (ENSPDR) was used as a guide for the digital retinal 
screen. Retinopathy was classified as either having or not having retinopathies. 
For renal complications, the renal status was classified by considering the Urine 
albumin-creatinine ratio (UACR) and the status was classed as low risk or high 
risk for progressive microalbuminuria (<10 or >10 mg/mmol). For the 
cardiovascular complications, the classification was based on the presence or 
absence of any previous cardiac, cerebral, or peripheral macrovascular event.  
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2.3.2.4 Methods of analysis  
 
The Diabetes Control and Complications Trial (DCCT) aligned HbA1c was used 
in the analysis as the HbA1c International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) values were available only from 1 June 2009. 
HbA1c was measured using high-performance liquid chromatography. According 
to the agreed conditions of collaboration with Nayak et al., the performance 
scores in the UK National External Quality Assurance Scheme (UK NEQAS) 
were used and are as follows: A (accuracy) score <100 and B (bias) score <2%, 
which were within the acceptable limits of the UK NEQAS for glycated 
hemoglobins (maximum limits: A score <200 and B score less than ±7.5%). The 
between-batch coefficient of variation was 1.8 and 1.4% for an HbA1c of 5.7% 
(39 mmol/mol) and 9.5% (80 mmol/mol), respectively. Fructosamine was 
measured by nitrotetrazolium-blue reduction. A Cobas kit with between-batch 
coefficient of variation 3.1% at a level of 263 µmol/L and 2.2% at 518 µmol/L 
was used (Nayak et al., 2013).  
 
2.3.2.5 Fructosamine-predicted HbA1c and the G-gap 
calculations 
 
According to Nayak et al. (2013), the predicted HbA1c (FHbA1c) was calculated 
from the simultaneously measured fructosamine standardized to the HbA1c 
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distribution according to the following equation: FHbA1c = {[(fructosamine – 
mean fructosamine)/SD fructosamine] × SD HbA1c} + mean HbA1c. In order to 
then calculate the G-gap, the predicted HbA1c (FHbA1c) was then subtracted the 
true HbA1c (G-gap = HbA1c – FHbA1c). Importantly the FHbA1c was not derived 
from HbA1c by correlation/regression methods. A negative G-gap is said to 
represent the true HbA1c reading lower than the FHbA1c, and a positive G-gap 
denotes the true HbA1c reading higher than that predicted by fructosamine. 
Among those with a second paired HbA1c-fructosamine estimation, in order to 
identify those with a consistent G-gap direction, the product of two G-gaps was 
calculated. If consistent, the G-gap product would be positive (positive × 
positive = positive; negative × negative = positive), but any discordance in 
direction of the G-gap over time in two paired readings would yield a negative 
G-gap product (negative × positive = negative) (Nayak et al., 2013).  
 
2.3.2.6 Categorization of the G-gap and statistical analysis 
 
To simplify things, the G-gap (unit = HbA1c %) was categorized as negative 
when less than or equal to −1 (i.e., more negative than −1), neutral greater than 
−1 to less than +1, or positive when greater than or equal to +1.  
In order to analyse the data statistically, the correlation between the 
leptin/adiponectin ratio and the parameters relating to the risk of developing 
retinal, renal and cardiovascular complications were done using the minitab 
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version 17 ANOVA and graphs drawn to represent these correlations, All 
statistical tests were considered significant at P < 0.05.  
 
2.3.3 Blood Sampling 
 
After recruitment, patients were given dates when blood sampling was done via 
the safe vacutainer system of venepuncture. These blood samples were then 
stored initially in a -20 degrees freezer and then transferred to a -80 degrees 
freezer for longer storage. 
 
2.3.4 Plasma sample analysis for Adipokines leptin and 
adiponectin 
 
The plasma sample was prepared by collecting plasma using heparin as an 
anticoagulant and centrifuging for 15 minutes at 1000 x g within 30 minutes of 
collection. The plasma samples were then stored frozen at -20 degrees after 
alliquoting (to avoid repeated freeze-thaw cycles) and were then assayed for 
the levels of leptin and adiponectin using the R and D Pharmaceuticals 
(Abingdon, UK) enzyme immuno-assay ELISA kit. The assay was carried out 
according to the recommendations of the manufacturer as stated in the protocol 
contained in the kit.  
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Chapter 3 
 
Regulation of gene expression for 
angiogenesis and atherosclerosis by 
leptin and adiponectin in endothelial 
cells 
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3.1 Introduction 
 
Cardiovascular disease (CVD) affects the blood vessels and the heart and 
atherosclerosis and angiogenesis (both stimulated by inflammation) have both 
been strongly linked with the pathogenesis of CVD. Atherosclerosis results from 
the development of an inflammatory point in the vascular lining (for example an 
injury from high blood pressure) which stimulates smooth muscle cell activation, 
migration and proliferation which may lead to occlusion of the vessels and CVD 
(Li et al., 2005). Angiogenesis is also said to be critical for the 
neovascularisation of an atheromatous plaque further predisposing to CVD 
(Park et al., 2001). This therefore makes it important to look more closely at the 
possible role of leptin and adiponectin in the expression of genes that code for 
proteins that influence atherosclerosis and angiogenesis. 
 
Leptin and adiponectin are adipokines secreted by fat cells from visceral 
adipose tissue and previous studies suggest leptin to be pro-inflammatory and 
to encourage the expression of angiogenic and atherosclerotic genes (Dubey 
and Hesong 2006). 
 
 Adiponectin however, has been reported to reduce inflammation and risk of 
cardiovascular disease as a result of its cardio-protective qualities (Adya et al., 
2012, Zhu et al., 2008, Okamoto et al., 2006). Other studies have suggested 
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that adiponectin, though not pro-inflammatory, may not confer a 
cardioprotective quality (Antoniades et al., 2009).  
 
Due to the controversies around the roles of these adipokines, attempts have 
been made to investigate the effect of various concentrations of these 
adipokines and the basis of these effects. Studies have shown that leptin, 
through the JAK-STAT pathways via MAPK encourages the entry of dimerised 
STAT3 into the nucleus to influence the expression of angiogenic and 
atherosclerotic genes, while adiponectin, via the IRS pathway down-regulates 
the expression of atherosclerotic and angiogenic genes via  AMPK. Few studies 
have investigated the effect of these counter-regulatory peptides in 
combination. 
 
Leptin plays a role in matrix remodeling as it influences the expression of TIMP 
and MMP genes (Sweeney 2010). The TIMP genes are natural inhibitors or 
regulators of the effect of MMPs which help to break down and remodel tissues 
in the cardiovascular system (and other systems) by making sure the structure 
of tissues are maintained and that excess tissues collagen matrices are broken 
down and that they do not accumulate. Derangements in the expression of the 
genes responsible for the remodeling may lead to accumulation of collagen 
matrices and excess blood vessel formation (angiogenesis) leading to 
artherosclerosis and other cardiovascular diseases and even cancer (Park et 
al., 2001). 
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Adiponectin on the other hand has been reported to have an opposite effect. It 
is however not completely clear how Leptin and adiponectin carry out their 
roles. 
 
The aim of this study is to explore the role of leptin and adiponectin in the 
expression of these genes and to explore the various pathways in order to 
better understand the mechanism by which leptin and adiponectin have these 
effects on the expression of the genes. Also, the combined effect of the 
adipokines has been poorly researched and poorly understood and so this 
study aimed to explore the effect of combining leptin and adiponectin and to find 
out what the basis for the effects seen on the gene expression is. 
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3.2 Materials and Methods 
 
The materials and the methods used for experiments that concern this chapter 
are detailed in the materials and method chapter (chapter 2). A summary of the 
process is stated as follows.  
 
The procedure for investigating the effect of leptin and adiponectin on the 
expression of angiogenic genes required growing EAHY cells in 6 well plates 
and starving the endothelial cells of protein by placing them in 2% media for 6 
hours to bring the cells to Go phase and then treating the cells with various 
concentrations of leptin and adiponectin in normal media (10%) while the 
controls were left untreated. This also involved adding AMPK, ERK and p38 
inhibitors in the investigation of the bases of the effects of leptin and 
adiponectin. The AMPK inhibitor used was 10µg/ml Dorsomorphine 
Dihydrochloride from Tocris Bioscience Bristol, UK. The ERK inhibitor was ERK 
Inhibitor II, FR180204 and the p38 MAPK inhibitor was TAK 715 both from 
Santacruz Biomedicals, USA). The cells were then collected and RNA 
extracted, reverse transcribed and PCR carried out and the product run on a gel 
to find out what the role of AMPKI is on the expression of angiogenic genes 
MMP2, TIMP2 TIMP3. 
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In Figures 3.1.1(a) and (b) to 3.1.3(a) and (b), (a) models the diabetic situation 
with high leptin (16ng/ml) and low adiponectin (36 ng/ml) while (b) represents 
the lean picture with High adiponectin (3.6µg/ml) and Low leptin (8ng/ml). All 
the cells used in the result below were grown in RPMI in 6 well plates, and 
serum starved, treated with adipokines and then the cells collected and RNA 
extracted from them. Total RNA was reverse-transcribed to cDNA and used to 
analyse gene expression by semi-quantitative PCR. Amplified products were 
run on 1% agarose gels and visualized under UV light to quantify the 
expression of each gene related to the amount of house-keeping gene (β-actin) 
present in the sample. 
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3.3 Results 
3.3.1 Regulation of expression of genes that code for 
angiogenesis by individual and combined leptin and 
adiponectin treatments. 
3.3.1.1 Effect of Leptin and Adiponectin on TIMP2 
a) 
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b) 
 
 
Figure 3.1.1 Effect of leptin and adiponectin individually and in 
combination on TIMP2 gene expression. (C- control, HL-high leptin, LL-low 
leptin, HA-high adiponectin, LA-low adiponectin, HL+LA- high leptin + low 
adiponectin, HA+LA- high adiponectin + low adiponectin) 
 
Results from figure 3.1.1 (a and b) shows that leptin increases while 
Adiponectin reduces the expression of TIMP2. The results show that leptin 
significantly increased TIMP2 expression in high concentrations (3.1.1a) while 
adiponectin increases the expression of TIMP2 in High concentrations (3.1.1b). 
Also there is a significant reduction in the expression of the gene when leptin 
and adiponectin was combined (3.1.1 a and b). p<0.05 using ANOVA and 
Tukey's multiple comparison tests for the comparison between untreated and 
leptin and adiponectin treated cells.   
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3.3.1.2 Effect of leptin and adiponectin on TIMP3 gene 
expression 
a) 
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b) 
 
Figure 3.1.2 Effect of leptin and adiponectin individually and in 
combination on TIMP3 gene expression. (C- control, HL-high leptin, LL-low 
leptin, HA-high adiponectin, LA-low adiponectin, HL+LA- high leptin + low 
adiponectin, HA+LA- high adiponectin + low adiponectin) 
 
The results in figure 3.1.2 show that leptin increased TIMP3 expression in high 
concentrations (3.1.2a) while adiponectin increases the expression of TIMP3 in 
High concentrations (3.1.2b). Also there is a significant reduction in the 
expression of the gene when leptin and adiponectin was combined (3.1.2 a and 
b). p<0.05 using ANOVA and Tukey's multiple comparison tests for the 
comparison between untreated and leptin and adiponectin treated cell. 
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3.3.1.3 Effect of leptin and adiponectin on MMP2 gene 
expression 
a) 
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b) 
Figure 3.1.3 Effect of leptin and adiponectin individually and in 
combination on MMP2 gene expression. (C- control, HL-high leptin, LL-low 
leptin, HA-high adiponectin, LA-low adiponectin, HL+LA- high leptin + low 
adiponectin, HA+LA- high adiponectin + low adiponectin) 
 
Figure 3.1.3 shows that leptin increases and adiponectin reduces the 
expression of MMP2 gene expression while combination of leptin and 
adiponectin down-regulates the expression of MMP2. The results from figures 
3.13 (a and b) show that leptin increased MMP2 expression in high 
concentrations (3.1.3a) while adiponectin reduces the expression of TIMP3 in 
High and low concentrations (3.1.3b). Also there is a significant reduction in the 
expression of the gene when leptin and adiponectin was combined (3.1.3 a and 
b). p<0.05 using ANOVA and Tukey's multiple comparison tests for the 
comparison between untreated and leptin and adiponectin treated cell. 
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3.3.2 Regulation of the effect of Leptin and adiponectin on 
angiogenic genes (MMP2, TIMP2, TIMP3) by AMPKI, ERKI and 
P38 inhibitor 
3.3.2.1 The effect of 24 hour exposure of EAHY cells expression 
of Angiogenic genes to AM PKI in the presence of leptin and 
adiponectin 
3.3.2.1.1 AMPKI has significant inhibitory effect on the effect of 
leptin on MMP2 gene expression 
 
Fig 3.1.4 Role of AMPK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the  expression of MMP2 
gene. (C AMPK MMP2- control, HL-high leptin, LA-low adiponectin, HL+LA- 
high leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, 
HL+AMPKI- high leptin +  AMPK inhibitor, LA+AMPKI- low adiponectin + AMPK 
inhibitor, HL+LA+AMPKI- high leptin + low adiponectin + AMPK inhibitor) 
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Figure 3.1.4 shows that the increase of the expression of MMP2 by leptin 
(16ng/ml) is blocked significantly by AMPKI (10µg/ml). The inhibitory effect of 
low adiponectin (36ng/ml) on MMP2 was also blocked but not significantly. 
Adiponectin in low concentration reduced the effect of high leptin on MMP2 
gene expression and blocking AMPK promotes the effect of leptin. P-
value<0.05 using the students T-Test (2 way) 
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3.3.2.1.2 AMPKI significantly inhibits the effect of leptin on 
TIMP2 gene expression 
 
Fig 3.1.5 Role of AMPK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP2 
gene. (C AMPK TIMP2- control, HL-high leptin, LA-low adiponectin, HL+LA- 
high leptin + low adiponectin, HA+LA- high adiponectin+ low adiponectin, 
HL+AMPKI- high leptin + AMPK inhibitor, LA+AMPKI- low adiponectin + AMPK 
inhibitor, HL+LA+AMPKI- high leptin + low adiponectin + AMPK inhibitor) 
 
Figure 3.1.5 shows that AMPKI inhibits the effect of high leptin concentration on 
TIMP2 expression. The increase of the expression of TIMP2 by leptin (16ng/ml) 
is blocked significantly by AMPKI (10µg/ml). The effect of low adiponectin 
(36ng/ml) on TIMP2 was also blocked by AMPKI but not significantly. 
Adiponectin in low concentration reduced the effect of high leptin on TIMP2 
gene expression and blocking AMPK promotes the effect of leptin.  . P-
value<0.05 using the students T-Test (2 way) to compare controls to samples. 
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3.3.2.1.3 AMPKI significantly inhibits the effect of leptin on 
TIMP3 gene expression 
 
Fig 3.1.6 Role of AMPK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP3 
gene. (C AMPK TIMP3- control, HL-high leptin, LA-low adiponectin, HL+LA- 
high leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, 
HL+AMPKI- high leptin +  AMPK inhibitor, LA+AMPKI- low adiponectin + AMPK 
inhibitor, HL+LA+AMPKI- high leptin + low adiponectin + AMPK inhibitor) 
 
Figure 3.1.6 shows that AMPKI inhibits the effect of high leptin concentration on 
TIMP3 expression. The increase of the expression of TIMP3 by leptin (16ng/ml) 
is blocked significantly by AMPKI (10µg/ml). The effect of low adiponectin 
(36ng/ml) on TIMP2 was not blocked by AMPKI. Adiponectin in low 
concentration reduced the effect of high leptin on TIMP3 gene expression and 
blocking AMPK inhibits the effect of the combination (not significantly). . P-
value<0.05 using the students T-Test (2 way) to compare control to samples. 
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3.3.2.2 The effect of 24 hour exposure of EAHY cells expression 
of angiogenic genes to ERKI in the presence of leptin and 
adiponectin 
3.3.2.2.1 ERKI significantly inhibits the effect of leptin and 
adiponectin on MMP2 expression 
 
Figure 3.1.7 Role of ERK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of MMP2 
gene. (C- control, HL-high leptin, LA-low adiponectin, HL+LA- high leptin + low 
adiponectin, HA+LA- high adiponectin + low adiponectin, HL+E- high leptin + 
ERK inhibitor, LA+E- low adiponectin + ERK inhibitor, HL+LA+E- high leptin + 
low  adiponectin + ERK inhibitor) 
 
Figure 3.1.7 shows that ERKI inhibits effect of high leptin and low adiponectin 
concentration on MMP2 expression.  The increase of the expression of MMP2 
by leptin (16ng/ml) is blocked significantly by ERK Inhibitor (10µg/ml). The 
effect of low adiponectin (36ng/ml) on TIMP2 was blocked significantly by ERKI. 
Adiponectin in low concentration reduced the effect of high leptin on MMP2 
gene expression and blocking ERK does not promote the overall effect of leptin 
but reduces it. P-value<0.05 using the students T-Test (2 way) to compare 
control to samples. 
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3.3.2.2.2 ERKI significantly inhibits the effect of leptin and 
adiponectin on TIMP2 expression 
Figure 3.1.8 Role of ERK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP2 
gene. (CTIMP2 ERK- control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+E- 
high leptin + ERKinhibitor, LA+E- low adiponectin + ERK inhibitor, HL+LA+E- 
high leptin + low adiponectin + ERK inhibitor) 
 
Figure 3.1.8 shows that ERKI inhibits the effect of high leptin and low 
adiponectin concentration on TIMP2 expression. The increase of the expression 
of TIMP2 by leptin (16ng/ml) and adiponectin low adiponectin (36ng/ml) is 
blocked significantly by ERK inhibitor (10µg/ml). The effect of low adiponectin 
(36ng/ml) on TIMP2 was blocked significantly by ERKI. Adiponectin in low 
concentration reduced the effect of high leptin on TIMP2 gene expression (with 
an overall increase in gene expression) and blocking ERK in the leptin and 
adiponectin combination leads to an inhibition of TIMP2 expression. . P-
value<0.05 using the students T-Test (2 way) to compare control to samples. 
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3.3.2.2.3 ERKI significantly inhibits the effect of leptin and 
adiponectin on TIMP3 expression 
 
Figure 3.1.9 Role of ERK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP3 
gene. (CTIMP3 ERKI- control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+E- 
high leptin + ERKinhibitor, LA+E- low adiponectin + ERK inhibitor, HL+LA+E- 
high leptin + low adiponectin + ERK inhibitor) 
 
Figure 3.1.9 shows that ERKI inhibits the effect of high leptin and low 
adiponectin concentration on TIMP3 expression. The increase of the expression 
of TIMP3 by leptin (16ng/ml) and adiponectin low adiponectin (36ng/ml) is 
blocked significantly by ERK inhibitor (10µg/ml). Adiponectin in low 
concentration reduced the effect of high leptin on TIMP3 gene expression (with 
an overall increase in gene expression) and blocking ERK in the leptin and 
adiponectin combination leads to an inhibition of TIMP3 expression. . P-
value<0.05 using the students T-Test (2 way) to compare controls to samples. 
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3.3.2.3 The effect of 24 hour exposure of EAHY cells to p38I on 
the expression of angiogenic genes in the presence of leptin 
and adiponectin 
3.3.2.3.1 p38 Inhibitor inhibits the effect of leptin on MMP2 gene 
 
Figure 3.1.10 Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of MMP2 
gene. (C-Control, HL-high leptin, LA-low adiponectin, HL+LA- high leptin + low 
adiponectin, HA+LA- high adiponectin + low adiponectin, HL+P- high leptin + 
p38 inhibitor, LA+P- low adiponectin + p38 inhibitor,  HL+LA+P- high leptin + 
low adiponectin + p38 inhibitor) 
 
Figure 3.1.10 shows that P38I inhibits effect of high leptin and low adiponectin 
concentration on MMP2 expression. The increase of the expression of MMP2 
by leptin (16ng/ml) is blocked by P38 inhibitor (10µg/ml). Adiponectin in low 
concentration (36ng/ml) reduced the effect of high leptin on MMP2 gene 
expression (with an overall increase in gene expression) and blocking p38 in 
the leptin and adiponectin combination leads to an inhibition of MMP2 
expression. The effect of the adiponectin appears not to be affected by the 
p38I. . P-value<0.05 using the students T-Test (2 way) to compare control to 
sample. 
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3.3.2.3.2 P38I inhibits the effect of leptin and adiponectin on 
TIMP2 gene expression 
 
Figure 3.1.11 Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP2 
gene. (CTIMP2 p38-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+P- 
high leptin + p38 inhibitor, LA+P- low adiponectin + p38 inhibitor,  HL+LA+P- 
high leptin + low adiponectin + p38 inhibitor) 
 
Figure 3.1.11 shows that P38I inhibits the effect of high leptin on TIMP2 
expression. The increase of the expression of TIMP2 by leptin (16ng/ml) is 
blocked by P38 inhibitor (10µg/ml). Adiponectin in low concentration (36ng/ml) 
reduced the effect of high leptin on TIMP2 gene expression (with an overall 
increase in gene expression) and blocking P38 in the leptin and adiponectin 
combination leads to an inhibition of TIMP2 expression (p<0.05). The effect of 
the adiponectin is inhibited by the p38I. . P-value<0.05 using the students T-
Test (2 way) to compare controls to samples. 
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3.3.2.3.2 p38I inhibits the effect of leptin and adiponectin on 
TIMP3 gene expression 
 
Figure 3.1.12 Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP3 
gene. (CTIMP3 p38-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+P- 
high leptin + p38 inhibitor, LA+P- low adiponectin + p38 inhibitor,  HL+LA+P- 
high leptin + low adiponectin+ p38 inhibitor) 
 
Figure 3.1.12 shows that P38I inhibits the effect of high leptin and low 
adiponectin on TIMP3 expression. The increase of the expression of TIMP3 by 
leptin (16ng/ml) and adiponectin (36ng/ml) is blocked by P38I (10µg/ml). 
Adiponectin in low concentration reduced the effect of high leptin on TIMP2 
gene expression (with an overall increase in gene expression) and blocking P38 
in the leptin and adiponectin combination leads to an inhibition of TIMP3 
expression (significant). The effect of the adiponectin is inhibited by the p38I. . 
P-value<0.05 using the students T-Test (2 way) to compare control to sample. 
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3.3.3 Regulation of genes that code for atherosclerotic proteins 
by leptin and adiponectin individually and in combination 
3.3.3.1 Effect of Leptin and adiponectin on LPL 
a) 
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b) 
Figure 3.2.1 Effect of leptin and adiponectin individually and in 
combination on LPL gene expression. (C- control, HL-high leptin, LL-low 
leptin, HA-high adiponectin, LA-low adiponectin, HL+LA- high leptin + low 
adiponectin, HA+LA- high adiponectin + low adiponectin) 
 
Figure 3.2.1 shows that leptin and adiponectin increases the expression of LPL 
gene expression while combination of leptin and adiponectin down-regulates 
the expression of LPL. The results show that Leptin increased LPL expression 
in high concentrations (3.2.1a) while adiponectin reduces the expression of LPA 
in High concentrations (3.2.1b). Also there is a significant reduction in the 
expression of the gene when leptin and adiponectin was combined (3.2.1 a and 
b). p<0.05 using ANOVA and Tukey's multiple comparison tests for the 
comparison between untreated and Leptin and adiponectin treated cell. 
HA+LLLLHAC
2.5
2.0
1.5
1.0
0.5
0.0
ADIPOKINES
R
A
T
IO
 N
U
M
B
E
R
Bars are One Standard Error from the Mean
Individual standard deviations were used to calculate the intervals.
EFFECT OF LEPTIN AND ADIPONECTIN ON LPL GENE EXPRESSION
XX
X
170 
 
3.2.2 Effect of Leptin and Adiponectin on LPA gene expression 
a) 
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b) 
 
Figure 3.2.2 Effect of leptin and adiponectin individually and in 
combination on LPA gene expression. (C- control, HL-high leptin, LL-low 
leptin, HA-high adiponectin, LA-low adiponectin, HL+LA- high leptin + low 
adiponectin, HA+LA- high adiponectin + low adiponectin) 
 
Figure 3.2.2 shows that leptin increases and adiponectin reduces the 
expression of LPL gene expression while combination of leptin and adiponectin 
down-regulates the expression of LPA. The results show that Leptin increased 
LPL expression in high concentrations (3.2.2a) while adiponectin reduces the 
expression of LPA in High and low concentrations (3.2.2b). Also there is a 
significant reduction in the expression of the gene when leptin and adiponectin 
was combined (3.2.2a and b). p<0.05 using ANOVA and Tukey's multiple 
comparison tests for the comparison between untreated and Leptin and 
adiponectin treated cell. 
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3.3.4 The effect of 24 hour exposing EAHY cells to AMPKI in the 
presence of leptin and adiponectin on angiogenic gene  
3.3.4.1 AMPKI inhibits the effect of leptin on LPA gene 
expression  
 
 
 
Figure 3.2.3 Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of LPA 
gene. (CAMPKI LPA-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+AM- 
high leptin+ AMPK inhibitor, LA+AM- low adiponectin + AMPK inhibitor,  
HL+LA+AM- high leptin + low adiponectin+ AMPK inhibitor) 
 
 Figure 3.2.3 shows that AMPKI inhibits the effect of high leptin concentration 
on LPA expression. The increase of the expression of LPA by leptin (16ng/ml) is 
blocked significantly by AMPKI (10µg/ml). The inhibitory effect of low 
adiponectin (36ng/ml) on LPA was also blocked but not significantly. 
Adiponectin in low concentration reduced the effect of high leptin on LPA gene 
expression and blocking AMPK promotes the effect of leptin. P-value<0.05 
using the students T-Test (2 way) to compare control to sample. 
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3.3.4.2 ERKI inhibits the effect of leptin and adiponectin on LPA 
gene expression 
 
Figure 3.2.4 Role of ERK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of LPA 
gene. (CLPA ERK-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+E- 
high leptin + ERK inhibitor, LA+AM- low adiponectin + ERK inhibitor,  HL+LA+E- 
high leptin + low adiponectin + ERK inhibitor) 
 
ERKI inhibits effect of high leptin and adiponectin in LPA expression. The 
increase of the expression of LPA by leptin (16ng/ml) and adiponectin is 
blocked significantly by ERKI (10µg/ml). Adiponectin in low concentration 
(36ng/ml) reduced the effect of high leptin on LPA gene expression and 
blocking ERK promotes inhibition of LPA in the leptin and adiponectin 
combination. P-value<0.05 using the students T-Test (2 way) to compare 
control to sample. 
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3.3.4.3 p38I inhibits the effect of leptin and adiponectin on LPA 
gene expression 
 
Figure 3.2.5 Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of LPA 
gene. (CLPA p38-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+p- 
high leptin +  p38 inhibitor, LA+P- low adiponectin + p38 inhibitor,  HL+LA+P- 
high leptin + low adiponectin + P38 inhibitor) 
 
Figure 3.2.5 shows that p38I inhibits effect of high leptin and adiponectin in LPA 
expression. The increase of the expression of LPA by leptin (16ng/ml) and 
adiponectin is blocked significantly by p38 inhibitor (10µg/ml). Adiponectin in 
low concentration (36ng/ml) reduced the effect of high leptin on LPA gene 
expression and blocking p38 promotes inhibition of LPA in the leptin and 
adiponectin combination. P-value<0.05 using the students T-Test (2 way) to 
compare control to sample. 
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3.3.5 Effect of p38 inhibitor and ERK inhibitor on 
MMP2,TIMP2,TIMP3 gene expression: further review with real 
time PCR 
Though the expression of the genes has been explored by reverse transcription 
PCR, it was important to carry out a real time PCR in order to more accurately 
measure the expression of the genes expressed in order to more qualitatively 
assess the gene expression. The genes were well expressed with a Ct value of 
between 23 and 25. 
3.3.5.1 Effect of P38 inhibitor on MMP2, TIMP2, TIMP3 gene 
expression  
3.3.5.1.1 Effect of P38 inhibitor on MMP2 gene expression 
Figure 3.2.6 Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of MMP2 
gene. (CMMP2 P-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+P high 
leptin + p38 inhibitor, LA+P- low adiponectin + p39 inhibitor,  HL+LA+P- high 
leptin + low adiponectin + p38 inhibitor) 
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Figure 3.2.6 shows the effect of p38 inhibitor on MMP2 gene expression. There 
is a significant increase in the MMP2 gene expression by the high leptin (HL- 
16ng/ml) which is reduced by the P38 inhibitor (10µg/ml). Low adiponectin 
(36ng/ml) reduced the expression of the MMP2 gene and this effect was 
blocked by the P38i. The combination of high leptin and low adiponectin 
(HL+LA) lead to a significant increase in the MMP2 gene expression which was 
reduced by the p38I. These results (from the real-time PCR) are equivalent to 
those obtained in the semi-quantitative PCR analysis. P-value<0.05 using the 
students T-Test (2 way) to compare control to sample. 
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3.3.5.1.2 Effect of P38 inhibitor on TIMP2 gene expression 
 
 
Figure 3.2.7. Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP2 
gene. (CP38i -Control, HL-high leptin, LA-low adiponectin, HL+LA- high leptin + 
low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+P38i- high 
leptin + p38 inhibitor, LA+P38i- low adiponectin + p38 inhibitor,  HL+LA+P38i- 
high leptin + low adiponectin + p38 inhibitor) 
 
Figure 3.2.7 shows that there is an increase in the TIMP2 gene expression by 
the high leptin (HL-16ng/ml) which is reduced by the P38 inhibitor (10µg/ml). 
Low adiponectin (36ng/ml) significantly increased the expression of the TIMP2 
gene and this effect was blocked by the P38i. The combination of high leptin 
and low adiponectin (HL+LA) lead to a significant increase in the TIMP2 gene 
expression which was reduced by the p38I. P-value<0.05 using the students T-
Test (2 way) to compare control to sample. 
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3.3.5.1.3 Effect of p38 inhibitor on TIMP3 gene expression 
 
Figure 3.2.8. Role of p38 in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP3 
gene. (CTIMP3 P38-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+P38i 
high leptin + p38 inhibitor, LA+P38i- low adiponectin + p38 inhibitor,  
HL+LA+P38i- high leptin + low adiponectin + p38 inhibitor) 
 
Figure 3.2.8 shows the effect of p38 inhibitor on TIMP3 gene expression. There 
is a significant increase in the TIMP3 gene expression by the high leptin (HL- 
16ng/ml) which is reduced by the P38 inhibitor (10µg/ml). Low adiponectin 
(36ng/ml) increased the expression of the TIMP3 gene and this effect was 
blocked by the P38i. The combination of high leptin and low adiponectin 
(HL+LA) lead to a significant increase in the TIMP3 gene expression which was 
reduced by the p38i. P-value<0.05 using the students T-Test (2 way) to 
compare control to sample. 
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3.3.5.2 Effect of ERK inhibitor on MMP2, TIMP2 and TIMP3 gene 
expression 
3.3.5.2.1 Effect of ERK inhibitor on MMP2 gene expression 
 
Figure 3.2.9. Role of ERK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of MMP2 
gene. (CMMP2 E-Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+Ei 
high leptin + ERK inhibitor, LA+Ei- low adiponectin + ERK inhibitor,  HL+LA+Ei- 
high leptin + low adiponectin +  ERK inhibitor) 
Figure 3.2.9 shows the effect of ERK inhibitor on MMP2 gene expression. There 
is a significant increase in the MMP2 gene expression by the high leptin (HL- 
16ng/ml) which is reduced by the ERK inhibitor (10µg/ml). Low adiponectin 
36ng/ml) reduced the expression of the MMP2 gene and this effect was blocked 
by the ERKI. The combination of high leptin and low adiponectin (HL+LA) lead 
to a significant increase in the MMP2 gene expression which was reduced by 
the ERKI P-value<0.05 using the students T-Test (2 way) to compare control to 
sample. 
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3.3.5.2.2 Effect of ERK inhibitor on TIMP2 gene expression 
 
Figure 3.2.10. Role of ERK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP2 
gene. (CERKi -Control, HL-high leptin, LA-low adiponectin, HL+LA- high leptin 
+ low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+ERKi high 
leptin +  ERK inhibitor, LA+ERKi- low adiponectin + ERK inhibitor,  
HL+LA+ERKi- high leptin + low adiponectin + ERK inhibitor) 
 
 Figure 3.2.10 shows that there is a significant increase in the TIMP2 gene 
expression by the high leptin (HL-16ng/ml) which is reduced by the ERK 
inhibitor (10µg/ml). Low adiponectin (36ng/ml) increased the expression of the 
TIMP2 gene and this effect was blocked by the ERKI. The combination of high 
leptin and low adiponectin (HL+LA) lead to a significant increase in the TIMP2 
gene expression which was reduced by the ERKI. P-value<0.05 using the 
students T-Test (2 way) to compare control to sample. 
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3.3.5.2.3 Effect of ERK inhibitor on the expression of TIMP3 
gene
 
Figure 3.2.11. Role of ERK in the effect of treating cells with leptin and 
adiponectin individually and in combination on the expression of TIMP3 
gene. (C TIMP3 ERK -Control, HL-high leptin, LA-low adiponectin, HL+LA- high 
leptin + low adiponectin, HA+LA- high adiponectin + low adiponectin, HL+ERKi 
high leptin + ERK inhibitor, LA+ERKi- low adiponectin + ERK inhibitor,  
HL+LA+ERKi- high leptin + low adiponectin + ERK inhibitor) 
 
Figure 3.2.11 shows the effect of ERK inhibitor on TIMP3 gene expression. 
There is a significant increase in the TIMP3 gene expression by the high leptin 
(HL-16ng/ml) which is reduced by the ERK inhibitor (10µg/ml). Low adiponectin 
(36ng/ml) significantly increased the expression of the TIMP3 gene and this 
effect was blocked by the ERKi. The combination of high leptin and low 
adiponectin (HL+LA) lead to a significant increase in the TIMP3 gene 
expression which was reduced by the ERKI. P-value<0.05 using the students T-
Test (2 way) to compare control to sample. 
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3.4 Discussion 
 
Leptin and adiponectin are adipokines secreted by visceral fat and have been 
suggested to be links between obesity and cardiovascular diseases (Balistreri et 
al., 2010). Obese individuals have been shown to have high levels of leptin (due 
to leptin resistance) and low levels of adiponectin and this is said to predispose 
to CVD. This is  because leptin, which has been associated with an increase in 
the risk of CVD is at higher than normal levels, and adiponectin which has been 
linked with a reduction in the risk of CVD is at lower than normal levels (Dubey 
and Hesong 2006). Previous studies have shown a reverse of this in lean 
individuals (Klaus 2001). Also it has been shown that leptin increases the risk 
for CVD by increasing the expression of atherosclerotic and angiogenic genes 
(Park et al., 2001, Koh et al., 2008,), while adiponectin reduces the risk for CVD 
by reducing the expression of atherosclerotic and angiogenic genes and also 
reducing inflammation (Mattu and Randeva 2012). Adiponectin has also been 
suggested to reduce the risk of leptin causing CVD by inhibiting its effect on the 
expression of angiogenic and atherosclerotic genes (Zhang et al., 2012).The 
mechanisms responsible for this are still not completely understood.  
 
In the present study, the results in the experiments with endothelial cells 
suggest that leptin increases the risk of CVD while adiponectin reduces it and 
various pathways have been explored in order to better understand the reasons 
why the results are so. This study provides novel insights into the basis of the 
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effects and also explores the effect of the adipokines when combined which 
provides strong and interesting evidence that suggest that the risk of CVD 
predisposition by high leptin can be reduced by adiponectin. 
 
Angiogenesis which is the formation of new blood vessels from pre-existing 
blood vessels is linked to atherosclerosis (formation of an atheromatous plaque 
in the blood vessels or heart) and both form most of the basis for CVD (Cao 
2007). Studies have shown that CVD occurs when there is a derangement in 
the balance in the remodeling process carried out by MMP (Matrix 
Metalloproteinases) which break down excess tissues and TIMPs which inhibit 
MMPS, thereby ensuring just enough tissue formation in injuries and 
inflammatory processes within the blood vessels (can also lead to excess 
accumulation of collagen or extracellular matrix if there is an expression in 
excess) (Dollery et al., 1995). In this study, the angiogenic genes that were 
expressed by the EAHY cells are TIMP2 and 3 (Tissue Inhibitor of 
Metalloproteinases 2 and 3) and MMP2 (Matrix Metallopeptidase 2). It must be 
noted that the TIMP in practical terms act as a balance to MMPs and TIMP can 
predispose to CVD (atherosclerosis) if there is over-expression without a 
corresponding amount of MMPs to inhibit, while the MMPs can lead to 
angiogenesis and excess expression can lead to weakening of blood vessels, 
and excess smooth muscle cell migration and macrophage activation leading to 
an atheromatous plaque (Dollery et al., 1995). 
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In summary, the result from the present study shows that treating the cells with 
16ng/ml of leptin had the maximal effect in upregulating the MMP2, TIMP2 and 
TIMP3 (p˂0.05) while 3.6µg/ml of adiponectin caused a maximal down 
regulatory effect on MMP2 and an up-regulatory effect on TIMP2 and TIMP3 
(p˂0.05) compared to cells left untreated (controls). At high concentrations, 
adiponectin appears to be able to inhibit the increase in the expression of 
angiogenic genes, while at low concentration, adiponectin did not have any 
effect on the increase in the expression of the expressed angiogenic genes.  
 
Leptin on the other hand appears to have an up-regulatory effect on the 
angiogenic genes at high concentration and at low concentration leptin showed 
no significant effect on increasing the expression of angiogenic genes (Figures 
3.1.1- 3.1.3). With regards to atherosclerosis, results from this study shows that 
leptin increases while adiponectin reduces the expression of atherosclerotic 
genes and combining leptin and adiponectin causes a reduction in the 
expression of atherosclerotic genes when the concentration of adiponectin is 
high as against when the concentration of adiponectin is low. All these effects 
were also linked to the enzymes AMPK, ERK and p38. At 16ng/ml leptin 
increases LPL and LPA expression (p˂0.05) while adiponectin at 36ng/ml had 
an inhibitory effect on the LPA and LPL and 3.6µg/ml increase the expression of 
LPA genes (p˂0.05). A combination of the adipokines showed adiponectin at 
high concentrations inhibiting the expression of atherosclerotic genes while in 
low concentration, had no significant effect in reducing the effect of leptin in 
increasing the expression of atherosclerotic genes. The role of AMPK, ERK and 
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p38 in the effect of leptin and adiponectin was also explored (Figure 3.2.1-
3.2.7). 
 
The normal adiponectin level in humans is reported to be 3-14µg/ml while the 
human leptin concentration is between 5-15ng/ml in lean (Zabadi et al., 2010) 
and 10-50ng/ml in obese (Kazmi et al., 2013). In this study 3.6µg/ml and 
36ng/ml of adiponectin were used as the high and low concentrations of 
adiponectin (HA, LA) while 16ng/ml and 8ng/ml were used as the high and low 
concentrations of leptin (HL, LL).  
 
The experiments that gave rise to the results were designed to simulate what 
would be found in an obese diabetic or non-diabetic (HL+ LA) and lean person 
(HA+LL) (diabetic or non diabetic). It is therefore important to look at the results 
as a whole and not individually. 
 
A general overview of the effect of leptin on the angiogenic genes in this study 
shows that leptin increases the expression of TIMP 2, 3 and MMP2 in high 
concentrations only and not in low concentrations. This shows a resultant 
increase of angiogenic genes which may predispose to CVD especially in 
conditions like obesity where leptin levels are very high. On the other hand, 
adiponectin in high and low concentrations increased the expression of all the 
TIMPs but inhibited the expression of MMP at all concentrations. This suggests 
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that adiponectin has a resultant effect of reducing MMP2 which contributes to 
plaque formation and increases the expression of TIMPS which inhibits MMPs 
(Hopps et al., 2011). This therefore suggest a pattern that discourages plaque 
formation and slows down the formation of plaque by the breakdown of tissues 
which form plaque by the increase in TIMP leading to damage of vascular 
endothelial cells and embolus formation. 
 
 The combination of leptin (LL, HL) with adiponectin (HA, LA) shows a pattern of 
significant inhibition of angiogenic genes (TIMPs and MMPs) when the 
combination is HA+LL and that of a significant increase when HL+LA 
suggesting that when adiponectin is in a high enough concentration, it may 
have a neutralizing effect on the up-regulatory effect of leptin. Therefore looking 
more closely, with regards to angiogenesis, the results from this study suggests 
that leptin increases angiogenesis while adiponectin reduces it. Furthermore, a 
combination of leptin and adiponectin appear to reduce angiogenesis with 
evidence linking the involvement of AMPK, P38 and ERK enzymes in the 
effects of leptin and adiponectin. 
 
 In vitro studies on the effect of leptin on angiogenesis have shown that leptin 
increases the expression of TIMP 2, TIMP3 and MMP2 at concentrations of 10-
40 ng/ml( Cao, 2007, Qi et al 2004, and Park et al 2001, Chen  et al 2012, 
Madani et al., 2005) thus suggesting that leptin increases the risk of 
angiogenesis. Therefore the data from the results in figure 3.1.1 to 3.2.11 
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strongly highlights the potential role of leptin in angiogenesis based on the 
significant (P <0.05) up-regulation of the three genes by 16ng/ml (HL) of leptin. 
The results show that at 8ng/ml (LL), leptin had no significant effect on these 
genes. This view is in contrast to the studies carried out by Xia et al (2006) 
which was done on rodents and which suggested that leptin inhibits TIMP2 
secretion. This highlights the variation in the results of in-vivo compared to in-
vitro studies and could suggest the need to do more in-vitro studies in order to 
further investigate the effect of leptin on TIMP2. 
 
 As stated earlier, the basis of the effect of leptin on the angiogenic genes was 
investigated by exploring the role of AMPK (5’ AMP- activated protein kinase), 
ERK (Extracellular signal-regulated kinase) and p38 (p38 mitogen-activated 
protein kinase). In the study by Li et al. (2005) and Madani et al. (2006), the 
effect of leptin on angiogenic genes was shown to be mediated through ERK 1 
and 2 and p38 MAPK. Minikoshi and Khan (2003), however suggested that 
leptin mediates fatty acid oxidation in skeletal muscles via AMPK, thus inhibiting 
the effect of fat cells on insulin sensitivity (lipid toxicity), but very little is known 
about the role of AMPK in the effect of leptin in angiogenesis. The present study 
strongly supports the view that leptin mediates its action on angiogenic genes 
via ERK and p38 MAPK. It is also interesting to note that the result from this 
study suggest that AMPK is involved in the effect of leptin in the expression of 
angiogenic genes. This may be another area for further studies in the future. 
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The studies by Kim et al. (2009), Nakasone et al. (2013), Chen et al. (2012) and 
Zhu et al. (2008) suggested that adiponectin has vaso-protective qualities and 
showed that adiponectin increases the expression of TIMP2 and TIMP3 and 
inhibits the expression of MMP2 at adiponectin concentrations between 30ng/ml 
to 20µg/ml. It was suggested by Madani et al. (2005) that MMP2 is mainly 
responsible for breakdown of extracellular matrix as it is said to be able to 
activate other MMPs. The implication of this is that if it is expressed in excess, it 
is able to break down scars from damages to the heart causing ballooning of 
the heart and may also dislodge atheromatous plaques thus predisposing to 
embolism (Madani et al 2005).TIMPs have been shown to balance this effect 
(Chen et al 2012). The data in figure 3.1.1 – figure 3.2.11 (especially the effect 
of high adiponectin- 3.6µg/ml), provides further support to these studies by 
further providing a strong evidence to support the view that leptin is vaso 
protective. However, not all the previous studies agree with this view as studies 
by Adya et al. (2012) and Benaitrueau et al. (2010) have suggested that 
adiponectin increases the expression of MMP2 and reduces the expression of 
TIMP2. The difference in results may be due to the fact that it was the globular 
adiponectin (gAd) that had the up-regulatory effect on MMP2 unlike the full 
length (fAd) which is what is used in the present study and elicits an inhibitory 
effect on the expression of MMP2 and Beaitrueau et al. (2010) used low doses 
(25-250ng/ml) which is much lower than the adiponectin concentration that 
inhibited MMP2 in the present study. 
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Adiponectin has been shown to mediate its effects on angiogenic genes via 
AMPK (Kim et al., 2009, Zhang et al., 2012, Mattu and Randeva 2012), ERK 1 
and 2 (Lee et al., 2008). Adiponectin has been suggested to increase fatty acid 
oxidation in skeletal muscles via p38 MAPK. This process has been shown to 
reduce “lipotoxicity” and reduces insulin resistance in skeletal muscles (Yoon et 
al., 2006).  Very little has however been done to explore the role of p38 MAPK 
in the pathogenesis of angiogenesis and atherosclerosis. It is interesting to note 
that the result from this study does not support (with a significant result) the 
suggestion that AMPK mediates the effect of adiponectin on the angiogenic 
genes as the effect seen was inhibited in a few cases (but not significantly) and 
in some not inhibited at all by AMPK inhibitor. The reason for the difference may 
be as a result of the fact that some of the previous studies have used 
concentrations of AMPKI ranging from 1-100µg/ml (against 10µg/ml in the 
present study) in in-vivo and in-vitro experiments with varying conditions. The 
role of ERK in the effect of adiponectin on angiogenic genes was strongly 
highlighted in figures 3.1.7-3.1.9 where the up regulatory effect of adiponectin 
was significantly (P<0.05) blocked by the ERK inhibitor. The results in figures 
3.1.10-3.1.12 suggests that p38MAPK may have a role in mediating the effect 
of adiponectin on angiogenic genes. Due to the fact that there are very few 
studies that have looked at this, the role of p38MAPK in angiogenesis in 
endothelial cells may need to be further explored in future research. 
 
With regards to the role of leptin in atherosclerosis, the expression of LPA and 
LPL was explored. Studies by Maingrette and Reiner (2003), Hirata et al. (1999) 
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and Mead and Ramji (2001), suggested that LPL is not synthesized in 
endothelial cells, but in parenchymal cells such as adipocytes, muscle cells and 
macrophages. LPL in the plasma is said to be anti-atherogenic while LPL 
secreted by macrophages in the arterial wall promotes the retention of 
lipoproteins in the subendothelial space and favours the adhesion of monocytes 
to the endothelium and the transformation of these monocytes to macrophages 
which further attracts more monocytes by the secretion of more LPL (Dubey 
and Hesong 2006). In these tissues however, it was shown that a concentration 
of 10nM of leptin (as against 1nM used in the present study) is able to increase 
the expression of LPL. Results from the present study provide evidence to show 
that the LPL gene is expressed by endothelial cells as against the view from 
previous studies that suggest that LPL is produced only by parenchymal cells.  
 
LPA (Lipoprotein a) has been suggested to be a risk factor for atherosclerosis 
and the basis of this has been explained to be due to similarities in structure 
between LPA and plasminogen. LPA binds to plasminogen activator receptor 
and interrupts the effect of plasminogen activator which converts plasminogen 
to plasmin thereby inhibiting the formation of plasmin, and therefore the 
breakdown of fibrin by plasmin leading to accumulation of fibrin and an increase 
in the risk of atherosclerosis (Buechler et al., 2001). The result from the present 
study therefore highlights the possible risk of leptin being an atherosclerotic 
factor as the result shows that 1nM leptin caused a significant up-regulation in 
LPA gene expression in endothelial cells. Therefore, result in figure 3.2.1 
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provides evidence that suggest that leptin at 1nM increases LPA gene 
expression. 
 
The experiments which form the basis of the results shown in figure 3.2.3 -3.2.5 
explore the possibility of AMPK, ERK and p38 MAPK forming the basis of the 
effect of leptin on LPA. The result suggest that the up-regulatory effect of leptin 
on LPA is mediated by AMPK, ERK and p38 MAPK. Most of the previous 
studies on the effect of leptin on LPA and LPL have not explored the basis of 
the effect. 
 
Studies by Ganguly et al. (2011), Qiaio et al. (2008) suggest that adiponectin 
increases the expression of LPL in cardiomyocytes (at 5µg/ml), skeletal 
muscles (at 10µg/ml) while the research by Sanchez-Gurmaches et al. (2011) 
suggests that adiponectin inhibits LPL expression at 2.5µg/ml. These varying 
results can be a challenge to interpretation but as the conditions for the various 
experiments varies, it must be stated that the conditions closest to the ones 
used in the present study are the ones in the study by Gurmaches et al in which 
2.5µg/ml (closer to the 3.6µg/ml in the present study) of adiponectin elicited an 
inhibition in LPL. This may suggest that adiponectin reduces the risk of 
atherosclerosis by reducing LPL gene expression. Due to the variation in the 
results, more studies need to be done to further understand the reason for all 
the variations in the results. The result in figure 3.2.2 suggests that 3.6µg/ml of 
adiponectin causes an inhibition in the expression of LPA. There are very few 
studies done previously to explore the effect of adiponectin on LPA gene 
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expression in endothelial cells. The present study therefore provides further 
evidence to support the suggestion that adiponectin is vasculo-protective. 
 
In the present study, the basis of the effect of adiponectin on atherosclerotic 
genes was explored by considering the possibility of the effects of adiponectin 
seen being mediated via AMPK, ERK, p38 MAPK. Figure 3.2.3- 3.2.5 provides 
evidence of the involvement of ERK and p38 MAPK and not AMPK. 
 
It is interesting to note that the effect of adipokines in combination are not 
completely understood and have not been explored by most of the previous 
studies. In the present study, it was therefore important to explore the effect of a 
combination of leptin and adiponectin on atherosclerotic and angiogenic genes 
and also to explore the basis of the effects seen in the combination (by 
exploring the roles of ERK, AMPK and p38 MAPK). From the results presented 
in figures 3.1.1- 3.2.11, adiponectin at high (3.6µg/ml) was able to inhibit the up-
regulatory effect of leptin on angiogenic and atherosclerotic genes while at low 
concentrations of adiponectin, the counter-regulatory effect was not as distinct 
and in some of the real-time PCR results, the combination of HL with LA acted 
synergistically to increase the expression of the angiogenic genes.  
 
The results also explored the roles of ERK, p38MAPK and AMPK in the effects 
seen in the combinations. ERK and P38 MAPK appeared to have the most 
consistent effect on blocking the effect of the combination leading to a gene 
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expression that was several 1-2 folds less than the up-regulatory effect of leptin 
seen in angiogenic and atherosclerotic genes. 
 
In the present study, it is interesting to see that LPA and LPL are well 
expressed in endothelial cells as against the suggestions by previous 
researchers that LPA and LPL are not expressed in endothelial cells. Also it is 
interesting to see that for the first time, this study has provided extensive 
evidence that adiponectin is able to reduce the risk of leptin causing 
angiogenesis and atherosclerosis (and therefore CVD) in endothelial cells, 
thereby reducing the risk of CVD. 
 
This study has therefore produced new evidence relating to the link between 
obesity and CVD and suggests that researchers and clinicians may work 
together to develop an adiponectin based therapy which may reduce the risk of 
CVD seen when leptin is high in obese and diabetic individuals.  
 
An area for future research will be to further explore other genes that have not 
been well expressed such as VEGF and ICAM which are very critical to 
angiogenesis and atherosclerosis.   
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Chapter 4 
Regulation of insulin and amylin 
secretion by Leptin and Adiponectin  
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4.1 Introduction 
 
Diabetes mellitus is a condition that arises from an absence or reduction in 
insulin secretion or when there is insulin resistance in the presence or absence 
of adequate insulin secretion (WHO 1999). The role of obesity in the 
development of diabetes has been linked with adipokines and in type 2 
diabetes, adipokines have been linked with beta cell failure or death which 
leads to a reduction in the cells mass and insulin production and also the 
development of resistance to insulin (Dunmore and Brown 2013). On the other 
hand, amylin has also been linked with the development of diabetes as it is said 
to aggregate at high concentrations to form amyloid which can be deposited in 
the pancreas and can destroy beta cells. Amylin is also said to inhibit insulin 
secretion (Ionescu-Tirgoviste et al., 2010).  
 
Previous studies have suggested that monolayer beta cells do not produce 
insulin in a way that is physiological enough for experimental investigation of 
insulin secretion and therefore, some research has been done which has lead 
to the growing of beta cells into clusters of cells that are morphologically similar 
to islets of Langerhans (thus called “pseudo-islets”) which have been shown to 
produce insulin in a more co-ordinated way (for example the exhibition of 
physiological biphasic response to high glucose) (Persaud et al., 2010). 
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The basis for beta cell dysfunction is not completely understood and based on 
the complexity of the processes involved, various biological and genetic 
pathways such as the influence of the PP-1 gene, have been explored and key 
to this are the pathways by which insulin is secreted and those which insulin 
influences. Also contributing is the possible effect of amylin on insulin secretion.  
 
Previous studies have tried to investigate what the effect of leptin and 
adiponectin has on insulin secretion and the basis of these effects. Leptin has 
been reported to inhibit insulin secretion in the majority of the studies, while 
adiponectin has been found to have a variable effect on insulin secretion (Lee 
et al., 2011; Dunmore and Brown 2013), in addition to reducing insulin 
resistance (Seufert 2004; Okamoto 2006). The roles of leptin and adiponectin 
are however still not completely understood. This study aimed to find out what 
the effect of leptin and adiponectin (individually and in combination) is on insulin 
secretion and to investigate the molecular basis of this effect in terms of the 
various signaling factors involved and also the genetic basis of the effect of 
leptin and adiponectin on insulin secretion. The present study also aimed to 
investigate the effect of these adipokines on amylin secretion.   
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4.2 Materials and Methods 
The materials and the methods used for experiments that concern this chapter 
are detailed in the materials and method chapter (chapter 2) 
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4.3 Results 
4.3.1 Dose response of monolayer β-cells versus pseudoislets 
to glucose   
a) 
 
b) 
 
Figure 4.3.1 Dose response of monolayer beta cells compared to 
pseudoislets. (a) Dose response for pseudoislets and (b) is dose response for 
monolayer beta cells 
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Figure 4.3.1 a and b show that pseudo-islets have better response to glucose 
than mono-layer cells. There is a significant 3 fold increase in the insulin 
secretion when insulin produced by 2mM is compared to the 25mM as against a 
2 fold increase in monolayers Cells. The pseudo-islets also have better controls 
and generally produce more insulin than mono-layer beta cells. P-value<0.05 
using the students T-Test (2 way) to compare control to sample. 
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4.3.2 The effect of leptin adiponectin on insulin secretion in low 
(2.2mM) and high glucose (22mM) in pseudoislets  
a) 
 
b) 
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c) 
 
d) 
 
Figure 4.3.2 Effect of leptin and adiponectin in low and high glucose on 
insulin secretion. a) Effect of leptin in low glucose, b) effect of leptin in high 
glucose, C) effect of adiponectin in low glucose  
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Figure 4.3.2 shows that leptin inhibits insulin secretion and adiponectin 
increases insulin secretion.  A concentration of 200 and 500ng/ml of leptin has 
a significant inhibitory effect on insulin secretion in high glucose(22mM) and low 
glucose (2.2mM) respectively , while 5µg/ml and 1µg/ml of adiponectin produce 
a significant increase in insulin secretion in low high and low glucose 
respectively. P-value<0.05 using the students T-Test (2 way) to compare 
control to sample. 
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4.3.3   Effect of leptin and adiponectin on amylin secretion in 
low (2.2mM) and high glucose (22mM) in pseudoislets  
a) 
  
b) 
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c) 
 
d) 
 
 
Figure 4.3.3 Effect of leptin and adiponectin in low and high glucose on 
amylin secretion. a) Effect of leptin in low glucose, b) effect of leptin in high 
glucose, C) effect of adiponectin in low glucose  
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Figure 4.3.3 shows that leptin increases amylin secretion and adiponectin 
reduces amylin secretion.  A concentration of 200 and 500ng/ml of leptin has a 
significant  effect on increasing insulin secretion in high glucose(22mM) and low 
glucose (2.2mM) respectively, while 5µg/ml  of adiponectin produced a 
significant decrease in amylin secretion in low glucose. P-value<0.05 using the 
students T-Test (2 way) to compare control to sample. 
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4.3.4 Comparing the effect of leptin and adiponectin on insulin 
to the effect on amylin 
a) 
 
b) 
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c) 
 
d) 
 
Figure 4.3.4 Effect of adiponectin on insulin compared to amylin in low 
and high glucose. a)Effect of adiponectin on insulin secretion in low 
glucose(2.2mM) b)effect of adiponectin on amylin in low glucose (2.2mM), C) 
effect of adiponectin on insulin secretion in high glucose(22mM), d) effect of 
adiponectin on amylin secretion in high glucose (22mM) 
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Figure 4.3.4 shows an increase in amylin secretion which corresponds to a 
reduction in insulin secretion and vice-versa. The amylin secretion at various 
concentrations in a treatment where the same cells were assayed for insulin 
and amylin showed a corresponding inverse pattern of secretion of amylin and 
insulin in the treatments with adiponectin in low and high glucose. P-value<0.05 
using the students T-Test (2 way) to compare control to sample. 
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a) 
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c) 
 
d) 
 
Figure 4.3.5 Effect of leptin on insulin compared to amylin secretion in low 
and high glucose. a)Effect of leptin on insulin secretion in low glucose(2.2mM) 
b) effect of leptin on amylin in low glucose (2.2mM), C) effect of leptin on insulin 
secretion in high glucose(22mM), d) effect of leptin on amylin secretion in high 
glucose (22mM) 
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 Figure 4.3.5 shows an increase in amylin secretion that corresponds to a 
reduction in insulin secretion and vice-versa. The amylin secretion at various 
concentrations in a treatment where the same cells treatments were assayed 
for insulin and amylin showed a corresponding inverse pattern of secretion of 
amylin and insulin in the treatments with leptin in low and high glucose. P-
value<0.05 using the students T-Test (2 way) to compare control to sample. 
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4.3.5 Role of Protein Phosphatase 1 (PP-1) in the effect of leptin 
in insulin secretion 
a) 
 
b) 
 
Figure 4.3.6 Effect of leptin on PP-1 gene expression in low and high 
glucose concentrations (a) effect in low glucose (2.2mM), (b) effect in high 
glucose (22mM) 
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Figure 4.3.6 shows that leptin Inhibits PP-1 gene expression. Results show 
500ng/ml of leptin in low glucose inhibiting the PP-1 gene expression 
significantly (p<0.05). P-value<0.05 using the students T-Test (2 way) to 
compare control to sample. 
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4.4.1 Discussion 
 
 Type 2 diabetes mellitus is a condition which results from insulin deficiency 
(either due to inadequate production of insulin or due to resistance to normal 
amounts of insulin, or both  as seen in obese individuals) (WHO1999). Diabetes 
is strongly linked to obesity and CVD (Ley et al., 2009; Mattu and Randeva 
2012). Obesity is a major factor in the development of type 2 diabetes partly 
because fat cells produce adipokines (such as leptin and adiponectin) and 
adipokines have been shown by numerous studies to be potential links between 
obesity and diabetes. Furthermore, obesity has been shown to cause insulin 
resistance due to the fact that fatty acid together with acyl-CoAs, ceramides, 
and diacyglycerol may act on the insulin signalling pathway by activating protein 
kinases such as Protein Kinase C (PKC), Jun kinase (JNK), and the inhibitor of 
nuclear factor-кB (NF-кB) kinase-β (IKKβ). These kinases are reported to impair 
insulin signalling by increasing the inhibitory serine phosphorylation of insulin 
receptor substrates (IRS) which is the main mediator of insulin signalling 
thereby inhibiting insulin secretion (Qatanani and Lazar 2007).  
 
It was shown in the study by Maedler et al (2008) that leptin which is usually 
high in obese individuals, inhibits insulin secretion and also causes beta cell 
death (therefore suggesting that leptin is one of the factors that link obesity to 
T2DM), while adiponectin increases insulin sensitivity and insulin secretion 
(Seufert 2004). Insulin secretion has been used extensively as an experimental 
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parameter to assess beta cell function (Persaud 2010). In order to assess what 
the possible basis of diabetes is, it was considered important in the present 
study to grow beta cells as pseudo-islets (which have not been widely used but 
have been shown by researchers to produce more insulin and secrete it in a 
more physiological manner than monolayer beta cells) and also to explore the 
effect of leptin and adiponectin on amylin secretion (Persaud 2010).  . 
 
Beta cells were grown in 24 well plates coated with gelatin leading to formation 
of pseudoislets and then treated in the presence of Krebs Hepes buffer with low 
and high glucose (2.2mM and 22mM respectively) together with a range of 
adipokine concentrations. The insulin and amylin secreted by the cells were 
then assayed. Results from this study suggest that leptin predisposes to T2DM 
(due to a reduction in insulin secretion and increase in amylin secretion) while 
adiponectin reduces the risk of T2DM (increases insulin secretion and inhibits 
amylin secretion. Amylin secretion and insulin secretion were compared and the 
insulin/amylin ratio in most of the samples was high compared to the reported 
normal ratio. 
 
Before initiating the adipokine experiments, it was important to find out if the 
cells responded to glucose with insulin release therefore the beta cells were all 
treated with a range of glucose concentrations in the absence of adipokines. In 
this study pseudoislets exhibited a dose response of increasing insulin 
secretion over a range of glucose concentrations, although this was only 
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significant at the higher glucose concentrations. In monolayer cells the 
response was relatively flat until higher concentrations of 25-30mM glucose 
which caused a 1.5-3 fold increase (p˂0.05) in insulin secretion when compared 
to the control or 1mM and 2mM treatment. (Fig 4.3.1), These results further 
support  the findings in the study by Chowdhury et al (2013) which suggested 
that there is more insulin secretion in pseudoislet compared to monolayers 
Cells. The data in figure 4.3.1 also suggest that pseudoislets have a better 
control response (at zero glucose concentration) when compared with 
monolayer cells.  
 
The results in figure 4.3.2 show a significant inhibition (p ˂0.05) of insulin 
secretion by 200ng/ml (12nM) leptin in high glucose (22mM) and 500ng/ml 
(30nM) in low glucose (2.2mM). In the previous studies (Lee et al., 2011, Brown 
et al., 2002, Roduit and Thorens 1999, Zhao et al., 1998) beta cells have been 
treated with leptin concentrations varying from 0.1 to 100nM and in various 
concentrations of glucose (representing very low glucose and high glucose as 
can be seen in diabetics.) The results of the current study provide further 
evidence which confirms the suggestion from previous research that leptin 
inhibits insulin secretion.  In the present study, there is evidence to suggest that 
the pattern seen in inhibition might be linear as suggested by Brown et al. 
(2002) or an inverted “U” shape as suggested by Roduit and Thorens (1999) 
where 10nM and 100nM of leptin was shown to have a significant inhibitory 
effect on insulin secretion. This is in contrast to the “U” shape reported by 
Brown et al. (2002) and the reason for this may be as a result of the batch of 
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cells used. The implication of this may be the possibility of obesity (high leptin) 
in diabetes leading to a further inhibition in insulin secretion which complicates 
the insulin resistance that may be present in obese diabetics as suggested by 
Zhao et al. (2004). 
 
 Adiponectin at 1 and 5 µg/ml increased insulin secretion significantly (p˂0.05) 
in the present study. This may suggest the possibility of adiponectin increasing 
insulin secretion even under diabetic conditions (very low and very high 
glucose), and this provides further evidence supporting the findings by Okamoto 
et al. (2008). 
 
The study of the effect of adiponectin on insulin secretion has been 
controversial as there has been varying views on the effect of adiponectin in low 
and high glucose on insulin secretion. Previous studies by Gu et al. (2006) 
suggest that 0.1µg/ml( 2.5nM) of adiponectin causes an increase in insulin 
secretion only in high glucose (16.7mM) while Okamoto et al. 2008 shows that 
10µg/ml (300nM) of adiponectin caused an increase in insulin secretion only in 
low glucose (5.6mM). In the present study 0.1, 0.2, 0.5, 1, and 5µg/ml of 
adiponectin were used in the treatment of beta cells in low (2.2mM) and high 
glucose (22mM) and the result are shown in figure 4.3.3. These variations in 
results may be a consequence of the differing concentrations of adiponectin 
and glucose used in these experiments and may therefore require 
standardization on future studies. 
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In investigating the effect of leptin and adiponectin on amylin secretion, 0.1, 0.2, 
0.5, 1 and 5µg/ml (3, 6, 15, 30 and 150 nM) of adiponectin and 10, 50, 100, 200 
and 500ng/ml (1, 3, 6, 12, 30nM) of leptin was used to treat beta cells. In the in-
vivo study in humans by Hwang et al. (2008) it was suggested that leptin had no 
effect on amylin secretion, while the in vitro study in rodents by  Karlsson et al. 
(1998) suggested that long term treatment with leptin (1-100nM for 2-5 days) 
inhibits amylin secretion at various glucose concentrations from 1.7mM to 
16.7mM. In the present study, the result depicted in figures 4.3.3 to 4.3.5 gives 
a different perspective as it suggests that leptin increases amylin secretion 
significantly at 500ng/ml (30nM). The difference seen in these studies may be 
as a result of the use of different species of subjects, the use of pseudoislets in 
the present study as against the treatment of pancreatic islets in previous 
studies and also the varying periods of treatment with leptin. This suggests that 
more studies may need to be done under similar conditions in the future to 
make comparison easier. As seen in the effect of leptin on amylin secretion 
(with very few studies done prior to the present study), there was no previous 
directly comparable study done previously on the effect of adiponectin on 
amylin secretion. Figures 4.3.3 to 4.3.5 in the present study show that 
adiponectin inhibits amylin secretion significantly at 5µg/ml (150nM) in low and 
high glucose concentrations. The results from the present study may be 
tentatively taken to suggest that leptin may predispose to diabetes as a result of 
an increase in amylin secretion leading to an increase in amyloid accumulation, 
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while adiponectin may reduce the risk of diabetes as a result of a decrease in 
amylin secretion. 
Amylin is a peptide that is co-secreted with insulin from the pancreas and one of 
the factors that keeps the glucose concentration in the blood stable by delaying 
gastric emptying and intestinal absorption when there is an increase in the 
amount of glucose in the body and vice-versa when there is a hypoglycaemia 
(Karlsson 2000). In the current study, pseudo-islets were treated with 
adipokines and the assay of the insulin and amylin secretion for the same 
sample was done to explore the hypothesis that the amylin/insulin ratio may 
change insulin secretion. 
 
 In figure 4.3.4, there appears to be an inverse correlation between insulin and 
amylin secretion in the samples treated with 1µg/ml and 5µg/ml of adiponectin. 
The amylin secretion in the sample treated with 1µg/ml is increased relative to 
the control and this is contrasted with a relative reduction in insulin secretion in 
the same treatment, and vice-versa in the treatment with 5µg/ml where the 
amylin secretion is relatively reduced when compared to the control and this is 
combined with a significant increase in insulin secretion. This is in agreement 
with the research by Karlsson et al., (1998) and is in contradiction to the 
suggestions by Tedstone et al., (1990) which suggested that amylin had no 
effect on insulin secretion. A similar pattern is seen in the cells treated in high 
glucose as the u shaped pattern of increase in insulin secretion by adiponectin 
correlates with the inverted “u” shape of the amylin secretion. This suggests an 
equal and opposite action on amylin compared to insulin secretion. This 
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suggest that high adiponectin, in low or high glucose even with an increase in 
amylin secretion may be able to boost insulin secretion. 
In figure 4.3.4, the pattern of the increase in amylin correlates with a 
corresponding reduction in insulin secretion in cells treated with leptin in low 
glucose. There is an exact equal and opposite significant reduction in insulin 
secretion which contrasts with an increase in amylin secretion. In the cells 
treated with leptin in high glucose (figure 4.3.5), there is a corresponding 
reduction in insulin secretion which correlates with a pattern of increase in 
insulin secretion in the treatments with 100, and 200ng/ml, and unlike this, the 
treatments with 500ng/ml of leptin in high glucose appears to inhibit both insulin 
and amylin secretion which suggest that at very high leptin concentrations, 
there may be a decline in all beta cells functions. This is in agreement the 
suggestions by Tedstone et al., (1990).The normal ratio of insulin to amylin is 
usually 100:1.  
 
The results show a consistent significant inhibition of insulin secretion by 
500ng/ml leptin and based on the leptin pathways explored, it has been 
suggested by Kuehnen et al., (2011) that Protein phosphatase (PP-1) mRNA 
and protein expression is down-regulated by leptin, which leads to the reduction 
of PP-1 enzyme activity in beta cells. In addition, glucose-induced insulin 
secretion was said to be inhibited by nuclear inhibitor of PP-1, which was in part 
mediated by a reduction of PP-1-dependent calcium influx into beta cells. 
Therefore in this study, beta cells treated with various concentrations of leptin 
(100, 200 and 500ng/ml) in low (2.2mM) and high (22mM) glucose were 
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collected, mRNA extracted from them and reverse transcription PCR done to 
assess the effect of leptin on the expression of PP1A gene. Figure 4.3.6 shows 
that 500ng/ml of leptin had a significant inhibitory effect on the expression of 
PP1A gene in low glucose which is in agreement with the findings in the study 
by Kushner et al., (2011) which suggests that the inhibition of PP1A gene which 
leads to a reduction in calcium influx and the secretion of insulin, is one of the 
pathways by which leptin inhibits insulin secretion and therefore predisposes to 
diabetes mellitus. 
 
From the results of the current study, it may be suggested that clinicians, 
researchers and pharmacologists can explore possible pharmacotherapeutic 
means of boosting adiponectin levels in-vivo and ways of reducing the 
concentrations of leptin and regulating the concentration of amylin as 
adiponectin had be shown to boost insulin secretion while leptin and amylin 
appear to inhibit insulin secretion making the T2DM condition worse. 
 
It is interesting to note that leptin and adiponectin have opposite effects on 
insulin compared with amylin secretion, thereby altering the insulin/amylin ratio 
with a possibility of this contributing to either making diabetes better or worse in 
an individual and this balance can be explored by pharmacotherapeutic means 
to improve diabetes. Also it is interesting to note that adiponectin in the present 
study increases the insulin secretion as against the contrasting positions of 
researchers some of who have suggested that adioponectin may not have any 
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effect on insulin secretion. Also interesting is the results which shows for the 
first time that adiponectin inhibits amylin secretion.  
As a result of the fact that the effect of adipokines on amylin secretion has been 
poorly studied, the conclusions on the study on amylin secretion should be 
viewed with caution as there is obviously a strong necessity to do more 
research on the effect of adipokines in a wider range of species and with 
various concentrations of adipokines. For future work, it will be interesting to 
explore the effect of adding amylin analogues to treat beta cells in order to 
objectively assess the quantities of amylin that has inhibitory effect on beta cells 
insulin secretion. Furthermore, there appears to be the need to confirm the 
possible effects of the insulin/amylin ratios in more physiological relevant 
models such as human islets and in-vivo. It will also be useful if more work is 
done to explore further the reason why monolayer beta cells produce so much 
insulin when placed in no Glucose.  
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Chapter 5 
Plasma levels of leptin and 
adiponectin in diabetic patients and 
relationship to beta cell failure and 
cardiovascular disease 
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5.1 Introduction 
  
Type 2 diabetes mellitus is a condition that occurs as a result of insulin 
deficiency (either due to inadequate production of insulin or the inability of 
insulin to carry out its normal function in target tissues) (WHO 1999). 
 
Data collected by the WHO shows that world-wide, diabetes affects about 520 
million people (WHO 2014). More recently, obesity has been linked with T2DM 
and CVD. Research has narrowed down on various peptide factors called 
adipokines as the link between obesity and CVD and T2DM (Bravo et al., 2006, 
Barnes 2011). 
 
In the present study, the effect of leptin and adiponectin on beta cell function 
and the risk of CVD have been explored. In vitro, leptin has been shown to 
promote the development of T2DM and CVD while adiponectin has been shown 
to reduce the risk (Bravo et al., 2006, Barnes 2011).  
 
The concept of using the leptin:adiponectin ratio as an index has been used in 
research for some time as it is said to be a good predictor of insulin resistance 
(Rashid 2013) and a good atherogenic index in T2DM (Satoh et al., 2004) and it 
was suggested that the leptin/adiponectin ratio is a better atherogenic index 
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than either leptin or adiponectin on its own. Ling et al. (2014) also proposed that 
the higher the leptin/adiponectin ratio, the higher the risk of developing insulin 
resistance. 
 
The G-gap is an empiric measure of disproportion or difference seen between 
HbA1c and fructosamine which are the two principal methods of estimating 
glycaemic control indirectly (Nayak et al., 2013). The G-gap has been 
suggested to be linked with diabetes complications (retinopathy, nephropathy, 
macrovascular disease, and mortality). In the present study, these 
complications were explored in diabetic patients and potential associations 
between leptin/adiponectin ratio, the G-gap and clinical outcomes were 
explored. The G-gap is used in this study in a similar way to the study by Nayak 
et al. (2013) and is proposed as a measure of the deviation of glycated HbA1c 
away from its expected value, such that a negative G-gap is taken as meaning 
a lesser level of glycation than expected and a positive G-gap meaning a higher 
level of glycation of proteins. Increased glycation of proteins has been linked 
with hyperglycemia in diabetes mellitus and is a strong indicator of possibility of 
complications in diabetes. G-gap is calculated using the following formula;  
G-gap= True HbA1c - FHbA1c  (Fructosamine-derived standardized predicted)  
FHbA1c = {[(fructosamine-mean fructosamine)/SD fructosamine] x SD HbA1c } + mean HbA1c 
(Nayak et al., 2013) 
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In the clinical part of the study, we examined possible associations of the 
leptin/adiponectin ratio with the complications seen in patients with T2DM and 
the relation of this to the G-gap.  
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5.2 Materials and Methods 
 
The materials and the methods used for experiments that concern this chapter 
are detailed in the materials and method chapter (Chapter 2) 
 
A summary of how the clinical part of the research was carried out is as 
reported as follows. The data collected in the present study required the 
recruitment of patients from the cohort of those with diabetes treated at the 
Diabetes Centre, New Cross Hospital, Wolverhampton, and approval of the 
relevant local U.K. National Health Service Research Ethical Committee was 
sought for this. Routine blood samples had been collected for the analysis of all 
HbA1c and fructosamine estimations at New Cross Hospital in Wolverhampton. 
The result of this analysis were then used for the identification and selection of  
all adults with diabetes (≥18 years of age) who had paired estimations of HbA1c 
and fructosamine performed on the same day from the same sample set and 
after this, clinical information was taken from the diabetes registry and linked to 
this dataset.  
 
As this part of the clinical part of the study was done in collaboration with Nayak 
et al, many of the conditions used in this part of the study are similar to those 
used by Nayak et al. (2013). In accordance with the suggestions by Nayak et 
al., the diabetes register, which is validated to be 99% accurate for the 
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identification of known diabetes and for mortality status in linkage with the 
National Health Service Strategic Tracing Service was used. Patients that were 
excluded from this study included pregnant women, those with creatinine levels 
greater than 200 µmol/L, those with a known hemoglobinopathy and those with 
an abnormal electrophoretic pattern on HbA1c testing. The G-Gap was then 
calculated for all the selected patients. Those with the clearest consistently 
negative or positive G-Gap was invited to participate in the study and 150 
patients participated in the study having given fully informed consent. Patients 
were invited to attend the clinic where fasting blood samples were collected in 
heparinised tubes. Blood samples were centrifuged to separate blood cells and 
plasma and the cells used in another part of the G-Gap project. Plasma 
samples were frozen at -80C until used for assays. The patient cohort included 
75 with a positive G-Gap and 75 with a negative G-Gap. 
 
The samples collected were then processed and analysed for the leptin and 
adiponectin concentrations and this was correlated with the G-gap (see formula 
above) and these parameters linked with complications in diabetics and also the 
levels of complications seen in the patients. The correlation was done using the 
minitab software and correlation grouped as strong (0.75-1.00), moderate (0.5-
0.75) and < 0.5 is a weak correlation. P values are < 0.05 or <0.00 to be 
significant. 
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5.3 Results 
5.3.1 Plot of Leptin/Adiponectin ratio for GGAP positive and 
negative 
 
Figure 5.1 Scatterplot of leptin/adiponectin ratio for all samples. 
 
 
Figure 5.1 shows the leptin/adiponectin ratio is plotted as a scatterplot in order 
to show the levels of the L/A ratio in all the patients (sample ID 2-150). This 
shows that most of the samples have L/A ratio less than 15 with majority being 
below 5. 
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5.3.2 Distribution of patients with positive and negative G gap 
a) 
 
b) 
 
Figure 5.2 Scatterplot of the distribution of distribution of patients with 
positive and negative G-Gaps. (a) Distribution of patients with positive G-
gap, b) distribution of patients with negative G-Gaps 
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Figure 5.2 shows the scatterplot for the distribution of patients with positive and 
negative G-gaps. It shows that the separate distribution of L/A ratio in positive 
has a higher range (Majority being from 2.5-10) than the lower L/A ratio in the 
negative (mostly 1.5-6.5). 
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5.3.3 Frequency distribution of L/A ratio in Positive vs. Negative 
GGAP 
a)
 
b)
 
Figure 5.3 Frequency of the distribution of patients with positive and 
negative G-Gaps. a) Frequency of patients with positive G-Gap, b) Frequency 
of patients with negative G-gap  
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Figure 5.3 shows the histogram of the frequency distribution of L/A ratio for 
patients with negative and positive GGAP. (a) Shows 43 of the 67 patients with 
GGAP negative being below the average value of 3.204, while there are 41 of 
the patients with a positive GGAP being below the average for positive GGAP 
(4.611) 
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5.3.4 Correlation of Leptin/Adiponectin versus leptin and 
adiponectin alone with Predictors of complications 
PARAMETERS LAR 
 R p-value 
BMI 0.752 0.000 (<0.001) 
HDL -0.304 0.000 
eGFR -0.080 0.336 
GGAP 0.356 0.000 
CHOLESTEROL -0.005 0.958 
ADIPONECTIN -0.057 0.494 
LEPTIN 0.779 0.000 
CVD RISK 0.109 0.191 
uACR -0.008 0.921 
ALBUMIN -0.306 0.000 
RETINOPATHY 0.101 0.228 
 
Table 5.1 Correlation of LAR with risk parameters in diabetics 
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PARAMETERS LEPTIN 
 R p-value 
BMI 0.473 0.000 (<0.001) 
HDL -0.165 0.048 
eGFR -0.189 0.023 
GGAP 0.266 0.001 
CHOLESTEROL 0.022 0.798 
ADIPONECTIN 0.166 0.046 
LEPTIN - - 
CVD RISK 0.070 0.401 
uACR 0.070 0.401 
ALBUMIN -0.287 0.000 
RETINOPATHY -0.015 0.854 
 
Table 5.2 Correlation of Leptin levels with risk parameters in diabetics 
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PARAMETERS ADIPONECTIN 
 R p-value 
BMI -0.083 0.322 
HDL 0.188 0.024 
eGFR -0.055 0.513 
GGAP 0.054 0.520 
CHOLESTEROL -0.038 0.664 
ADIPONECTIN - - 
LEPTIN 0.166 0.046 
CVD RISK -0.161 0.048 
uACR -0.095 0.255 
ALBUMIN 0.054 0.522 
RETINOPATHY -0.053 0.530 
   
 
Table 5.3 Correlation of adiponectin levels with risk parameters in diabetics 
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5.3.5 Distribution of leptin/adiponectin ratio vs. Body Mass 
Index (BMI) 
 
 
 
Figure 5.4 Scatterplot of the distribution of Leptin/Adiponectin ratio 
plotted against Body Mass Index (BMI). This shows a positive linear 
regression  
 
Figure 5.4 shows that there is a positive linear relationship between L/A ratio 
and the BMI with a correlation factor of 0.752 (p <0.001) showing a strong 
correlation between the L/A ratio and the BMI. 
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5.3.6 Correlation of the Leptin/adiponectin ratio vs. Leptin 
 
 
 
Figure 5.5 Scatter plot of the distribution of leptin/adiponectin ratio plotted 
against leptin. This shows a positive regression line. 
 
Figure 5.5 shows that there is a linear relationship and a strong correlation 
(r=0.779 and p<0.001) between the leptin/adiponectin ratio and the leptin levels 
in the patients. This shows leptin to be positive linear relationship to L/A and 
also most of its possible complications. 
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5.3.7 Correlation of leptin/adiponectin ratio with High density 
lipoprotein levels (HDL) 
 
Figure 5.6 Scatterplot of distribution of Leptin/Adiponectin ratio plotted 
against the levels of High Density Lipoprotein.  
 
This shows a weak negative linear correlation (- 0.304 with p<0.001) between 
the leptin/adiponectin ratio and the concentration of HDL in the patients’ blood 
showing the link between L/A ratio and possible cardiovascular complications. 
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5.3.8 Correlation of Leptin/adiponectin ratio with the Albumin 
levels  
 
 
 
Figure 5.7 Scatterplot of the distribution of Leptin/Adiponectin ratio 
plotted against albumin levels in the blood of patients. This shows a 
negative linear relationship 
 
Figure 5.7 shows that there is a weak negative correlation (r= -0.306 and 
p<0.001) between L/A ratio and the albumin levels in the blood of patients 
showing the link between L/A and renal complications. 
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5.3.9 Correlation of leptin/adiponectin ratio with GGAP  
a) 
 
b) 
 
Figure 5.8 Scatterplot and interval plot of the distribution of L/A ratio 
plotted against G-Gap (positive and negative) a) Scatter plot of L/A ratio 
plotted against positive and negative G-Gap, b) Interval plot of L/A ratio plotted 
against positive and negative G-Gap. (1) is negative and has a lower mean 
(3.6) L/A ratio than (2) which is positive with a higher mean (5.1).     
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Figure 5.8 shows that there is a weak positive correlation (r= 0.356 and 
p<0.001) between L/A ratio and the G-Gap of patients. The scatterplot shows 
the patients with the negative G-gap(1) having lower L/A ratios than those with 
Positive GGAP(2) showing that negative G-Gap may be associated with less 
complications than positive GGAP. Also the interval plot shows a lower mean 
for the patients with a negative G-gap than those with positive G-Gaps. 
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5.3.10 Effect correlation of leptin Vs BMI, HDL, GGAP, 
Adiponectin, Albumin and eGFR 
 
Figure 5.9 Scatterplot of Leptin levels vs. BMI, HDL, GGAP, Adiponectin, 
Albumin, and eGFR.  
 
Figure 5.9 shows that there is a weak positive correlation between leptin and 
BMI (r= 0.473, p<0.001) a weak negative correlation between leptin and HDL 
(r= -0.165, p< 0.048), weak positive correlation between leptin and GGAP( r= 
0.266, p<0.001), weak correlation with adiponectin (r=0.166, p< 0.046), weak 
negative correlation with albumin (-0.287, p<0.000), and a weak negative 
correlation with eGFR9 -0.189, p<0.023. 
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5.3.11 Correlation of Adiponectin VS BMI, HDL, CVD risk, leptin 
and albumin 
 
 
Figure 5.3.10 Scatterplot of Adiponectin levels vs. BMI, HDL, CVD risk, 
Albumin, and eGFR.  
 
Figure 5.3.10 shows that there is a weak negative correlation between 
adiponectin and BMI (r= -0.083, p<0.322) a weak positive correlation between 
adiponectin and HDL (r= 0.188, p< 0.024),  weak correlation with leptin 
(r=0.166, p< 0.046), weak positive correlation with CVD risk(r= 0.161, p<0.048) 
with those with primary risk (1) having a wider range (3.8 to 9) than the 
secondary risk (4.7 to 9), and a weak negative correlation with eGFR9 -0.189, 
p<0.023. 
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5.3.4 Discussion 
 
The preceding chapters have explored the role of leptin and adiponectin in the 
regulation of beta cell and endothelial cell function. Obesity has been linked to 
T2DM and CVD via adipokines (Bravo et al., 2006, Barnes 2011).The 
adipokines of interest in this study are leptin and adiponectin and the 
leptin/adiponectin ratio has been used as an index for assessing the risk of 
developing complications in CVD and insulin resistance (Ling et al., 2004). 
Leptin and adiponectin on their own were both suggested to reduce insulin 
resistance and due to the fact that leptin increases with obesity and adiponectin 
reduces, the leptin and adiponectin ratio has been used as a more objective 
method to assess insulin resistance and predisposition to cardiovascular 
diseases (Oda et al., 2007).  
 
Another factor which has been associated with an altered risk of diabetic 
complications is the G-gap (this is a measure of the deviation of glycated HbA1c 
away from its expected value, such that a negative G-gap is taken as meaning 
a lesser level of glycation than expected and a positive G-gap meaning a higher 
level of glycation of proteins) (Nayak et al., 2013).  
 
Previous studies have suggested that the leptin/adiponectin ratio (LAR) is linked 
to insulin resistance and insulin resistance has been linked to obesity, 
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hypertension, atherosclerosis and diabetes (Rashid 2013; Assiri and Kamel 
2012). Also attempts have been made over the years to find a good parameter 
for measuring glycaemic control as glycaemic control or appropriate glucose 
homeostasis is the main key to preventing diabetic complications (Nayak et al., 
2013). Glycated haemoglobin (HbA1c) has been used for a long time (over 40 
years) as it was considered to reflect glycaemia over the preceding 12 weeks 
(WHO 2011). Glycated haemoglobin is formed from non-enzymatic 
concentration-dependent covalent bonding of glucose to haemoglobin within 
erythrocytes, however, fructosamine measures the plasma concentration of 
glucose over a period of 2-3 weeks (Rashid 2013). Previous studies have 
however suggested that due to the fact that many factors influence the protein’s 
turn-over (erythropoietic processes,  blood and protein losses), HbA1c may not 
be as reliable as it has always been thought to be by previous studies (Nayak et 
al., 2013). Further studies have shown that in contrast to the non enzymatic 
process of protein glycation, there is also the fructosamine 3-kinase enzyme 
that deglycate protein within the cell (including most probably HbA1c) (Nayak et 
al., 2013). Although fructosamine has the potential to be used as a parameter to 
assess glucose homeostasis, it is not without its issues such as the fact that it is 
only an indirect measure if glycation of plasma proteins such as albumin, and 
that it doesn’t predict glucose homeostasis for as long a period as HbA1c. 
 
Because of this, the concept of G-gap, even after having been associated with 
an altered risk of diabetic complications still has a number of issues over its 
relevance in the assessment of glycaemic control (Sacks et al., 2011). 
Therefore, in the present study, a new attempt at finding parameters for 
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assessing the possible risk of complications arising from diabetes was 
developed by comparing or correlating the G-gap to the leptin/adiponectin ratio. 
 
The clinical aspect of the present study, therefore aimed to look at the following 
critically; the correlation between the leptin/adiponectin ratio and the 
parameters linked with complications in diabetes such as BMI, cholesterol 
levels, HDL levels, eGFR, albumin. Also the individual correlation of leptin and 
adiponectin with the parameters linked with complications in diabetes. This 
comparison was made to see if the leptin/adiponectin ratio is a better predictor 
of complications in diabetes. 
 
Previous studies suggest that a positive G-gap correlates well with higher levels 
of complications, while a negative G-gap in diabetic patients correlates with 
lower levels of complications (Nayak et al., 2013). Therefore, in the present 
study, the G-gap is used as an important predictor of risk of complications. The 
leptin/adiponectin ratio has been shown to be predictor of atherosclerosis, 
insulin resistance and diabetes risk and is said to be a better predictor of T2DM 
complications and CVD (Kappelle et al., 2012). 
 
The result from the present study shown in figure 5.3 demonstrates that diabetic 
patients with negative G-gap had lower LAR (mean 3.204) than those with 
positive G-gap (mean 4.611). This supports the hypothesis that the higher the 
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L/A ratio, the higher the risk of developing complications as a positive G-gap 
has been linked with greater risk of complications as suggested by Nayak et al. 
(2013).  
 
The studies by Ling et al. (2014) and Oda et al. (2007), highlight the link 
between LAR and BMI. In the present study, the results in figure 5.4 shows a 
significantly strong positive linear correlation between leptin/adiponectin ratio 
and the body mass index of the patients ( r= 0.752 with p<0.0001). This shows 
support for the hypothesis that individuals with high leptin/adiponectin ratios will 
be likely to have higher levels of insulin resistance as the higher the LAR, the 
higher the BMI (and the higher the BMI the greater the insulin resistance.) (Ling 
et al. 2014). These results also highlights the suggestion by Oda et al. (2007) 
and Rashid (2013) that LAR is better at predicting risk factors for complications 
as the correlation between LAR and BMI is higher than the correlation between 
leptin and BMI or adiponectin and the BMI (seen in figures 5.9 and 5.10). These 
figures also show that just like the LAR, leptin has a direct linear relationship 
with the BMI, while adiponectin has a negative linear relationship with BMI  
though not significant which is in agreement with the studies by Bahathiq (2010) 
and Oda et al. (2007). These results are also consistent with the findings in 
chapter 3 and 4 and support the hypothesis which suggest that the higher the 
BMI, the higher the leptin levels (a positive linear relationship) and vice-versa 
for low BMI. Also it suggests that the higher the BMI the lower the adiponectin 
and vise-versa for low BMI (a negative linear relationship) (Oda et al. 2007). 
The relevance of this finding is the possibility of using LAR as another 
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parameter for predicting the risk of developing complications as BMI has been 
used over the years. 
 
In the present study therefore, the complications considered are the commonest 
ones associated with diabetes which are CVD complications, renal and retinal 
complications.  
 
In the assessment of the CVD complications, tables 5.1 and 5.2 show that LAR 
and leptin correlated positively with CVD risk (weakly and non-significantly) 
while adiponectin is negatively correlated with CVD risk (weakly but significantly 
r= -0.161, p<0.048). This is in agreement with studies that suggest that high 
adiponectin reduces the risk for CVD (Zhu et al., 2008) as the present study 
shows that the higher the levels of adiponectin, the lower the risk of CVD. This 
is in contrast to the views of Vega et al. (2013) and Vesilescu et al. (2010) and 
Kapelle et al. (2012)  which suggest that LAR is a better predictor of CVD risk 
than adiponectin since the present study shows that adiponectin better 
correlates negatively with a reduction in CVD risk. One of the possible reasons 
for the differences seen in the results is the fact that Kapelle et al. (2012) used 
only men in their studies unlike the current study. Also, in the present study, the 
classification of the risk of CVD was based on the presence or absence of any 
previous cardiac, cerebral or peripheral macrovascular event unlike the study by 
Vasilescu et al. (2010) in which the CVD risk was based on CIMT (carotid 
intima-media thickness). 
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In the present study, the parameters for monitoring or assessing the risk for 
renal diseases (eGFR, albumin), CVD (Cholesterol, HDL) and liver function 
(albumin) were also considered and correlated with the LAR, adiponectin and 
leptin levels in the patients plasma. Table 5.1, 5.2 and 5.3 show the various r 
(correlation coefficient) and p-values of the correlation of LAR, adiponectin and 
leptin levels with the various parameters.  
 
With respect to renal function, leptin levels were significantly negatively 
correlated (weakly, r=-0.189 and -0.287 respectively) to the eGRF and the 
albumin levels (with no correlation between LAR and eGFR but only with 
albumin) (Table 5.1 and 5.2). This suggests that the LAR may not be as strong 
in predicting renal dysfunction in diabetic patients as leptin. This suggests that 
the higher the levels of leptin and LAR the lower the eGFR suggesting that 
diabetics with high levels of leptin and LAR may be more predisposed to 
developing renal complications which is in agreement with Chou et al. (2013). 
The result in table 5.3 shows no significant correlation between adiponectin and 
the parameters that represent the renal function (negative correlation to eGFR 
and positive correlation to albumin). This is in disagreement with the study of 
Jung et al. (2012) where it was reported that adiponectin has an inverse 
relationship with nephropathy. It is however important to note that there have 
been a lot of controversies concerning the outcomes of results from previous 
studies and the reasons that have been put forward by Jung et al. (2012) may 
apply to the conditions chosen for the present study. The reasons suggested 
are the fact that the differences may be due to differences in study populations 
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according to the various diagnostic criteria. Also, it was suggested that different 
distributions of the severity of the microangiopathies and ethnic variations in the 
selected volunteers may be reasons for the differences in results. In the present 
study, the ethnic origins have not been taken into consideration.  
 
With regards to retinopathy, the LAR, leptin and adiponectin did not significantly 
correlate with the retinopathy levels seen in patients and therefore the results 
suggest that LAR is not a very good predictor of retinopathy risk in diabetic 
patients in contrast to the study by Kato et al. (2008) which suggested that the 
levels of adiponectin were higher in those with retinopathy than those diabetics 
without retinopathy and that of Jung et al. (2012) that found that adiponectin 
was lower in those with nephropathy. The LAR however has a linear positive 
correlation with retinopathy as against the leptin and adiponectin levels which 
supports the hypothesis that LAR may be a better predictor of retinopathy that 
either of leptin or adiponectin. 
 
This study has provided support for a number of theories. The results from this 
study confirm that the adipose tissue is definitely more than an energy storing 
organ as the adipokines released from them (in this case leptin and 
adiponectin) correlates with risk of developing CVD or renal complications in 
diabetic patients which agrees with the research by Koves et al. (2008). Also, 
results from this study show that leptin and the LAR are good predictors of the 
implications of high BMI on the CVD and renal complications in diabetics as 
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suggested by Vega et al. (2013) and Ling et al. (2014). Also the result in this 
study support the theory that high adiponectin may prevent CVD.  
 
It is however surprising that adiponectin appears to have very little implication in 
the possible risks of the development of retinopathy and nephropathy in 
contrast to the findings of Jung et al. (2012) which suggested that the patients 
with nephropathy had low adiponectin while those with retinopathy had high 
concentrations of adiponectin.  
 
This study therefore shows that clinically, if interventions can be made to 
increase the levels of adiponectin and reduce the levels of leptin, there is a high 
possibility of reducing the risk of development of CVD and renal complications 
in diabetic patients. 
 
In conclusion, this chapter has considered the relevance of the LAR in the 
development of complications in diabetic patients by correlating the assayed 
levels of leptin and adiponectin ratio with the predictors of complications in 
diabetic patients. This study shows that the LAR linearly correlated with the BMI 
which suggest that the LAR is a good indicator of all the issues that may be 
linked with having high BMI. Also this study shows that leptin is better at 
predicting renal complications and adiponectin better at predicting CVD 
complications in diabetic patients than the leptin/adiponectin ratio. 
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Chapter 6 
 
Final discussion, conclusion and 
implications for future research 
studies 
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6.1 Final Discussion 
 
Obesity has been shown to now affect about 520 million people and has been 
linked with type 2 diabetes mellitus (WHO 2014 review). It is estimated that 
there are about 382 million people (between the ages 20 and 79) worldwide 
affected by diabetes and in the UK, about 3.2 million people are affected (DUK 
2014). Despite the fact that it has been suggested that obesity is linked to 
T2DM and CVD, the basis of this link is not completely understood. Due to the 
increasing incidence of obesity and the corresponding increase in T2DM and 
CVD, it is important to note that it has been demonstrated that adipose tissue, 
which used to be seen only as a metabolic storage tissue, also has endocrine 
functions and produces proteins termed adipokines that influence metabolism in 
the human body (Trayhurn and Wood 2004). 
 
In the present study, the opposing effects of adipokines leptin and adiponectin 
reported by previous research were investigated to clarify their role as a link 
between obesity and CVD and T2DM since the basis of their possible role is not 
well understood. Many of the previous studies have looked at the effect of these 
adipokines individually but not in combinations and therefore one of the aims of 
this present study was to explore the effect of these adipokines in combination 
especially in CVD while for the first time the effect of a combination of 
adipokines on pseudoislets (clumps of beta cells that are similar to islets of 
Langerhans and prepared in vitro) was reported in this study. Also one of the 
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aims of this study was to explore the impact of the leptin/adiponectin ratio on 
the complications seen in diabetic patients and to examine the role of 
adipokines in amylin secretion. 
 
In the present study, the results illustrated in chapter 3 show the potential role 
of leptin and adiponectin in the pathogenesis of CVD. Angiogenesis and 
atherosclerosis have been shown to be important processes in the 
pathogenesis of CVD (Lip 2004), and therefore the effect of leptin and 
adiponectin on genes that code for angiogenesis (MMP2, TIMP2, TIMP3) and 
atherosclerosis (LPA, LPL) was explored. 
 
Prior to this study, there have been attempts to explore the effects of leptin and 
adiponectin on the angiogenic and atherosclerotic genes in order to better 
understand the pathogenesis of CVD, but very little was understood of the 
effect of combining these adipokines (leptin and adiponectin) on atherosclerotic 
and angiogenic genes. Also the basis of the effect of the adipokines in the 
process of pathogenesis of CVD is not completely understood.  
 
The result from the present study shows that leptin at high concentrations (at 
16ng/ml) increases the expression of all angiogenic and atherosclerotic genes, 
and has very little effect in lower concentrations (8ng/ml). This suggests that 
leptin in high concentrations (that is in the region of 16ng/ml which is similar to 
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that seen in obese individuals) may predispose to CVD while lower 
concentrations such as those seen in lean individuals poses less risk. This is in 
agreement with the findings of Dubey and Hesong (2006) and provides 
evidence to support the suggestion that leptin is one of the links between 
obesity and CVD. This is important in the management and reduction of 
obesity-related cardiovascular diseases as a strategy of weight loss which may 
lead to a reduction in leptin levels could improve the outcomes of CVD risk in 
obese individuals. 
 
The present study also showed that the treatments with high adiponectin 
(3.6µg/ml in the range observed in lean individuals) caused an increase in the 
expression of Tissue Inhibitors of Metalloproteinases 2 and 3 (TIMP2 and 3) 
and an inhibition in the expression of the Matrix Metalloproteinase 2 and an 
inhibition of the atherosclerotic genes. At lower concentrations of adiponectin, 
the results were not as significant and consistent as those with a high 
adiponectin concentration but followed a similar pattern to that observed in the 
latter. A number of studies have suggested that MMP2 plays a key role in the 
pathogenesis of CVD while TIMPs modulate this effect. The results from the 
present research therefore suggest that adiponectin at high concentrations (as 
seen in lean individuals) may lead to a reduction in the risk for angiogenesis 
and atherosclerosis linked with CVD.  
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The data from the current work also shown that adiponectin in high 
concentrations (3.6µg/ml) when combined with leptin (16ng/ml) is able to 
reduce the up-regulatory effect of leptin on atherosclerotic and angiogenic 
genes, but lower concentrations of adiponectin (36 ng/ml) did not have the 
same effect on the up-regulatory effect of leptin on angiogenic and 
atherosclerotic genes. This is in agreement with the study by Handy et al. 
(2011) but this study provides further evidence of the effects of low leptin and 
low adiponectin in combinations which is lacking in previous studies. It is 
interesting also to see, however, that the real time PCR results suggests that 
combining high leptin with low adiponectin seems to have an additive effect in 
the expression of many of the angiogenic and atherosclerotic genes, (except 
MMP2 showing consistency in the effect of adiponectin on its own and in 
combinations) a result which may suggest that in obese individuals, the 
individual actions of leptin on angiogenic and atherosclerotic genes may be 
accentuated leading to even more risk for CVD. 
 
The observations from the present work support the model which suggests that 
high levels of adiponectin as seen in lean individuals may have a protective 
effect on the cardiovascular system. The results also suggest that individuals 
with low adiponectin as seen in obesity may be more predisposed to CVD. This 
is important for further research into possible adiponectin therapy that can 
reduce the effect of leptin on the risk for developing CVD, especially in obese 
people with high levels of leptin. 
 
258 
 
Also in the current study the role of AMPK, ERK and P38 MAPK in the 
mechanism of lepton’s and adiponectin’s effect was explored. The three 
enzymes were shown to be involved in the effects of leptin and adiponectin on 
angiogenic genes which is in agreement with the work of Lee et al. (2008) 
which suggests the role of ERK in the effect of adiponectin and Chandraseker 
et al. (2008) which suggested the role of AMPK. It is however surprising that the 
role of AMPK in the effect of adiponectin was not as clear as has been reported 
by some previous studies (Kim et al., 2009, Zhang et al., 2012, Mattu and 
Randeva 2012).  
 
Many researchers including Ley et al. (2009), Mattu and Randeva (2013), Bravo 
et al. (2006) and Barnes (2011) have suggested that leptin and adiponectin as 
adipokines are an important link between obesity and CVD and diabetes 
mellitus. The data in chapter 3 showing the effects of leptin and adiponectin on 
angiogenic and atherosclerotic genes (thus CVD), agrees with this suggestion 
and it was logical to explore the effect of leptin and adiponectin in the beta cell 
functions in order to better understand the role of obesity in diabetes mellitus. 
 
Insulin and amylin secretion were used as parameters to assess beta cell 
function as the most important functions of the beta cells relate to the secretion 
of insulin and amylin; the latter is said to be co-secreted with insulin and to 
affect the function of the hormone in many tissues as it is related to insulin 
resistance (Karlsson et al. 1998). Therefore it was important to be able to 
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effectively measure the secretions of insulin and amylin from treated beta cells 
in-vitro. Most researchers in the past have used beta cells grown in monolayer 
cells, but the study by Persaud et al. in 2010 suggested that growing the beta 
cells into “pseudo-islets” allows the cells to mimic real islets of Langerhans. 
Beta cells are reported said to produce insulin in a more physiological way and 
also in larger quantities when they work together (as in the islets of Langerhans 
or the pseudo-islets), than when they produce insulin as monolayer beta cells 
possibly as a result of different cell to cell interactions. Therefore, in this study, 
pseudo-islets were used to explore the effects of leptin and adiponectin on beta 
cells. 
 
Results from the current study agrees with the suggestions by Persaud et al. 
(2010) as the insulin secretion by the pseudo-islets was about an average of 2 
folds the secretion seen in monolayer beta cells and there appeared to be a 
better step-wise glucose response and better control secretion in the pseudo-
islet. 
 
The data show that leptin at 200 to 500 ng/ml appear to have a significant 
inhibitory effect on insulin secretion with an inverted “U” shape  in contrast to 
the reports described by Dunmore and Brown (2013). This is also consistent 
with the normal function of leptin in-vivo in which leptin at reported 
concentrations (5-15ng/ml) increases insulin secretion and in which very high 
leptin concentrations are said to inhibit insulin secretion (Zhao et al. 1998). This 
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result is consistent for the cells treated in low and high glucose thus suggesting 
that the two extremes of the diabetic glucose derangements may have similar 
implications on the resulting factors which lead to diabetes and which 
complicate diabetes. The importance of this is similar to that relating to the role 
of leptin in CVD as discussed in chapter 3, as this study suggests that a 
reduction in weight in an obese individual may lead to a reduction in the leptin 
levels and therefore a boost for insulin secretion and a reduction in diabetic 
complications and even a delay in the onset of diabetes. 
 
This study also shows that 1 and 5µg/ml of adiponectin in both low and high 
glucose increased the secretion of insulin significantly. This is in agreement with 
the study by Okamoto et al. (2008) and Seufert et al. (2004). This result suggest 
that even at low concentrations (as seen in obesity), adiponectin may still 
increase insulin secretion but not significantly in the present study, suggesting 
that any measures that can boost adiponectin levels may boost insulin 
secretions. This therefore underlines the possible benefit of weight loss in the 
management of CVD and diabetes as it has been shown that adiponectin levels 
are higher in lean individuals than in obese individuals. 
 
The result of the current study may also support a role for amylin on insulin 
secretion. The normal molar insulin: amylin ratio is about 100:1 but for the beta 
cell treatments, the average ratio was between 8:1 to 25:1 which suggests that 
diabetic models reflected in the design of the experiments resulted in high 
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amounts of amylin secretion which may inhibit insulin secretion. The result 
shows that adiponectin in low glucose, appears to increase the secretion of 
both insulin and amylin and that there appears to be no corresponding effect of 
high amylin levels on insulin levels as suggested by Tedstone et al (1990). This 
is however the opposite of what was found in high glucose and in the leptin 
treatment in low and high glucose. In the present study, there was an opposite 
corresponding secretion of amylin and insulin which may suggest that the 
amylin may be contributing to the effect on insulin secretion. This may suggest 
why there is more insulin secretion by adiponectin in high glucose and why 
leptin is consistently inhibited in low and high glucose as it may be as a result of 
contributions by amylin. The relevance of this to clinical practice may be seen in 
the role of adiponectin in possibly altering the insulin: amylin ratio in a beneficial 
way (more insulin less amylin). This could suggest potential pharmaceutical 
approaches to treating diabetes by boosting insulin and reducing amylin 
secretion (thus also reducing the collection of amylin in tissues and the 
formation of amyloid which may damage beta cells and reduce insulin secretion 
as a result of fewer numbers of beta cells).  
 
As leptin had the most consistent effect, the basis of these effect were 
investigated by the exploration of PP-1 gene expression which is suggested to 
be the gene that leptin blocks in order to prevent the influx of calcium into beta 
cells, thus inhibiting insulin secretion. The result from the present study show 
that treatment with 500ng/ml of leptin in low glucose caused a significant 
inhibition in PP1 gene expression (as mRNA) which may be the basis for the 
262 
 
effect of leptin on insulin secretion at 500ng/ml. In high glucose, however the 
opposite was found as 500ng/ml of leptin caused a significant increase in 
insulin secretion, 
  
Most of the studies done initially were in-vitro. As suggested by Mattu and 
Randeva (2012), in vitro studies may not reflect all the interplay between the 
adipokines and the human body in obesity, CVD and diabetes. Therefore in the 
current study, diabetic patients were recruited and blood samples collected from 
them in order to measure the levels of leptin and adiponectin in the blood so as 
to be able to correlate this with the parameters that suggest risk linked to 
developing complications in diabetes (those such as renal, retinal and CVD 
complications). 
 
As shown in chapter 5 in the present study, leptin:adiponectin ratio (LAR) was 
examined as a parameter to predict the risk for complications since other 
studies suggest that because the amount of adiponectin and leptin varies with 
obesity (and amount of adipocytes.) the LAR was a more objective measure 
(Oda et al., 2007). 
 
The results showed that both the LAR and leptin were positively linearly related 
with the BMI with strong correlation factors of 0.752 (p-value <0.0001) and 
0.779 (p-value<0.0001) respectively. This may suggest that people with higher 
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BMI are likely to have a higher LAR and therefore be more predisposed to the 
complications related to obesity and high levels of leptin. When considering the 
complications, retinal, CVD and renal complications which are the commonest 
seen in diabetic patients  were examined for correlation with the measured 
adipokine levels. Adiponectin was mostly negatively correlated with most of the 
risk parameters, but had a significant weak correlation with CVD (r= -0.161 p-
value< 0.05) which does not entirely agree with the view put forward by Vega et 
al. (2013) which states that LAR is a good predictor of CVD risk. Adiponectin 
also has little implication in the present study in relation to the risks of 
developing retinopathy and nephropathy as compared with the suggestions by 
Jung et al. (2012).  
 
This part of the study re-iterates the fact that the adipose tissue is more than 
just a storage organ as it is an active tissue with wide-ranging metabolic effects 
on other tissues through the secretion of adipokines. It is important to also note 
that the LAR of patients with negative G-Gaps (associated with lower incidence 
of complications) was lower (mean 3.204) than the LAR of those with positive 
G-Gap (associated with more complications) with a mean of 4.611. 
 
This therefore suggests that the LAR, according to the result is not as good in 
predicting the retinal and renal complications complication but is relevant in 
predicting the CVD risk as a result of its correlation with BMI and HDL and high 
leptin. 
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6.2 Conclusion 
 
The present study was carried out to explore the role of obesity in the 
development of diabetes mellitus and cardiovascular disease as it was 
considered that the increasing incidence of obesity may be related to that of 
CVD and T2DM. This was done by assessing the concentrations of leptin and 
adiponectin (individually and in combination) that has effects on beta cell and 
endothelial cell function in order to ascertain the most effective exact 
concentrations of leptin and adiponectin that affect beta cell and endothelial cell 
function. Another aim of this study was to explore the role of amylin in type 2 
diabetes and also the effect of combining the adipokines. 
 
Previous literatures have reported on some of these issues and have not been 
conclusive on some issues which form the questions for the current study. One 
of our questions explored what concentrations of leptin and adiponectin have an 
effect on beta cells and endothelial cells and also what the effect is. Also the 
current study looked into what the effect of the combining leptin and adiponectin 
will be and another area of interest was to ask whether there is a correlation 
between the concentrations of leptin and adiponectin in the diabetic patient and 
the complications seen in patients and also to ask if there is a correlation 
between the effect of leptin and adiponectin in the patients and the effects seen 
in the lab. 
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This study has shown that leptin in high concentration (16ng/ml), predisposes to 
CVD by increasing the expression of angiogenic genes and atherosclerotic 
genes, while adiponectin in high concentrations( 3.6µg/ml) reduces the risk of 
cardiovascular disease by reducing the expression of some of the 
atherosclerotic and angiogenic genes and promoting the expression of the anti-
angiogenic genes. Also for the first time it has been shown consistently that 
there is a significant reduction in the expression of the angiogenic and 
atherosclerotic genes when high levels of adiponectin and low levels of leptin 
are combined. Also, this study has been able to show that AMPK, ERK and P38 
enzymes are involved in the function of leptin and adiponectin.  
 
For assessment of T2DM, this study has shown that leptin inhibits insulin 
secretion while adiponectin increases it. Also it was shown that the insulin 
/amylin ratio of the treatments were quite high and that leptin increases amylin 
secretion. Adiponectin (5µg/ml) is shown to increase insulin secretion and 
reduce amylin secretion. This may be relevant in the development of 
therapeutic measures that may increase adiponectin secretion, thereby altering 
the insulin/amylin ratio to favour a boost in insulin secretion in diabetics. 
 
Also it has been shown in this study for the first time that high leptin/adiponectin 
ratio correlates with indicators that suggest risks of complications in diabetes 
patients. 
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Overall the evidence provided suggests that leptin increases the risk for CVD 
and T2DM while adiponectin reduces the risk of CVD and promotes insulin 
secretion and reduces amylin secretion, thereby possibly improving or 
preventing T2DM. More interestingly, a high concentration of adiponectin is 
shown to reduce the risk of CVD. This will make an interesting basis for the 
development of pharmacologic interventions for T2DM. 
 
It is clear from this study that leptin potentially predisposes to CVD and T2DM 
while adiponectin on its own and when combined with Leptin reduces the risk of 
CVD and T2DM.  
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6.3 Future Research 
 
The results from this study show that leptin promotes the development of CVD 
and T2DM and adiponectin discourages it and the basis for this has been 
explored. The results also shows that a combination of the adipokines appear to 
inhibit the risk of CVD. 
 
With regards to CVD, more research needs to be done to explore the basis for 
the reduction in the expression of angiogenic and atherosclerotic genes when 
leptin and adiponectin are combined. Also further research needs to be done on 
the role of varying concentrations of adiponectin on the expression of 
angiogenic and atherosclerotic genes as low concentrations of adiponectin 
appears not to have consistent effects unlike high concentrations of 
adiponectin. 
 
With regards to diabetes mellitus, more studies need to be done to find out the 
effects of combining adipokines on insulin and amylin secretion. Also more 
research needs to be done on the effect of the absence of glucose on beta cells 
as the results from this study suggest that the absence of glucose destroys the 
beta cells leading to leakage of insulin and high levels of insulin in samples with 
no glucose. Also some very high concentrations of glucose (22mM) appeared 
not produce the expected response in insulin secretion when compared to 
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some lower concentrations (15 mM) and higher concentrations (30mM). More 
studies may need to be done to find out why these concentrations of glucose 
were not sensed by beta cells as this may be important for selecting glucose 
concentrations to treat cells with in future studies.  Also, the effect of amylin on 
insulin secretion is not very clear from this study and for the purposes of future 
research, more research needs to be done to explore the direct effect of amylin 
on insulin secretion as the results from this study show that the cells have very 
high levels of insulin/amylin ratio. 
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Appendices 
Appendix1 
Appendix 1.1 Equipment, specialized kits and reagents and 
chemicals  for beta cells experiments 
 
1.1.1 Equipments for beta cell experiments 
Centrifuges                                                                     M.S.E Mistral 200,Fision, 
                                                                                                    Instruments U.K. 
 
CO2 Incubator                                                                   Jensons Scientific Inc, 
                                                                                  Bridgeville, PA 15017, USA.  
 
Inverted Microscope Celti                                         Optical Instruments, 
Belgium. 
 
Magnetic Stirrer Hotplate                                      Stuart Scientific, Beacon Road 
                                                                                                   Staffordshire, UK 
 
Platform Shaker STR6                                         Stuart Scientific, Beacon Road, 
                                                                                                  Staffordshire, UK. 
 
Vortex                                                                       Sigma-Aldrich Company Ltd, 
                                                                                                            Dorset, UK. 
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Waterbaths                                                    Grants Instruments 
(Cambridge)Ltd, 
                                                                                                     Cambridge, UK. 
 
 
1.1.2 Specialized kits for beta cell experiments 
 
 
Mouse insulin secretion ELISA kit                              Mercodia, Upsulla Sweden. 
 
 
1.1.3 Reagents and chemicals for beta cell experiments 
 
Beta Mercaptoethanol                                                   Bio-Rad Laboratories Ltd, 
                                                                                         Hemel Hempstead, UK. 
 
DMSO                                                                      Sigma-Aldrich Company Ltd, 
                                                                                                            Dorset, UK. 
 
Hanks Buffered Salt Solution                                   Sigma-Aldrich Company Ltd, 
                                                                                                            Dorset, UK. 
 
L-glutamine                                                              Sigma-Aldrich Company Ltd,     
                                                                                                            Dorset, UK                                                                                                                                                                                                              
Penicillin-Streptomycin Solution                              Sigma-Aldrich Company Ltd 
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                                                                                                          Dorset, UK                                                                                                                                                                                                                               
                                                                                                                          
RPMI 1640 without Glucose                                     Sigma-Aldrich Company Ltd,     
                                                                                                            Dorset, UK                                                                                              
Trypsin/EDTA                                                           Sigma-Aldrich Company Ltd,  
                                                                                                             Dorset, UK                                                                                         
                                                                                                                              
Appendix 1.2 Equipments. Specialized kit and reagent and 
chemicals for endothelial cell experiments 
 
1.2.1 Equipments for endothelial cell experiments 
Block  Heater                                                                                Wolf laboratory,        
                                                                                                                York,UK 
 
Centrifuges                                                                             M.S.E Mistral 200, 
                                                                                       Fision Instruments, U.K. 
 
CO2 Incubator                                                                   Jensons Scientific Inc. 
                                                                                   Bridgeville, PA 15017,USA  
 
Coulter Counter Z1                                              Beckman Coulter Limited, High   
                                                                                                      Wycombe, UK 
Hybaid PCR Express Thermocycler                                  Hybaid,  Action Court,  
                                                                                                      Middlesex, UK 
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Inverted Microscope                                                       Celti Optical 
Instruments,  
                                                                                                                Belgium. 
 
Magnetic Stirrer Hotplate                                     Stuart Scientific, Beacon Road,     
                                                                                                 Staffordshire, UK. 
 
Platform Shaker STR6                                         Stuart Scientific, Beacon Road,  
                                                                                                  Staffordshire, UK. 
 
Vortex                                                                      Sigma -Aldrich Company Ltd.  
                                                                                                            Dorset, UK 
 
Waterbaths                                                    Grants Instruments 
(Cambridge)Ltd.  
                                                                                                      Cambridge, UK 
 
 
1.2.2 Specialized kit for endothelial cell experiment 
Precision Nanoscript Reverse Transcription Kit.                             Primer design                                                                 
                                                                                                  Northampton, UK 
 
Total RNA Purification Kit.                                           Norgen Biotek  
Corporation 
                                                                                                    Thoroid, Canada 
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1.2.3 Chemicals and reagents for endothelial cell experiments 
 
Bovine serum albumin                                              Sigma-Aldrich Company Ltd. 
                                                                                                             Dorset, UK 
 
dNTP mix                                                                                         Promega UK, 
                                                                                                Southampton, UK 
 
Ethidium bromide                                                     Sigma-Aldrich Company Ltd, 
                                                                                                            Dorset, UK. 
                                                                                                                               
Fetal Bovine Serum                                                            PAA Laboratories Ltd, 
                                                                                                              Yeovil, UK  
                                                                                                                               
Hanks Buffered Salt Solution                                   Sigma-Aldrich Company Ltd, 
                                                                                                             Dorset, UK       
Hyper Ladder- 100bp                                                                         Bioline Ltd,    
                                                                                                           London, UK 
 
L-glutamine                                                              Sigma-Aldrich Company Ltd, 
                                                                                                            Dorset, UK 
 
Low EEO agarose gels('Hi-Pure')                                                    BioGene Ltd,  
                                                                                                      Kimbolton, UK 
 
Nuclease-Free Water                                                                      Promega UK,  
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                                                                                                 Southampton, UK 
 
Penicillin-Streptomycin Solution                               Sigma-Aldrich Company Ltd, 
                                                                                                           Dorset, UK. 
 
RPMI 1640 without Glucose                                    Sigma-Aldrich Company Ltd, 
                                                                                                           Dorset, UK. 
 
Trypsin/EDTA                                                          Sigma-Aldrich Company Ltd, 
                                                                                                           Dorset, UK 
                                                                                                                            
1.3 Equipment, specialized kits, chemical and reagents for 
clinical research 
 
1.3.1 Equipment for clinical research 
Roche Modular P analyzer                                               Roche Diagnostics Ltd.,  
                                                                                                  West Sussex, UK 
 
Tosoh G7 analyzer (HbA1c )                                              Tosoh Bioscience Ltd,  
                                                                                              Worcestershire, UK 
 
 
1.3.2 Specialized Kits for clinical research 
  
Duoset Elisa kit for Human Adiponectin.                       R&D systems Europe Ltd 
                                                                                                        Abingdon, UK 
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Duoset Elisa kit for Human Leptin.                               R&D systems Europe Ltd 
                                                                                                       Abingdon, UK 
                                                                                                                         
1.3.3 Reagents and Chemicals for clinical research 
 
PBS - 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 
1.5 mM KH2PO4, pH 7.2-7.4, 0.2 mm filtered. 
Wash Buffer - 0.05% Tween  20 in PBS, pH 7.2-7.4 
 
Reagent Diluent1 - 1% BSA in PBS, pH 7.2-7.4, 0.2 mm filtered. Quality of BSA 
is critical (see Technical Hints). 
 
Substrate Solution - 1:1 mixture of Color Reagent A (H2O2) and Color Reagent 
B (Tetramethylbenzidine). 
 
Stop Solution - 2 N H2SO4 
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Appendix 2 
 
Table 3 Serial dilution of standard stock solution 
Standard No. Std. volume 1x Assay Buffer Concentrations 
Stock 1000ul --------- 1000ng/ml 
#1 100ul of stock 900ul 100ng/ml 
#2  100ul of #1    900ul 10ng/ml 
#3 100ul of #2 900ul 1ng/ml 
#4  100ul of #3 900ul 0.1ng/ml 
#5 100ul of #4 900ul 0.01ng/ml 
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Appendix 3 
 
Conference Presentations 
 
Conference presentations 
 
Majebi, A.O, Dunmore, S.J., Brown, J.E.P. (2014) Role of adipokines leptin and 
adiponectin in obesity and diabetes mellitus related cardiovascular disease. 
Newzealand Society for the Study of Diabetes (NZSSD) Annual Scientific 
Meeting, Queenstown, Newzealand 2014. 
 
 
